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ABSTRACT
NG2 is a transmembrane protein expressed by cells as both a chondroitin sulphate rich
proteoglycan or a CS unmodified core protein. It is expressed by neuronal and glial cells.
Recent studies have shown NG2 to be identical to human melanoma proteoglycan, which is
expressed predominantly by melanoma cells. It is thought to be a cell surface receptor for
extracellular matrix proteins including type VI collagen and fibronectin, as well as being
involved in the response of some cells to platelet derived growth factor. It may also be a site
for intracellular phosphorylation. NG2 is therefore potentially important in cell adhesion,
proliferation and signal transduction in these cells. In view of the expression ofNG2 by
developing cartilage in rats and putative roles in cell-matrix interactions we have
investigated the expression ofNG2 by normal human cartilage and adult osteoarthritic
cartilage and its potential to function as a cell signalling molecule.
Cryostat sections of human fetal knee joints and articular cartilage from
macroscopically normal and osteoarthritic adult knee joints obtained at autopsy were
immunostained with a panel of antibodies against rat NG2 and HMPG. Chondrocytes in
fetal cartilage and normal adult cartilage showed strong immunoreactivity with anti-
NG2/HMPG antibodies. NG2 is also present in osteoarthritic cartilage, but expression is
down regulated. Western blots of whole cell lysates from macroscopically normal and OA
femoral condyles, revealed a smeared component ofmolecular weight greater than 400 kD
and a faint band at 250 kD. The 250 kD protein became predominant upon digestion with
chondroitinase ABC. Autoradiographs of I125 labelled chondrocyte lysates which had been
precipitated with anti-HMPG antibody confirmed NG2 was present in human adult articular
chondrocytes. Immunofluorescence staining of cultured chondrocytes revealed that NG2 is
distributed in a punctate pericellular pattern which does not appear to coincide with that of
ECM proteins type II or VI collagen and FN, actin stress fibres or PDGF aR. Anti-FIMPG
antibodies increase chondrocyte adhesion to type VI collagen and this modulation of cell
adhesion can be inhibited by pertussis toxin.
These studies show that NG2 is expressed by human fetal and adult chondrocytes.
In adult articular chondrocytes the core protein is chondroitin sulphated and both CS
modified and CS free fonns are simultaneously expressed. Expression is down regulated in
OA cells. NG2 appears to influence chondrocyte interaction with type VI collagen, via a
pertussis sensitive G protein. Cell matrix binding functions and cell signalling activity
suggest that NG2/HMPG has important roles in the regulation of articular chondrocyte
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1.0. INTRODUCTION
1.1. HUMAN ARTICULAR CARTILAGE
1.1.1. Cartilage structure and function
Articular cartilage is a specialised connective tissue whose function is to dissipate
compressive loads and protect the underlying bone. Adult cartilage is a hypocellular,
hyperhydrated, avascular, aneural, alymphatic tissue. No mitotic division occurs in
healthy cells. It contains a small number of cells (chondrocytes) which secrete an
abundant extracellular matrix (ECM). Chondrocytes in normal cartilage maintain a
balance between synthesis, secretion and deposition, and degradation and removal of
matrix molecules. Collagen is the major structural component of cartilage, and
provides the strength of the tissue by resisting shear and tensile forces. Type II
collagen (CII) is the most abundant protein in cartilage, where it forms a fibrillar
network which is found throughout the entire ECM. The minor collagens, type EX
and XI, are closely associated with CII fibrils and support the tensile strength of the
CII network. Type VI collagen (CVI) also forms a fibrillar network, however it is
preferentially located in the pericellular matrix of cartilage. Proteoglycans (PGs)
constitute 10% of cartilage dry weight. Aggrecan, a chondroitin sulphate
(CS)/keratin sulphate (KS) PG, is the major non-collagenous component of cartilage.
It interacts with hyaluronic acid (HA) and link protein to form large aggregates
within the collagen framework of the ECM. The negatively charged
glycosaminoglycans (GAGs) of the aggregates create an osmotic swelling pressure
which enables the tissue to become highly hydrated, giving cartilage its compressive
resistance. Other PGs are expressed in cartilage, including versican, glycan, decorin
and fibronectin (FN). These smaller PGs interact with other components of the
ECM, for example collagen, and are involved in providing a structurally stable
support for chondrocytes and modulating cellular behaviour by interacting with cell
surface receptors (Heinegard 1989, Horton 1989).
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Chondrocyte-ECM interactions are important in the regulation of cartilage
function. Amongst the important molecular interactions are those involving the cell
surface adhesion molecules CD44 and integrins.
In cell types other than chondrocytes, integrins have been shown to play a role
in the regulation ofmany cell functions, including embryonic development,
maintenance of tissue architecture, differentiation, proliferation, programmed cell
death, tumour metastasis, and the response of cells to mechanical stress (Solursh
1989). The interaction of integrins with ECM molecules, including FN and collagen,
results in the clustering of integrins and the formation of focal adhesion complexes,
where integrins link the ECM and cytoskeleton. The assembly of focal contacts plays
an important role in modulating cell adhesion and regulating changes in cell shape
involved in cell spreading and locomotion. Focal contacts also serve as a framework
for the association of signalling molecules involved in integrin regulation of cell
behaviour. Protein phosphorylation is amongst one of the earliest events activated,
involving molecules including focal adhesion kinase (FAK) and protein kinase C
(PKC). Other events include changes in intracellular calcium concentration and pH,
and alterations in gene expression (Clarke 1995).
In cartilage, integrin-ECM interactions are thought to be important in many
aspects of chondrocyte function. Integrins mediate chondrocyte adhesion to many
ECM proteins. As well as interacting with other components of the ECM, molecules
which are localised specifically to the pericellular matrix, immediately adjacent to the
chondrocyte, for example CVI (Poole 1988, 1992) and FN (Clemmensen 1982),
interact with the chondrocyte via cell surface receptors, including al, a3, a5 and pi
integrins (Salter 1992, Loeser 1995, Enomoto 1993). In vitro chondrocyte spreading
and migration on C13 and FN substrates is mediated by interactions with p 1 integrins
(Enomoto 1997). Integrins are thought to be involved in the regulation of cartilage
matrix synthesis and integrity, for example inhibition of integrin function also
inhibits CII synthesis by chondrocytes in culture (Beekman 1997). However
integrins are also involved in cartilage breakdown. FN fragments stimulate
chondrolysis and decrease PG synthesis in cartilage explants, which is blocked by
inhibitors ofFN-integrin interaction (Homandberg 1994). Other chondrocyte
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processes, for example proliferation and chondrogenesis, involve integrin interaction
with the ECM. The interaction of a5pi integrin with CII and FN is essential for in
vitro chondrocyte colony formation and DNA synthesis (Enomoto 1997). In vitro
chondrogenesis is inhibited by function blocking anti-J31 integrin antibodies
(Shakibaei 1998), and expression of specific integrin subunits changes to correlate
with the type of collagen synthesised (Shakibaei 1995). Chondrocyte pi integrin-
ECM interactions are required for chondrocyte survival, matrix deposition and
differentiation in models of chondrocyte development (Hirsch 1997). Integrins have
been shown to regulate chondrocyte production of cytokines in vitro, for example FN
stimulated production of EL-6, which is mediated by interactions with a5pi integrins
at the cell surface (Yonezawa 1996). Ligation of a5pi integrin with FN in
chondrocyte cultures results in the formation of focal adhesion complexes comprising
actin, FAK and the G protein Rho (Clancy 1997), although much less is known about
the intracellular signalling pathways which follow. Signal transduction through
integrins is known to upregulate metalloproteinase expression, which is mediated
through IL-1 binding to its cell surface receptor (Arner 1995).
Similarly, CD44 is involved in several cellular functions, including adhesion,
T cell activation, differentiation and embryogenesis. Its major ligand is HA, but it
also binds to FN and CVI. Binding ofHA results in the activation of several
intracellular pathways, including serine phosphorylation ofCD44, GTP binding,
changes in calcium concentration, alterations in the cytoskeleton, and release of
cytokines. The presence ofmany ofCD44's ligands in the pericellular matrix of
cartilage suggests that it may also act in the regulation of chondrocyte function in a
similar manner (Lesley 1993). CD44 has been shown to play a role in chondrocyte
adhesion, regulation of matrix synthesis and degradation, and cell proliferation. In
vitro adhesion of chondrocytes to HA is mediated by CD44, which results in
increased proliferation of cells and expression ofproteins, including TGF-P (Ishida
1997). In chondrocyte cultures IL-1, which inhibits PG synthesis, stimulates CD44
expression (Chow 1995). This suggests that stimulatory signals which regulate
chondrocyte catabolism and matrix synthesis are mediated by CD44. In chondrocyte
cultures and cartilage explants, inhibition ofCD44 expression results in a decrease in
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PG synthesis and matrix deposition, suggesting that CD44 is required for
maintenance ofmatrix integrity (Chow 1998). Electron microscopy has also shown
that antibodies which block CD44 function also inhibit chondrocyte pericellular
matrix assembly (Knudson 1996).
Chondrocyte adhesion molecules therefore play many important roles in
cartilage by mediating cell interaction with the ECM.
1.1.2. Osteoarthritis
Osteoarthritis involves cartilage breakdown and progressive destruction of the joint.
A number of factors, including trauma, metabolic abnormality, and genetic defects,
can trigger the onset of osteoarthritis. In osteoarthritis, the protease content of
cartilage increases, along with a downregulation in the levels ofprotease inhibitor.
This leads to a net increase in protein degradation and fibrillation of cartilage. The
tissue reacts to this destruction by remodelling. The chondrocytes assume a fetal
phenotype; they increase in size and number, increase rates ofDNA synthesis and
proliferation, and form clones. (Poole 1993). The ECM is also altered. Cleavage of
CII occurs. This is initially most pronounced in the superficial zone; however, with
increasing severity of osteoarthritis the damage spreads to the mid and deep zones.
The synthesis of new collagen increases to compensate for this loss, however the
fibrils formed are thinner, appear disorganised and are eventually degraded. This
results in a loss of tensile strength of the cartilage. Damage to the collagen network
also leads to increased swelling of PGs and an increased tissue water content (Poole
1993).
PGs are also degraded, this loss occuring initially at the articular surface. As
the disease progresses the PGs become larger and chemically different, often
containing new structural epitopes on CS chains which are normally only found in
fetal cartilage, suggesting that the degraded molecules are being replaced with newly
synthesised PGs. In advanced osteoarthritis PG levels decrease further, with an
eventual extensive reduction in PG content (Poole 1993).
The synthesis of other matrix components increases in an effort to repair
tissue damage, for example FN (Burton-Wurster 1990), CVI (Swoboda 1998) and
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tenascin (TN) (Salter 1993). The destruction of cartilage is accompanied by changes
in growth factor and cytokine receptor expression, suggesting that these molecules
are involved in the pathogenesis of the disease (Poole 1993).
The expression of cell adhesion molecules changes in OA cartilage.
Immunohistochemical staining of articular cartilage has shown that CD44 expression
in normal cartilage varies between the superficial and deep zones. An upregulation
in the expression of CD44 in the chondrocytes located in the deep zones ofOA
cartilage results in a uniform expression throughout the whole tissue (Ostergaard
1997a). Integrin expression also changes in OA cartilage. Studies carried out in vivo
and in vitro have shown that p 1 integrin expression increases in OA cartilage (Loeser
1995) and a2 and 4 and P2 integrins, which are not expressed in normal cartilage, are
expressed in OA cartilage (Ostergaard 1998). This suggests that normal cell-ECM
interactions are perturbed during the disease process, and this may play a role in the
onset and progression of osteoarthritis.
The progression of osteoarthritis occurs as a result of the increased rate of
synthesis ofECM being insufficient to compensate for the degradation, resulting in
net loss ofPGs and other proteins from cartilage, and the tissue is destroyed
(Heinegard 1989). Changes in ECM content and expression of cell surface receptors
affects cell-ECM interactions and the regulation of chondrocyte function by cell
adhesion molecules, and therefore may be important in the development and
progression of osteoarthritis.
1.1.3. NG2/Human melanoma proteoglycan (HMPG) and human
cartilage
Monoclonal antibody technology (Kohler 1975) has identified the antigen
NG2/HMPG. NG2 is a unique single span transmembrane chondroitin sulphate rich
proteoglycan, expressed by cells as both a 250 kD core protein and a chondroitin
sulphate proteoglycan (CSPG) ofmolecular weight greater than 400 kD (Stallcup
1983). It shows restricted distribution, being seen in rat neuronal and glial cells and
developing mesenchymal tissues, including cartilage (Stallcup 1983, Nishiyama
1991a). NG2 is however lost from cartilage during maturation, and is not expressed
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by chondrocytes in adult rat cartilage (Nishiyama 1991a). Recent studies have shown
NG2 to have significant homology with HMPG, a molecule expressed by melanoma
cells but by few other adult human tissues (Nishiyama 1991b).
Evidence is increasing for roles for NG2/HMPG in cell matrix interactions.
The observation that NG2/HMPG is present in developing rat cartilage, and has been
shown to be a receptor for CVI, CII and FN molecules (Burg 1996, Iida 1995),
recognised to be important in cartilage structure and regulation of chondrocyte
function, raises the possibility that this molecule may have previously unrecognised
roles in human articular cartilage. Furthermore the changes in expression ofECM
molecules and cell adhesion molecules in OA cartilage, where chondrocytes are
known to alter expression of cell adhesion molecules to that reminiscent of fetal
cartilage, raises the possibility that NG2/HMPG expression may be seen during the
onset and progression of osteoarthritis.
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1.2. CELL AND TISSUE DISTRIBUTION OF NG2
1.2.1. Expression in the rat central nervous system (CNS)
Immunological techniques have been used to identify specific surface markers to
classify cell types and trace cell lineages in the CNS. Nitrosoethylurea-induced cell
lines derived from rat CNS (Schubert 1974) were screened using ion flux assays and
divided into excitable (nerve) and non excitable (glial) types. Antisera were
produced which recognisedN or G antigens expressed by either neurones or glia
respectively (Stallcup 1976). However some cell lines could not be defined by
simple classification. These did not generate action potentials or express N antigens,
which is indicative of a glial cell type, but did express voltage dependent sodium
channels typical ofneurones (Arner 1981). Antibodies were raised against three
pseudo glial/neuronal cell lines B9, 49 and 92 (Wilson, S.S. 1981a, Stallcup 1983),
one of these recognised an antigen NG2, so called as it is expressed only by cell lines
with characteristics of both nerve and glial cells. Cell lines which exhibit properties
of both nerve and glial cells are proposed to be undifferentiated precursors that can
become either cell type. NG2 is therefore a potentially useful marker ofCNS
progenitor cells (Stallcup 1983).
In vitro cultures of embryonic and postnatal rat whole brain and isolated
cerebrum and cerebellum contain NG2-expressing cells, which have properties of
both glia and neurones (Stallcup 1981, 1983). This indicates that they may be
developmental precursors similar to cell lines.
In vivo NG2 is expressed by normal rat brain (Wilson S.S 1981a). NG2 is
first identified in the embryo. The number ofNG2-positive cells increases during
development, peaks at postnatal day 4/5 and decreases thereafter until postnatal day
19. Thereafter expression is down regulated by 50% to a steady state which is
maintained in the adult (Levine 1987a). NG2-expressing cells have been reported to
resemble astrocytes (Levine 1987a) and stellate and basket interneurones (Stallcup
1983).
Environmental conditions can influence the phenotype of cells which express
NG2. Cerebellar cultures isolated from postnatal rats and grown in fetal calf serum
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(FCS) become type 2 fibrous astrocytes, but without serum they become type 1
smooth protoplasmic astrocytes. This suggests that plastic cells that can acquire
mature astrocyte properties express NG2 (Levine 1987b). This exogenous
modulation ofphenotype is similar to that of 0-2A precursor cells identified in optic
nerves which differentiate into either oligodendrocytes or astrocytes in vivo (Raff
1983, Stallcup 1987). 0-2A cells isolated from rat postnatal optic nerves express
NG2. When grown in FCS they mature into type 2 astrocytes and retain NG2
expression, but in serum free conditions they lose NG2 and cells mature into
oligodendrocytes (Raff 1983, Stallcup 1987).
NG2-positive 0-2A progenitor cells are detected in vivo in the rat cerebellum,
from the last 3-4 days of gestation until the first 10 postnatal days (Stallcup 1987).
Some blood vessels also express NG2 over this time (Miller 1995). The human
cerebral cortex contains 0-2A cells with similar features to NG2-positive rat
cerebellar cells, suggesting that NG2 may also be expressed in the human CNS (Ong
1996).
NG2 has been used as a marker for 0-2A precursor cells to monitor the
immortalization ofprecursor cell lines (Redies 1991), and to identify 0-2A cells in
the study of cell-cell interactions in the development of the brain. Neuronal cells
present in the cerebellum influence the differentiation of progenitor cells. A-
neuronal optic nerve 0-2A cells differentiate into oligodendrocytes in the absence of
serum. Cerebellar 0-2A cells do not differentiate into oligodendrocytes unless
neurones are removed from the culture, illustrating the importance of cell-cell
interactions in differentiation (Levine 1989).
1.2.2. Expression in the rat developing limb
Immunohistochemical staining of a wide range of rat tissues showed that NG2 is
expressed outside the CNS, predominantly in tissues ofmesenchymal origin,
including developing cartilage, skeletal muscle, smooth muscle and heart. NG2
expression in the developing rat limb was further studied. Apart from some weak
reactivity in the endothelial and smooth muscle, all NG2 is found in the chondrogenic
tissue, hi the limb expression is developmentally controlled, with high levels of
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protein and 8.9 kb mRNA expressed in the late embryonic and early postnatal rat by
differentiating chondrocytes. As chondrocytes mature expression is down regulated
(Nishiyama 1991a).
1.2.3. Expression in the rat vasculature
NG2 is expressed by rat embryonic blood vessel cells in vivo. In brain capillaries the
endothelial cells are NG2-positive, up to the second postnatal week. In contrast, in
the capillaries of the spinal cord and aorta of embryonic, postnatal and adult rats,
NG2 is found in the smooth muscle cells adjacent to the endothelial cells. In vitro
cultures of smooth muscle cells from postnatal rat aorta express NG2. This suggests
a difference in cell type and timing ofNG2 expression within and outside the CNS
(Grako 1995).
1.2.4. Expression in rat chondrosarcomas
Rat chondrosarcoma cells express NG2 but normal adult rat chondrocytes do not
(Leger 1991).
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1.3. PHYSICAL CHARACTERISTICS OF NG2
1.3.1. Biochemical analysis
NG2 can be precipitated as a well defined 300 kD band and a smeared 400-500 kD
band from surface labelled NG2-expressing rat cell lines but not NG2-negative cell
lines (Stallcup 1983), from optic nerve 0-2A precursor cells (Stallcup 1987), from
chondrosarcomas (Leger 1994, 1995) and from cultures of rat developing limb
chondrocytes (Nishiyama 1991a). The high molecular weight component (HMWC)
ofNG2 is a CSPG, as indicated by labelling with radioactive sulphate and the
accumulation of the 300 kD protein in the presence of agents which prevent GAG
attachment to core protein (p-nitrophenylxyloside) or remove CS GAGs
(chondroitinase ABC (cABC)). Both components ofNG2 are glycoproteins, as they
are labelled with radioactive galactose and mannose. NG2 can be extracted from
cells using non-ionic detergent but not ethylene diaminetetraacetic acid (EDTA),
suggesting that it is tightly associated with the membrane. A smaller form of 290 kD
is secreted and can be detected in the tissue culture medium (Stallcup 1983).
1.3.2. Biosynthesis
Pulse labelling ofB49 rat cell lines with radioactive leucine shows that a 260 kD
protein is made. This is N-glycosylated with immature unbranched high mannose
oligosaccharides to form a 275 kD, tunicamycin- and endoglycosidase H (Endo HQ-
sensitive glycoprotein. The addition of sialic acid forms the 300 kD, neuraminidase
sensitive, Endo H resistant glycoprotein, after which the addition ofGAGs yields the
HMWC. The HMWC is detected after 15 min and increases in intensity upto 30 min
at which point the 275 kD glycoprotein ceases to be detected (Stallcup 1983).
1.3.3. Cell surface localisation
NG2 is distributed in a speckled pattern over most of the surface ofB49 cells
(Stallcup 1983) and in embryonic and postnatal rat brain primary cultures (Stallcup
1981). It is expressed at the cell surface of rat cerebellum in vivo (Levine 1987a).
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1.4. CELL AND TISSUE DISTRIBUTION OF HUMAN
MELANOMA PROTEOGLYCAN (HMPG)
1.4.1. Expression in human melanoma cells
Malignant transformation results in the expression of novel antigens by cells. In
particular PG expression varies between normal and transformed cells (Natali 1981).
Many polyclonal and monoclonal antibodies have been raised to melanoma specific
antigens, which have identified the presence of a unique PG in human melanoma
cells (TABLE 1.1.).
These melanoma-specific antibodies recognise the same antigen, HMPG
(Harper 1982, 1984, Herlyn 1987, Imai 1980, 1981, Johnson 1982, Morgan 1986,
Nagelhus 1993, Ng 1982, Real 1985, Ross 1982, 1984), which is similar to other
melanoma-associated antigens described (Bumol 1982, Carrel 1980, Hellstrom 1983,
Ng 1982). Much of this information was consolidated at an anti-melanoma
workshop using pooled resources, and excellent agreement between labs was
achieved. Epitope analysis revealed that antibody 9.2.27 recognises a different
epitope than 225.28S, 763.24TS (Harper 1982) and 155.8 antibodies (Harper 1984).
The epitope recognised by 9.2.27 is more widely distributed than those recognised by
other monoclonal antibodies (Harper 1982, 1984, Kantor 1982). The expression of
HMPG was studied using these melanoma-specific antibodies, and found to be of
limited distribution in human cells (Carrel 1980, Giacomini 1984, Harper 1984,
Hellstrom 1983, Herlyn 1983, Imai 1981, Koprowski 1978, Morgan 1981, Natali
1981, 1983, 1984, Real 1985, Ross 1984, Wilson B.S 1981b). (TABLES 1.2. and
1.3.). Extensive screening of fresh tissue and cultured cells indicates that HMPG has
a unique distribution, it is most strongly associated with melanoma cell surfaces from
which it is also secreted, both in vitro and in vivo. All reactivity to the antibodies
was specific for melanoma cells with the exception of some weak blood vessel
staining. HMPG is not expressed by normal adult or fetal melanocytes, unless the
cells are stimulated to proliferate with cholera toxin (Lloyd 1982), tumour inducer
12-0-tetradecanoylphorbol-13-acetate (Real 1985) or other phorbol esters (Kantor
1982). HMPG is not expressed by any other normal or tumour cell types tested.
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TABLE 1.1.
Monoclonal and polyclonal antibodies raised against human melanoma cells, which
recognise the antigen HMPG.
ANTIBODY IMMUNOGEN REF.
Polyclonal antiserum 6522 M21 cell lines McCabe 1978,
McCabe 1979
9.2.27 M14 melanoma cell line extracts
with competing antigens, FN and
HLA removed.
Morgan 1981
155.8 Ml4 cell line membranes Harper 1984
48.7 Ml733 melanoma cell lines Hellstrom 1983
225.28S, 138.13, 149.53 M21 melanoma cell lines Wilson 1981
653.40S, 165.28T, 653.25N M21 melanoma cell lines Imai 1981
01-95-45,691-19-19 Melanoma-mice cell hybrids Koprowski 1978
M28B5 SKMEL 93 cell lines Houghton 1982
AMF-6, NKI.M6 melanoma cell lines DeVries 1986
a-mel/4, a-mel/5, Mel-14 Me-43 melanoma cell lines Carrel 1980
15-43, 18-90, 95-45, 19-19,
60-23
melanoma cell lines Herlyn 1983




M21 and Colo 38 melanoma cell
lines
Kantor 1982
763.24TS melanoma cell lines Harper 1982
Mel-14 melanoma cell lines Herlyn 1982
G7A5 melanoma cell lines Johnson 1988




Expression ofHMPG in vitro. HMPG was identified by immunological staining of
cells in culture and shows a restricted distribution, being expressed predominantly by
melanoma cell lines.
HMPG +VE CELLS "
metastatic and primary melanoma cells lines
(A375, BE, BP, BwV, CAR#2, Colo 38, Colo 55, IGR3, LIN, M10, M14, M16, M21,
M51, Me-8, Me-33, Me-43, Me25-1, Me-85, Mel-2AM, Mel-2AP, Mel-Ei-78, Mel-
57, Mel-67, MP-6, MP-8, SCRE, Skmel-1, Skmel-23, Skmel-25, Skmel-93, WM9,
WM22, WM28, WM35, WM75, WM115, WM164, WM165, WM272)
capillary endothelium (weak)
melanoma cell culture medium
neuroblastomas
NORMAL ADULT HMPG -VE CELLS ~
B cell lines, kidney fibroblasts and epithelium, melanocytes, T cell lines, skin
fibroblasts
NORMAL FETAL HMPG -VE CELLS
brain, erythroblastoid cell lines, fibroblasts, melanocytes, human lymphoid, B
lymphoblasts, fibroblasts, erythrocyte cell lines.
TRANSFORMED HMPG -VE CELLS
Astrocytoma
carcinomas ofB cell, bladder, breast, cervical, chorio, colorectal, endometrial,
epithelial cells, fibroblastoid, GI, heart, HELA, lung, mammary, ovarian, pancreatic,
prostate, renal, T cell, thyroid, vulva, chemoectoma, EBV transformed malignant





Expression ofHMPG in vivo. HMPG was identified by immunological staining of a
panel of frozen sections taken from a wide range of tissues. Expression is limited to
melanoma tumour cells and blood vessels.
ADULT HMPG +VE TISSUES ~
astrocytoma, blood vessels, primary, metastatic and recurrent melanoma (cutaneous,
mucosal and uveal) tumour cells, serum (from melanoma patients, normal patients and
non melanoma patients), senile freckle, skin carcinomas
NORMAL ADULT HMPG -VE TISSUES
bladder, breast, cartilage, duodenum, endometrium, epidermis, lymph node,
lymphocytes, melanocytes, ovary, peripheral nerve, salivary gland, normal skin,
stomach, testes, tonsil
NORMAL FETAL AND ADULT HMPG -VE TISSUES ~ ~~~
adrenal gland, brain cortex, colon, pancreas, kidney, lung, nerves, squamous cells or
dermal collagen, heart, kidney, liver, lung, lymph node, oesophagus, pancreas, prostate,
skeletal muscle, skin, smooth muscle, spleen, thyroid, uterus
TRANSFORMED HMPG -VE TISSUES ~~~~ —
benign: breast dysplasia and cyst, fibroma of soft tissue, interstitial pneumonitis,
intestinal polyp, lymphangioma, neurinoma, prostatic and thyroid adenoma, skin
lesions (dysplasia, basal cell papilloma keratoacanthoma, verruca vulgaris,
leukoplakia)
malignant: bladder, breast, endometrial, epithelial, gastro-intestinal, kidney, liver, lung,
ovary, squamous cell and testes carcinoma, meningioma, neuroblastoma, astrocytoma,
glioblastoma, leukaemia, liposarcoma, rhabdomyosarcoma, sarcoma
neoplastic tumour types ofnon melanocyte origin (sclerosing angiomas, warts, basal
cell and squamous carcinoma)
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Although the antibodies against HMPG were derived using metastatic cutaneous
melanoma, HMPG is expressed by all types ofmelanoma tumour tested, including
mucosal melanoma from the head and neck (Henzen-Logmans 1988), uveal
melanoma (Natali 1989), acral lentigenous melanoma, and nodular melanoma lesions
(Kageshita 1991).
HMPG is expressed by metastatic, recurrent and primary melanomas.
Expression has been reported to remain constant in tumours of all sizes (Johnson
1988), in lesions from different sites in the same patient, and to have no correlation
with degree of transformation or prognosis (Giacomini 1984, Morgan 1986, Natali
1983, 1985, Wilson 1982, Ziai 1987). However some evidence suggests that
expression is increased in metastatic melanoma compared to benign lesions
(Kageshita 1991, Wilson 1982), with significantly shorter patient survival in HMPG
positive cases (Kageshita 1993, 1994).
HMPG is secreted by melanoma cells lines (Giacomini 1983, Imai 1981,
Natali 1981, Wilson 1983) and is also found in the serum (Giacomini 1984). The
highest levels ofHMPG in the serum are detected in patients with advanced
metastatic melanoma (Herlyn 1982) or gross tumour bearing patients, when
compared to normal donors, or patients with other cancers (breast, lung, cervix and
prostate carcinoma) or with non malignant disease (Ross 1984). Secretion ofHMPG
was increased by human leukocyte interferon (Matsui 1987). The significance of the
shedding of HMPG into serum may be significant in affecting distant cells, but its
function in the circulation is unclear.
Expression ofHMPG was maximal during G2 andM cell cycle phase of
melanoma cell lines Colo 38, M16 and M21 (Burchiel 1982). Higher amounts of
HMPG were seen in cells that had the medium changed more frequently, where no
contact inhibition occurred and which were significantly larger, suggesting a decrease
in less healthy cells (Lindmo 1984). Hyperthermia (42°C) reduces HMPG expression
up to 24 h after treatment at which point it returns to normal levels (Davies 1985).
Ligation ofHMPG by 9.2.27 induces internalisation ofHMPG at 37°C. This is
increased by hyperthermia (Davies 1990). Hypoxic conditions and photoactivated
hematoporphyrin derivatives reduce HMPG expression (Davies 1988).
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HMPG shows limited expression in the human tissues studied. However it has been
identified in a few cell types other than melanoma by the antibodies M28B5, 9.2.27 ,
225.28S, Mel 14, 0-95-45, A092 and 122 (Garin-Chesa 1989) (TABLE 1.4.)
1.4.2. Expression in human pericytes
HMPG expression in blood vessels in the tumour stroma (Real 1985) is restricted to
the pericytes of capillaries and venules (Schlingemann 1990), which are similar to
smooth muscle cells of arteries (Sims 1986). Pericytes of other lesion types
associated with vascular proliferation or angiogenesis, for example granulation tissue
ofwound healing and synovitis, also acquire HMPG, but normal capillaries of the
kidney, muscle, thyroid, placenta, and colon or ovarian carcinoma do not
(Schlingemann 1990).
1.4.3. Expression in Acute Myeloid Leukaemia (AML) and Acute
Lymphoblastic Leukaemia (ALL) blasts
Malignant AML blasts express different antigens from normal mature cells. They are
not novel proteins but are expressed during blast development. HMPG is specifically
expressed by transformed marrow cell lines and some cell lines of non hematopoietic
origin, such as those derived from smooth muscle, marrow stroma, cervical
carcinoma and epithelial cells. It is not expressed by mature cells from normal adult
marrow or developing cell lines of hematopoietic origin. This novel expression of
HMPG by AML blasts but not normal haematopoietic cells at any point during
development could prove to be significant in diagnosis and prognosis ofAML cases
(Smith F.O. 1996a).
Leukaemic marrow from children with AML that express HMPG all have the
same 1 lq23 chromosomal abnormalities, namely myeloid/lymphoid leukaemia
(MLL) gene rearrangement. The MLL gene is thought to encode a transcription
factor that could control HMPG gene expression, alterations in which may lead to
aberrant expression ofHMPG. The prognosis ofHMPG positive patients is poor,
with a greater rate of death than HMPG negative patients (Hilden 1997).
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ALL blasts from children with poor outcome often have MLL gene
rearrangements (Borowitz 1993, Pui 1991), and also express HMPG. Blasts that do
not have these specific alterations fail to express HMPG, as does normal lymph node
tissue (Behm 1996). This unique reactivity with neoplastic leukocytes withMLL
disruption could be clinically useful, as a highly specific and sensitive marker.
1.4.4. Expression in human astrocytomas
Astrocytoma cells express HMPG in vivo and in vitro, as detected by the monoclonal
antibody AO122. This antibody also reacts with fibroblasts and adult and fetal brain
homogenates. This antibody does not react with neuroblastomas, epithelial cancer
cells of lung, breast, colon, renal, bladder and cervix origin, transformed B cells, T
cell leukaemia, kidney epithelial cells or erythrocytes (Cairncross 1982).
1.4.5. Expression in human glioblastoma and capillaries
Adult human glioblastoma tissues express HMPG in vivo, in the proliferative
endothelial cells, perivascular ECM and weakly in the glioma cells themselves. In
contrast, glia, neurones, endothelial cells, endothelial basement membrane or
structures in the peri-endothelial space of capillaries in normal brain do not express
HMPG. HMPG is absent from other tumour types including low grade brain tumours
and non proliferative tumours, for example anaplastic astrocytoma, medullablastoma,
primary CNS lymphoma and meningioma, which lack endothelial proliferation. This
suggests that HMPG is a marker ofproliferative brain capillary endothelial cells in
the most malignant transformed astroglial cells (Schrappe 1991).
1.4.6. Expression in human sarcomas
Anti-HMPG antibody 9.2.27 was included as a negative control in human sarcoma
detection. However it showed significant binding to several human sarcoma lines
and fibroblasts. Tissue sections from sarcomas, osteosarcomas, malignant
schwannomas, malignant fibrous histocytomas and synovial sarcomas also express
HMPG, whereas normal fibrous connective tissues do not (Godal 1986).
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TABLE 1.4.
Human tissues which show positive reactivity with anti-HMPG antibody M28B5.
Expression ofHMPG detected by M28B5 staining of frozen sections from normal
and transformed human tissues. Expression is less restricted than previously thought,
with a wide variety of cells showing strong immunoreactivity with M28B5 (Garin-
Chesa 1989).
NORMAL TISSUES TUMOUR TISSUES
Adrenal Cortex Adrenal cortical carcinoma
Bile duct epithelium Astrocytoma
Bronchial epithelium Basal cell carcinoma
Capillary endothelium Bladder carcinoma
CNS neurones, astrocytes Breast carcinoma
Fibroblasts (subset) Chondrosarcoma
Intestinal mucosa Colon carcinoma
Keratinocytes Embryonal rhabdomyosarcoma
Kidney tubules Gastric carcinoma
Leydig cells Leiomyosarcoma
Mammary glands acini, ducts Lung carcinoma
Myoepithelial cells Melanoma
Pancreatic acini Meningioma
Parotid gland ducts acini Mesothelioma
Pneumocytes Nevus
Schwann cells Osteogenic sarcoma
Seminiferous tubules (weak) Ovarian carcinoma
Skeletal muscle Prostate carcinoma
Skin appendages Rhabdomyosarcoma
Smooth muscle Squamous cell carcinoma
Thyroid epithelium Synovial sarcoma
Thyroid carcinoma
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1.5. PHYSICAL CHARACTERISTICS OF HMPG
1.5.1. Biochemical analysis
HMPG comprises two components which are expressed simultaneously. A 250-280
kD protein and a heterogeneous HMWC (>400 kD) can be immunoprecipitated from
the surface ofmelanoma cell lines, (Bumol 1982, Harper 1984, Hellstrom 1983,
Kantor 1986, Koprowski 1978, Morgan 1981, 1986, Natali 1981, Ng 1982, Real
1985, Ross 1982, 1984, DeVries 1986, Wilson 1981, 1982, Ziai 1987), cultured
pericytes from human adult brain (Schlingemann 1990), AML and ALL blasts (Smith
F.O 1996a), glioblastoma cell lines and brain capillary endothelial cells from
glioblastoma tissue (Schrappe 1991), and cultured sarcoma cells (Godal 1986). A
210 kD protein is precipitated from cultured fibroblasts, indicating a less modified
form is expressed by these cells (Godal 1986).
HMPG is also secreted from melanoma cells. Both the HMWC (Hellstrom
1983) and the 280 kD protein (Ng 1982, Ross 1984, Wilson 1981, Ziai 1987) have
been detected in the tissue culture medium ofmelanoma cells, which is increased by
interferon (Wilson 1983). HMPG has a dual distribution, being expressed both at the
cell surface and released from cells in vivo and in vitro.
The HMWC is a CSPG, first suggested by its large size and confirmed by
sulphate labelling ofmelanoma cells, susceptibility ofO-linked GAG groups to
P elimination reactions, and loss of the HMWC after digestion with cABC or
treatment of the cells with monensin (a monovalent ionophore which inhibits cell
surface expression of PGs) (Bumol 1982, Harper 1984). GAG analysis by cellulose
acetate electrophoresis against heparin sulphate (HS), CS and HA standards also
confirmed that HMPG is a CSPG (Harper 1984). High performance liquid
chromatography (HPLC) against co-migrating standards revealed that HMPG
contains both delta Di-6S and -4S sulphate types (Bumol 1982). The HMWC barely
entered a 5% acrylamide gel, and 3% acrylamide and 0.75% agarose gels show that
HMWC consists not of a single component but of a disperse smear ranging from 300-
700 kD (Wilson 1983), implying that 3-12 60 kD GAG chains can be attached to the
protein (Garrigues 1986, Ross 1983).
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The 250 kD protein is not sulphated but is susceptible to neuraminidase
indicating that it is anN-linked, sialated glycoprotein (Bumol 1982). This protein has
a isoelectric point of 6.9, is a polar molecule with a high leucine, low lysine content
and is heat and trypsin sensitive (Ross 1983).
Treatment with cABC results in the loss of the HMWC and a qualitative
increase in the 250 kD protein, suggesting that the HMWC has been converted into
the 250 kD protein. A similar result occurs upon addition ofp-nitrophenylxyloside,
an exogenous GAG chain acceptor. Tryptic peptide map analysis of digests of both
the 250 kD protein and CSPG confirm that they consist of identical peptides. HMPG
is therefore expressed as two forms at the cell surface, a CS free glycoprotein core
which, upon GAG addition, forms the CSPG (Ross 1983).
1.5.2. Cell surface localisation
HMPG is distributed in a punctate pericellular pattern on melanoma cell surfaces
(Bumol 1984). At higher magnification HMPG is seen in filamentous structures that
interact with the underlying substratum (Harper 1984), suggesting a functional role at
discrete areas of the cell surface. Reactivity with anti-HMPG antibody was seen in
all cells but was heterogeneous, with greater intensity in some cells (Harper 1984).
Ultrastructural study of the distribution of both HMWC and unmodified core in
melanoma cells revealed an expression restricted to clusters on upper, peripheral and
lower cell surface projections, but no expression on smooth membrane areas or blebs
(Garrigues 1986, Hellstrom 1983). No co-localisation ofHMPG with FN could be
detected (Bumol 1984). Focal adhesion plaques do not contain HMPG (Cheresh
1984). Light and electron microscopy revealed that HMPG distribution is limited to
microspikes in clusters on the cell membrane of cultured pericytes (Schlingemann
1990). Expression in glioblastoma cells is localised to structures on the outer surface
of the basement membrane and the subendothelial space of the small capillaries,
suggesting a functional role in cell-ECM interactions. FfMPG expression in vitro on
glioblastoma cell lines is located in a punctate pericellular distribution, and
quantification of 9.2.27 binding revealed 10,000-400,000 binding sites per cell
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depending on the cell line type, compared to 600,000 for M21 melanoma cells
(Schrappe 1991).
1.5.3. Biosynthesis
The biosynthesis ofHMPG was studied by pulse chase analysis using antibodies
9.9.27, 149.53, 225.28S and 763.74T which recognise intracellular precursors of
HMPG and fully processed products (Bumol 1982,1984, Kantor 1986). In the first
10 min after pulse, 210, 220, 240 kD Endo H sensitive proteins are synthesised with
high mannose, non processed oligosaccharides attached. At 20 min a Endo H
resistant 250 kD protein and the HMWC are detected, which possess processed
complex oligosaccharides. At 60 min the levels of the 250 kD protein remain
constant but production of the HMWC increases, up to 120 min when synthesis
levels off. At 48 h both the 250 kD protein and the HMWC are present, however the
250 kD protein is lost at 72 h, when only the HMWC can be detected. No proteins
are detected from 72 h up to 96 or 148 h. This half life of expression at the cell
surface is unusual compared to typical PG half lives of 70-90 min (Bumol 1984).
Monensin treatment of melanoma cells causes inhibition ofmature CSPG
assembly and 250 kD protein maturation, and results in an arrest in HMPG synthesis
with a 245 kD Endo H resistant precursor (Bumol 1984, Harper 1986). Ammonium
chloride disrupts ATP-driven membrane-bound proton pumps that acidify
intracellular vesicles. Treatment ofmelanoma cells with ammonium chloride results
in normal HMPG synthesis up to expression of the 250 kD protein at the cell
membrane, but no CSPG is made. (Harper 1986). This shift towards the CS GAG
free form suggests that ammonium chloride acts after the maturation of the core
protein, but before the addition ofGAGs which occurs in a low pH dependent
compartment of the golgi. GAG addition is not a prerequisite for HMPG cell surface
expression, nor a sorting signal, leading to speculation about the function of the GAG
chain, and which form of the PG is functionally active. Diethylcarbamazine (DEC)
inhibits the secretion ofPGs from cells and the addition ofGAGs in melanoma cells
(Spiro 1986); HMPG synthesis is halted at the Endo H sensitive 240 kD step, no 250
kD protein or CSPG is made. DEC acts at a point where N-linked oligosaccharides
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are processed, perhaps by inhibiting transport from the endoplasmic reticulum to the
golgi (Spiro 1986). Tunicamycin, which inhibits N-linked glycosylation ,results in
the expression of an Endo H resistant 200 kD protein, suggesting that the unmodified
core is not competent for GAG chain addition (Spiro 1989). Cells treated with
glucosidase I and II inhibitors accumulate a 240 kD Endo El sensitive, high mannose
form ofHMPG, suggesting that removal of glucose is required to allow GAG
addition. In contrast mannosidase inhibitors show no effect on the ability of the cell
to produce CSPG, suggesting that proteins which have not been fully processed to the
complex form still acquire GAGs. Transport to the cell surface is inhibited by
glucosidase but not mannosidase inhibitors, suggesting that initial trimming but not
final processing is required. This indicates that glucose removal is an important step
in signalling of intracellular transport of the core to the site ofGAG addition and
subsequently to the cell surface (Spiro 1989).
Combinations of inhibitors have mapped the synthesis ofHMPG as well as
deriving useful information about PG synthesis in general. HMPG synthesis occurs
via several metabolic intermediates and vesicular shuttling pathways between
intracellular compartments which house modifying and processing enzymes to the
cell surface.
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1.6. COMPARATIVE ANALYSIS OF NG2/HMPG
The complete cDNA sequence ofNG2 was determined, from which the primary
structure was deduced (Nishiyama 1991b). A short sequence of the amino terminal
of HMPG was reported to be identical to that ofNG2 (Nishiyama 1991b), and when
the primary structures of the two proteins were published they were found to be
identical.
1.6.1. Primary structure ofNG2
Antibodies raised to intact NG2 and fragments ofNG2 purified from B49 rat cell
lines were used to immunoscreen B49 cDNA libraries. An NG2-expressing clone
was used to isolate the entire sequence ofNG2. It is expressed as a 8.9 kb mRNA in
NG2-positive cell lines and consists of 8071 nucleotides and 2325 amino acids (AA)
giving a calculated MW of 251,470 D. (FIGURE 1.1.)
Transmembrane Domain.
Hydropathy analysis reveals a putative signal peptide following the initiation codon
(ATG) at the N terminus and a second hydrophobic sequence near the C terminus.
The latter sequence comprises 25 hydrophobic AA followed by several basic AA
which meet the criteria for a transmembrane domain. Within the transmembrane
domain there is a single cysteine, which is also found in CD44 (Goldstein 1989),
syndecan (Saunders 1989) and the FGF-binding protein (Kiefer 1990), the function of
which is unknown. Antibodies against N and C terminal peptides were used to stain
both live and permeabilised B49 cells to reveal that the N terminus is extracellular
and the C terminus is intracellular.
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Cytoplasmic Domain.
The small cytoplasmic domain ofNG2 consists of 76AA. It contains three threonine
residues which together with surrounding AA conform to the motif for PKC
phosphorylation sites. Threonine 2255 and its neighbouring AA most closely match
the consensus sequence ofR(K)-XXT(S)XR(K) (Kemp 1990). Database searches
revealed no other homology between the cytoplasmic domain and any other protein.
Extracellular Domains.
The larger extracellular region contains 15 potential N-linked glycosylation sites
(NXS/T) and can be divided into 3 domains, two cysteine-rich domains separated by
a serine/glycine-rich domain.
The first domain (AA 30-640) contains 8 cysteines with surrounding AA
unlike those common in many large ECM or cell surface molecules, for example
epidermal growth factor like repeats (Doolittle 1984), immunoglobulin like repeats
(Williams 1988) or link protein sequences (Neame 1986). Other notable features
include a short stretch of acidic AA between the 4th and 5th cysteines, which are
considered unusual in extracellular regions. Their function is unclear, but similar
sequences exist in the link protein-like globular domain, the GAG attachment site of
versican (Zimmerman 1989) and basic fibroblast growth factor receptor (Lee 1989).
There is also a hydrophobic cluster at AA 424-440. The first extracellular domain
contains 3 of the 15 potential glycosylation sites.
The second domain (AA 641-1590) contains no cysteines but has 9
serine/glycine pairs. The AAs around serines 998 and 1342 conform to consensus
sequences for CS GAG attachment sites (E/DGSGE/D) (Zimmerman 1989), or
(SGXG) (Bourdon 1987). The second extracellular domain contains 6 of the 15
potential glycosylation sites.
The last domain (AA 1590-2325) contains 8 cysteines, 6 ofwhich are
clustered into a 35 AA stretch near the transmembrane domain. Cysteines that lie
just outside the transmembrane domain have been implicated in the formation of
intermolecular disulphide bonds, for example in the NOTCH protein of Drosophila
(Kidd 1989), or intersubunit disulphide bonds, for example in insulin receptor-like
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receptor (Shier 1989). Whether they perform these functions in NG2 is unknown.
Data base searches revealed that AA 2050-2064 have 40% identity to a segment near
the C terminal of the a subunit of the human insulin receptor-related receptor (Shier
1989). hi particular 3 cysteines are conserved in both these proteins and insulin
receptor and insulin like growth factor I receptor. The third domain contains 1
potential GAG attachment site and 6 of the 15 potential glycosylation sites.
Biochemical Analysis.
A 300 kD protein can be precipitated from whole cell lysates ofB49 rat cell lines.
Mild trypsinisation of the cells releases a 120 kD N terminal cysteine-rich fragment.
On reducing gels this fragment exhibits a slower motility indicating the presence of
disulphide bond formation and a globular conformation in the native protein. This
fragment is not affected by cABC treatment. Treatment of cells with EDTA releases
a 200 kD fragment containing the N terminus and the serine rich region. In the
absence of cABC this fragment forms a heterodisperse component of >400 kD,
suggesting that it contains GAG attachment sites. Due to the lack of cysteines, this
domain is likely to have an extended conformation similar to that predicated for the
serine/glycine rich domains of other PGs (Doege 1987, Zimmerman 1989). This
conformation was confirmed by electron microscope studies (Tillet 1997) (FIGURE
1.2.)
Southern blot analysis of genomic DNA isolated from rat cell lines revealed a
single band indicating that NG2 is coded for by a single gene.
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NG2/HMPG is a single span transmembrane protein with a
short cytoplasmic domain and a large extracellular region.
The extracellular segment consists of 2 cysteine-rich domains
which form globular configurations, separated by a rod




A search for internal repeats in the sequence ofNG2 revealed that there are four
200AA long negatively charged and glycine containing sequences that evenly span
the extracellular region. These are similar to chick N-cadherin calcium binding
domains. The region of highest homology was found in a 12 AA stretch at the C
terminus of the second N-cadherin repeat. This has been proposed to form a P sheet
followed by a P turn or coil, and be involved in calcium binding (Hatta 1988),
suggesting a similar function in NG2. There is a 30 AA long repeat in the C terminal
third of the extracellular domain which is unique to NG2. A tripeptide, FRV, appears
five times in the extracellular domain ofNG2 within the serine/glycine rich domain,
four ofwhich are clustered in the N terminal half of the area.
NG2 is a novel integral membrane protein with a large extracellular region and a
small cytoplasmic domain. Unlike other large PGs, for example the syndecan family
which have a common cytoplasmic domain (Kiefer 1990), NG2 shares little
homology with any other protein, including other membrane spanning PGs (Fransson
1987) such as CD44 (Goldstein 1989), thrombomodulin (Jackman 1986) and the
invariant chain of the class II histocompatability antigen (Strubin 1984).
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1.6.2. Primary structure of HMPG
HMPG was cloned and sequenced by screening cDNA libraries from M21 melanoma
cells with a 4 kb rat NG2 cDNA probe. The resulting cDNA from a positive clone
was used as a PCR primer to generate a series of overlapping clones, which DNA
was sequenced and from which the 2322 amino acid sequence was deduced.
Northern blots ofRNA from various sources were probed with HMPG
cDNA. A 9 kb transcript is expressed only in HMPG-positive cell lines No
transcript was seen in any other cell type tested. In situ hybridisation of human
melanoma cells using the same probe gave strong signals in all cell lines that reacted
with anti-HMPG antibody.
HMPG is almost identical to rat NG2, with small variations found in the third
domain. NG2 has a cluster of 6 cysteines at AA 2043-2091 which HMPG does not.
hi HMPG there are an additional 3 bases, the first at position 6128 causing a shift in
the reading frame, which continues after the second at 6244, but is resolved after the
third at position 6273 (Pluschke 1996).
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1.7. FUNCTION OF NG2/HMPG -INTERACTIONWITH ECM
1.7.1. Cell surface localisation
NG2/HMPG is localised to the cell surface of rat cell lines (Levine 1987a). In human
melanoma cells NG2/HMPG is expressed at the cell surface in filaments/microspikes
often connected to the underlying substratum (Harper 1984, Garrigues 1986).
Microspikes make initial contact with adjacent cells or the underlying substratum,
suggesting a role for NG2/HMPG in cell surface interactions (Albrecht-Buehler
1976). In non-transformed cells microspikes also mediate contact inhibition growth,
but not in tumour cells (Albrect-Buehler 1976). The presence ofNG2/HMPG in
tumour microspikes may account for the lack of contact inhibition.
1.7.2. Direct interaction ofNG2/HMPG with ECM proteins
Purified NG2/HMPG from melanoma cells interacts with HA (Bumol 1982).
NG2/HMPG purified from B49 rat cell lines binds to CII, type V collagen and CVI,
TN and laminin (LN) (Burg 1996). This is mediated by the protein core (Burg 1996).
Decorin inhibits NG2/HMPG binding to these collagens but not to TN, suggesting
that interaction between NG2/HMPG and collagen is mediated by a domain shared
with decorin, but interaction with TN is at a site distinct from its collagen-binding
domain. The only homology between NG2/HMPG and decorin is a leucine-rich
region in the central extracellular domain ofNG2/HMPG (Kjellen 1991). No
significant binding was seen with NG2/HMPG and type I, IH, or IV (CIV) collagens
(Burg 1996). The best characterised interaction is that ofNG2/HMPG with CVI.
Interaction ofNG2/HMPG with CVI
NG2/HMPG purified from B49 rat cell lines binds the a2 chain of triple a helical
CVI, but not the al chain (Burg 1996). Anti-NG2 antibodies co-precipitate
NG2/HMPG and CVI from B49 rat cell lines (Stallcup 1990). Several NG2/HMPG
expressing cell lines including B49 exhibit co-localisation ofNG2/HMPG and CVI
on the cell surface in a punctate pattern (Stallcup 1990). The distribution ofCVI on
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B28 rat cell lines, which do not express NG2/HMPG, is fibrillar in nature. Other
ECM molecules, for example CIV, FN and LN, do not show the same degree of co-
localisation with NG2/HMPG. Perturbation ofNG2/HMPG distribution by
antibodies results in parallel changes in CVI distribution (Stallcup 1990). This
suggests that CVI and NG2/HMPG interact directly via protein-protein binding, and
that NG2/HMPG may organise CVI distribution.
B28 rat cell lines and U251NG human glioma cell lines do not endogenously
express NG2/HMPG. They synthesise and secrete CVI, but do not retain it at the cell
surface. Transfection of these cell lines with NG2/HMPG cDNA results in
expression ofNG2/HMPG protein, and retention ofCVI at the cell surface. CVI is
distributed in a punctate pattern that co-localises with NG2/HMPG, as seen on cells
that endogenously express NG2/HMPG. This effect is specific for CVI, transfection
ofNG2/HMPG has no effect on the distribution ofFN or LN. This confirms that
NG2/HMPG acts as a cell surface receptor for CVI, and that expression of
NG2/HMPG is sufficient for anchorage ofCVI (Nishiyama 1993).
Three different forms ofNG2/HMPG exist, with MW of 275, 290 and 300
kD. Rat cell line B49 and human glioma cell line U251NG35, which express
NG2/HMPG and anchor CVI, express NG2/HMPG as a 300 kD protein core.
Human glioma cell line U251NG52, which expresses NG2/HMPG but fails to anchor
CVI, expresses NG2/HMPG as 300 and 275 kD forms. The appearance of the 275
kD species correlates with the inability of the cells to anchor CVI. B49 cells treated
with anti-NG2 antibodies, which block interaction with CVI, no longer retain CVI
and produce both the 275 and 300 kD protein, suggesting that B49 cells are able to
produce the 275 kD protein but do not do so under normal circumstances. These
different forms are not due to alternative splicing ofmRNA, so must result from post
translational modification. Trypsin treatment ofB49 and U251NG32 cells results in
conversion of all the 300 kD protein to the 275 kD protein, which is missing the
cytoplasmic domain and 64 AA of the transmembrane domain, but still remains
associated with the cell surface (Nishiyama 1995).
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The 290 kD form ofNG2/HMPG is secreted from cells and is also missing a
part of the cytoplasmic domain (Nishiyama 1995). This has also been seen with the
LI adhesion protein (Prince 1989).
Production of the 275 kD form may be regulated by interaction with CVI.
The a3 chain has a protease inhibitor sequence (Chu 1990) which may protect
NG2/HMPG. Therefore in cells such as U251NG52, which do not retain CVI,
NG2/HMPG is not protected and expressed as both intact and cleaved protein
(Nishiyama 1995).
Phorbol esters PMA and PDBu, which activate PKC, and phosphatase
inhibitor okadaic acid cause a shift towards the production of the 275 kD protein and
a decrease in the 300 kD protein in a dose dependent manner. Treatment of the cells
with the PKC inhibitor staurosporine results in a quantitative decrease in the 275 kD
form and an increase in the 300 kD form. These events occur within minutes
(Nishiyama 1995). PKC may activate de novo synthesis of a protease. Phorbol esters
stimulate stromelysin and collagenase activity to cleave aggrecan at asparagine-
phenylalanine sites (Frisch 1987) ofwhich there are two in NG2/HMPG. Phorbol
esters also activate elastase which cleaves at alanine-valine (Pandiella 1991) ofwhich
there are two in NG2/HMPG. NG2/HMPG contains numerous lysine-arginine sites
at which trypsin is known to act (Bernfield 1992).
NG2/HMPG has been reported to act as a CVI receptor in other cell types. In
corneal fibroblasts and undifferentiated peri-ocular mesenchyme in vivo, and in
mesenchymal cells grown in vitro on CVI, NG2/HMPG and a3pi localise to focal
contacts and interact with CVI (Doane 1998).
Mechanism ofNG2/HMPG Interaction with CVI
Precise characterisation of the domains ofNG2/HMPG responsible for its collagen
binding properties was achieved by electron microscopy of recombinant NG2/HMPG
(Tillet 1997). NG2/HMPG comprises two cysteine-rich domains joined by a
cysteine-free domain. Domains 1 and 3 exhibit a globular conformation stabilised by
disulphide bonds and are separated by the extended cysteine free second domain.
Electron microscopy ofNG2/HMPG-CVI mixtures shows that the collagenous triple
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helical domain aligns with the central rod like domain 2 ofNG2/HMPG. Fragments
ofNG2/HMPG used in binding assays confirm that domain 2 is the site of attachment
for CVI. This domain alone supports CVI binding and proteins lacking this segment
do not. Domain 2 is also responsible for CS GAG attachment. CS GAGs are not
thought to have a direct role in CVI binding, although NG2/HMPG synthesised
without the addition of CS is unable to bind CVI. This suggests that GAG chains
may modulate the folding ofNG2/HMPG into a conformation able to interact with
extracellular ligands (Tillet 1997). FIGURE 1.3a.
A series ofNG2/HMPG variants, with deletions throughout the entire coding
sequence of the protein, were expressed in B28 rat cell lines, to study the effect of the
specific mutations on the ability to interact with CVI. All but three of the mutant
NG2/HMPG molecules enable cells to anchor CVI at the cell surface. Analysis of
the deleted sequences of the three revealed that a 469 amino acid segment between
residues 575 and 1044 ofNG2/HMPG protein core are essential for CVI binding.
These are found in the extracellular central domain 2 ofNG2/HMPG (Burg 1997).
Amino acids 750-850 of domain 2 ofNG2/HMPG are predicted to form a
similar type of secondary structure conformation to the leucine-rich repeats of
decorin and related PGs, which consist of an alternating a-helical and P-turn units
that form an open horseshoe-like structure in which the collagen helices are proposed
to bind (Scott 1996). FIGURE 1.3b.
Functional Relevance ofNG2/HMPG Interaction with CVI
CVI is found in most if not all connective tissues, as a heterotrimer. The chains form
a small triple helical domain which separates the large globular domains at the N and
C terminus. These trimers form large aggregates stabilised by disulphide bonds
(Ayad 1994).
0-2A cells do not express CVI, but areas in the developing rat do co-express
CVI and NG2/HMPG, for example some blood vessels, spinal column, intestines and
the cartilaginous structures of the head. This suggests that the interaction between





Interaction of NG2/HMPG with CVI.
NG2/HMPG at the cell surface directly interacts with CVI in the ECM.
NG2/HMPG
Domain 2
a helix/p turn/ a helix
Figure 1.3.b
Interaction ofNG2/HMPG with CVI (detail).
The CVI triple helix inserts into the horse shoe like
configuration of domain 2 of the NG2/HMPG molecule.
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Cell adhesion
CVI is localised to the pericellular matrix and basement membranes, close to the cell
surface in a number of cells, including developing nerves (Keene 1988). It interacts
with many ECM proteins including HA (McDevitt 1991, Kielty 1992), TN (Faissner
1990), fibrillar collagens I and II (Hedbom 1993, Bonaldo 1989, Bidanset 1990,
Keene 1988), type XIV collagen (Brown 1993), decorin (Hedbom 1993) and
fibromodulin (Vogel 1984, Bonaldo 1989), as well as with cell surface receptors such
pi integrins (Aumailley 1989), al, a2 and a3 integrins (Pfaff 1993, Doane 1992,
Wayner 1987), and PGs including CSPGs (Bray 1990) and CD44 (Gallatin 1986,
Carter 1982). CVI therefore is important in anchoring cells to the ECM, in a manner
similar to the points of attachment provided by the interaction ofFN with collagens
and integrins (Ruoslahti 1988).
These points of adhesion are also involved in signal transduction between the
ECM and the inside of the cell. Interactions between CVI and NG2/HMPG may
provide alternative means of transmitting information across the cell membrane,
raising the possibility that these molecules are important not only in structural roles
(organisation of the ECM, binding of cells to the matrix and determination of cell
morphology) but also in modulation of cellular processes including proliferation,
migration and differentiation.
Cell migration
NG2/HMPG negative rat B28 cell lines and human U251NG glioma cell lines can
migrate towards CVI, suggesting that, in the absence ofNG2/HMPG, these cells still
have CVI recognition molecules, which may include aipi, a2pi integrins (Pfaff
1993, Doane 1992) and CD44 (Carter 1982). However, NG2/HMPG expression in
these cells specifically enhance this migratory response. This stimulation requires the
same region ofNG2/HMPG that is responsible for interaction with CVI, AA 575-
1044. Deletion mutants missing this domain fail to produce a similar enhanced
migration (Burg 1997). There are a number ofmechanisms by which this may occur,
NG2/HMPG may act to alter the actin CS conformation resulting in increased
cellular motility, as NG2/HMPG has been shown to interact with actin in actively
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spreading glioma cells (Lin 1996a,b). Alternatively NG2/HMPG may alter the
interaction of CVI with its other receptors in such a way that potentiates cell motility,
for example by modulating CVI interaction with integrins in the same way that
NG2/HMPG does with a4(31 with melanoma cell spreading on FN (Iida 1995). CVI
is found along neural migratory pathways in developing CNS (Perris 1993). Neural
crest cells bind to, and migrate, along CVI in vitro (Perris 1993). Glial cells (Han
1995) and uveal melanoma cells (Daniels 1996) that produce more CVI are more
invasive than those that do not, suggesting a correlation between CVI expression and
malignancy.
Tumour cell invasion andproliferation
NG2/HMPG is expressed in the most malignant of glioma phenotypes (Schrappe
1991). During transformation glioma ECM composition changes, including
increased expression of TN, HA and CVI (McKeever 1989, Chintala 1996), which is
thought to stimulate the spread of cells throughout the brain, possibly by interacting
with CIV in endothelial basement membrane (Kuo 1997). NG2/HMPG binds both
TN and CVI, so may assist in promoting interaction with the ECM under these
circumstances, indicating a possible role for NG2/HMPG in tumour cell invasion and
migration of neoplastic cells (Nishiyama 1993).
Platelet derived growth factor (PDGF) and receptor are also upregulated in
malignant glioma cells (Westermark 1995). CVI binds PDGF to form a functional
complex (Somasundaram 1996). NG2/HMPG has been shown to potentiate smooth
muscle and 0-2A progenitor cell response to PDGF by interacting with the
PDGFa receptor (PDGFa-R), it may do the same in glioma cells. This could be of
interest, as NG2/HMPG and CVI co-localise in some tissues in developing rat
cartilage, where NG2/HMPG-CVI interactions may be important during development
but less so after maturation, at which time NG2/HMPG expression is down regulated
(Nishiyama 1991a).
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1.7.3. Modulation of human melanoma cell interaction with FN by
NG2/HMPG
FN interacts with many ligands, including other FN molecules, ECM proteins and
cell surface receptors. Integrins mediate cell adhesion to FN (Akiyama 1996, Hynes
1987), leading to the activation of numerous intracellular responses, including
cytoskeletal reorganisation and tyrosine phosphorylation (Clark 1995, Lafrenie 1996).
Integrins are important in modulating tumour cell migration and adhesion (Albeda
1990, Hynes 1992). Several PG also interact with FN (Hook 1984), for example
syndecan (Gallagher 1989) and CSPG expressed by chick embryo fibroblasts
(Yamagata 1989), although the molecular nature of the downstream events are less
well characterised.
NG2/HMPG and FN co-localise during initial condensation of rat
chondrocytes (Nishiyama 1991a). Anti-HMPG antibody AMF-6 inhibits melanoma
cell migration along FN concentration gradients, a process by which cells adhere to,
and invade the vascular endothelium in vivo. It has no effect on cell adhesion,
suggesting that NG2/HMPG is not involved this process, but in the chemotactic
response and kinetic motility ofmelanoma cells (DeVries 1986).
A 33 kD fragment from the C terminus ofFN promotes mouse melanoma
adhesion and spreading (McCarthy 1990). Melanoma cell adhesion to this fragment
can be completely blocked by anti-a4pi antibodies and inhibited 55% by agents that
block CSPG function by removing CS GAGs. This suggests that melanoma cell
adhesion to this FN fragment involves specific integrin subunits, and is partially
mediated by CS GAG chains (Iida 1992). Melanoma cells adhere to anti-HMPG
antibody 9.2.27, FN, a FN peptide (CS1), laminin, CIV, and chimeric substrates
comprising LN and 9.2.27 or CIV and 9.2.27 (Iida 1995). However, no cell
spreading, focal contact and stress fibre formation, cell flattening, microspike and
lamellopodia production, or paxillin recruitment to focal contacts is observed unless
melanoma cells are grown on a chimeric substrate of both FN/CS1 and 9.2.27.
a4pi/NG2/HMPG-stimulated spreading on CS1 and 9.2.27 is sensitive to tyrosine
kinase inhibitors, and two proteins of molecular weight 120 and 130 kD,
immunologically unrelated to pl25FAK, are phosphorylated on tyrosine residues.
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This does not occur during melanoma adhesion (Iida 1995). This suggests that both
NG2/HMPG and a4(31 must be stimulated to promote these events.
Mechanism ofModulation ofHuman Melanoma Cell Interaction with FN by
NG2/HMPG
NG2/HMPG and a4pi co-ordinately mediate melanoma cell interaction with FN.
However, they need not be in close proximity on the cell surface to stimulate
melanoma cell spreading and focal contact formation. a4pi must be in contact with
the substrate, but NG2/HMPG need not. Melanoma cells already adherent on CS1
can be stimulated to spread and form focal contacts by addition of 9.2.27 coated
beads, however cells adherent on 9.2.27 can not be stimulated to spread by CS1
coated beads. This suggests that NG2/HMPG maymodify a4pl binding to FN by an
inside out mechanism (Iida 1995). This has been described in other cell types;
integrin conformation is altered by signals within the cell involving the cytoplasmic




Role of NG2/HMPG in mediating human melanoma cell interaction
with FN.
NG2/HMPG indirectly modulates melanoma cell adhesion to FN.
By inside out signalling NG2/HMPG alters the affinity ofa4pi integrin
for FN. This results in cell spreading, focal contact formation,
microspike and lamellopodia extension and tyrosine kinase
recruitment.
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Functional Relevance ofModulation ofHuman Melanoma Cell Interaction with FN
by NG2/HMPG
Integrins are important in mediating cell adhesion to ECM, but they do not alone
deliver the entire range of signals required by a cell to undergo associated processes
such as spreading and focal contact formation. Chinese hamster ovary cells that are
HS deficient form fewer focal contacts than normal cells (Lebaron 1988). Both
integrin and PG binding fragments ofFN are required for fibroblast focal contact
formation (Woods 1992). Syndecan regulates integrin function via inside out signals
involving PKC (Woods 1992, 1993, 1994). NG2/HMPG contains three threonines
which are potential targets for PKC phosphorylation (Nishiyama 1991b), however
there is no sequence homology between NG2/HMPG and P1 integrin cytoplasmic
domains as has been observed for syndecan (Argraves 1987). Alternative means of
NG2/HMPG regulating integrin interaction with FN may involve tyrosine
phosphorylation. Tyrosine phosphorylation of P1 in transformed cells leads to a
decrease in its affinity for FN and talin (Hynes 1992). Two proteins are specifically
phosphorylated during HMPG and a4pl-stimulated spreading, however their identity
is unknown (Iida 1995). NG2/HMPG may act as a co-receptor for FN, co-ordinating
cell adhesion and signal transduction.
Comparison ofNG2/HMPGInteraction with CVI and FN
NG2/HMPG expressed in B49 rat cell lines interacts directly with CVI. In contrast
NG2/HMPG expressed by human melanoma cells indirectly affects cell adhesion by
modulating P1 integrin interaction with FN. Evidence suggests that cell surface PGs
and integrins exert a co-ordinated effect on matrix functions, although there is no
difference in the distribution of pi integrin in control or NG2/HMPG transfected rat
cell lines, indicating that NG2/HMPG-CVI interaction is pi-independent. This
suggests that NG2/HMPG mediates interactions with different ECM proteins via at
least two different pathways.
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1.7.4. Induction of HMPG expression by ECM
The relationship between NG2/HMPG expression and cell-ECM interaction has been
studied (Rettig 1986). Human chromosomes retained in rodent-human melanoma
hybrid clones were determined by karyotype and cell surface marker analysis.
Expression ofNG2/HMPG was mapped to chromosome 15. NG2/HMPG expression
can be induced by fusion of specific cell types which retain chromosome 15, for
example, non NG2/HMPG-expressing human kidney epithelial cells and mouse
fibroblasts. In contrast, human kidney cells fused with mouse renal carcinoma cells
did not express NG2/HMPG, even though chromosome 15 is retained. NG2/HMPG
expression can also be induced by the ECM. Human and mouse neuroblastoma
chromosome 15-containing hybrids grown on plastic are loosely attached, appear
rounded with extended processes, and do not express NG2/HMPG or become
confluent. However on plates coated with ECM derived from bovine corneal
epithelial cells, NG2/HMPG expression is induced, cells adhere strongly, spread and
become confluent. NG2/HMPG-negative cell lines of epithelial and hematopoetic
origin did not show induced NG2/HMPG expression, and SV13 and F23 proteins,
also encoded for by chromosome 15, show no change in expression, suggesting that
this effect is specific for NG2/HMPG and target cell type. NG2/HMPG is the first
antigen shown to be regulated in this way. Expression ofNG2/HMPG specifically
induced by the presence of the ECM is accompanied by changes in cell morphology
and adhesive ability. This suggests alterations in multiple pathways and genes, and
that both intrinsic and extrinsic signals, provided by the rodent partner and the ECM
respectively, can induce NG2/HMPG expression in previously non-expressing cells.
1.7.5. Tumour metastasis
Tumour invasion and metastasis requires cell detachment from the primary tumour
and relocation to secondary tissue sites where colonies of cells are established
(Cifone 1980). Inhibitors of the cell surface receptors a2pi, CD44 andNG2/HMPG,
which are expressed at high levels in melanoma cells, inhibit melanoma invasion
through basement membranes. CD44 and a2[31 do this by mediating interactions
with the dV component of the membranes, however NG2/HMPG does not and
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therefore must modulate invasion in an alternative manner (Knutson 1996).
Antibodies against NG2/HMPG inhibit melanoma cell colony-forming ability
(Harper 1983), tumour growth in mice (Bumol 1983), and cell spreading on bovine
aorta endothelial basement membranes, but have minimal effects on cell adhesion
(Bumol 1984, DeVries 1986). This suggests that NG2/HMPG is important in
melanoma cell spreading and stabilising cell substrate interactions, and that anti-
HMPG antibodies inhibit processes essential for tumour growth by interfering with
cell-cell/substratum interactions. Anti-HMPG antibody 155.8 inhibits adhesion of
melanoma cells to plastic, FN, collagen, and collagen/FN substrates (Harper 1984),
suggesting that NG2/HMPG is important in interaction with these ECM molecules
1.7.6. Functions implicated by NG2/HMPG primary structure
Internal repeats in the sequence ofNG2/HMPG are similar to those found in chick N-
cadherin (Hatta 1988), the highest similarity being in a proposed calcium-binding site
(Hatta 1988, Ringwald 1987). Cadherins are calcium dependent cell adhesion
molecules. They are important in mediating cell-cell interactions via
homo/heterotypic extracellular interactions and intracellular interactions with catenin
molecules which link them to the actin cytoskeleton to construct ordered
multicellular tissues and structures. Cadherins are important in the formation ofCNS
architecture (Redies 1996), in axonal guidance and in conveying adhesive flexibility
required during tumour cell invasion and metastasis (Bussemakers 1996).
NG2/HMPG may have a similar function.
SUMMARY
The localisation ofNG2/HMPG at the cell surface indicates a role in cell interaction
with the ECM. In rat cell lines NG2/HMPG binds directly to a number ofECM
proteins, the best studied ofwhich is CVI. NG2/HMPG modulates the interaction of
human melanoma cells indirectly, by outside in signalling resulting in an increase in
adhesion of integrins to FN. NG2/HMPG appears to play a key role in the adhesion
of both normal and transformed cells to ECM components, and also in other cell
functions including spreading, focal contact formation and migration.
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1.8. FUNCTION OF NG2/HMPG AS A SIGNAL TRANSDUCTION
MOLECULE
1.8.1. Interaction of NG2/HMPG with actin in rat cell lines
As a membrane spanning protein NG2/HMPG is able to interact with molecules on
both the inside and outside of cells. In rat cell lines NG2/HMPG is expressed in a
punctate pattern on the cell surface in ordered linear arrays, which co-localise with
actin stress fibres. This is most obvious in extremely flattened cell lines, for example
Bill. Disruption of the cytoskeleton by cytochalasin D causes NG2/HMPG to
aggregate into patches, and results in an increase in the amount ofNG2/HMPG
released from the cells. No co-localisation occurs with tubulin or vimentin,
suggesting that NG2/HMPG interacts specifically with actin (Lin 1996a).
Transfection ofB28 rat cell lines, which do not endogenously express
NG2/HMPG, with NG2/HMPG cDNA results in a punctate distribution similar to
Bill cells, indicating that anchorage ofNG2/HMPG to actin occurs via an
mechanism not specific to endogenous NG2/HMPG expressing cells (Lin 1996a).
Other molecules which interact with actin in B28 cells, endogenous oc5[31 and
CD44, and transfected LI, also form linear arrays on the cell surface, which co-
localise with stress fibres. The cytoplasmic domains of these proteins and
NG2/HMPG show no similarity, indicating that they interact with actin via different
linker molecules (Lin 1996a).
B28 cells treated with colchicine undergo retraction of the cytoplasm, loss of
flattened morphology and retention of resistant tendrils. These tendrils express
NG2/HMPG, a5pl and actin, but not myosin, CD44 and LI. Chimeras of
NG2/HMPG cytoplasmic domain and LI ectodomain localise as full length
NG2/HMPG in the tendril, whereas expression of chimeras containing the
cytoplasmic domain ofLI and the ectodomain ofNG2/HMPG is restricted to the
soma. This suggests that the specific sequence of the intracellular domain determines
whether a molecule can interact with actin in the soma, or in the colchicine resistant
tendrils (Lin 1996a).
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Transfected B28 cell cultures not treated with colchicine often contain a small
population of cells which have a naturally rounded morphology in preparation for
division, or to respond to changes in the local environment (Lin 1996a). These cells
retain NG2/HMPG-positive tendrils which function as retraction fibres (Cramer
1993), and remain attached to the substratum during mitosis to provide a framework
for resulting cells to adhere to the substratum and rapidly spread (Lin 1996a).
In actively spreading B28 cells, integrin mediated binding to FN promotes
stress fibre formation with which NG2/HMPG co-localises. Electrostatic attachment
to poly-L-lysine (PLL) results in cells that are less flattened with no stress fibres, but
a dense array of actin containing projections radiating from the soma, which express
NG2/HMPG at the ends. The actin binding protein fascin is expressed by similar
radial projections in cells grown on PLL (Adams 1995). However the NG2/HMPG
positive projections are individual self contained units ofmembrane and cytoplasm
i.e. filopodia, which are distinct from, and extend beyond, the area occupied by fascin
containing lamellopodia sheets ofmembrane. NG2/HMPG-positive projections
contain a5pi integrin, but not LI, myosin or focal adhesion plaque markers vinculin
or phosphotyrosine, which are present in fascin positive projections. B28 cells
spreading and migrating on PLL are highly polarised with NG2/HMPG-positive
filopodia at one pole and fascin-positive lamellopodia at the other. Migration occurs
in the direction of the lamellopodia (Lin 1996b).
The cytoplasmic domain ofNG2/HMPG is responsible for targeting the
protein to the projections, but the exact sequence required for this specific targeting is
unknown (Lin 1996b).
The extent ofNG2/HMPG's involvement in cell spreading is unclear. Some
NG2/HMPG-positive cells do not form filopodia when grown on PLL, and
untransfected B28 cells still form these projections. For most cell lines tested, a
substrate was identified that promoted NG2/HMPG positive filopodia formation, for
example U251NG35 human glioma cell lines require PLL and FCS. This suggests
that NG2/HMPG expression in insufficient to cause filopodia formation, but in
appropriate conditions that allow formation, NG2/HMPG is preferentially associated
with them. It is unclear whether these processes are exploratory filopodia or
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retraction fibres. The fact that they are expressed by rounded up cells treated with
colchicine, and at the trailing edges ofmigrating cell, suggests that they provide a
more supportive function in allowing cells to release from the substrate and migrate.
However, they are also seen on freshly plated B28 cells grown on PLL, indicating a
function in extending cell membrane over an area not previously occupied by the cell,
i.e. filopodia. NG2/HMPG's role appears to be indirect in the formation of these
projections, and associated with integrins (Lin 1996b).
Functional Relevance ofNG2/HMPG Interaction with Actin
Actin is one of the most abundant proteins in the cell. It forms part of the
cytoskeleton, which is involved in many cellular functions, including shape
regulation, migration, mitosis and anchorage dependent growth. Actin forms an
integral part of focal adhesion plaques, which are essential in the adhesion of cells to
ECM, and transmission of signals between the inside and outside of cells. This
suggests that the association of actin and NG2/HMPG may participate in such
cellular functions.
Changes occur in the melanoma cell cytoskeleton, the amount of actin
increases in parallel with an increase in migration and metastatic ability (Gabbiani
1979). a-actinin and pi integrin expression increases in focal adhesions in
melanoma cells, which correlates with an increase in migration rate (Byers 1992).
NG2/HMPG is thought to modulate pi integrin interaction with FN in melanoma
cells (Iida 1995), and may do this by participating in focal adhesion binding to actin.
NG2/HMPG plays a role in melanoma cell spreading on FN, NG2/HMPG in rats may
also have a role in cell spreading. In rat cells actin and NG2/HMPG protein and
mRNA expression decreases throughout development with increasing age (Schmitt
1977, Nishiyama 1991a).
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1.8.2. Inhibition of rat neurite growth by NG2/HMPG
NG2/HMPG is involved in the interactions needed during nervous system
development (Dou 1994). LI, a cell adhesion glycoprotein abundant in the
developing CNS, supports neuronal cell attachment and promotes elongation in vitro.
The core protein ofNG2/HMPG purified from B49 rat cell lines inhibits rat neurite
growth on LI. Neurites grown on borders ofNG2/HMPG and LI avoid
NG2/HMPG. Ll-Ll interactions are important in CNS tissue formation (Appel
1993) and LI activation of neurite growth involves several intracellular second
message systems including regulation of intracellular pH, calcium concentration, and
tyrosine kinase activity (Williams 1994), which could be modulated by NG2/HMPG.
Developing rat neurites do not express NG2/HMPG, but do express a specific, high
affinity 280 kD cell surface receptor for NG2/HMPG whose identity is unknown
(Dou 1997). NG2/HMPG acts by binding to this receptor and altering intracellular
pathways, which results in a change in neural cell growth capacity. Pharmacological
analysis reveals that this occurs by G protein-mediated closure of calcium channels
and inhibition of adenylate cyclase, decreasing intracellular calcium and cAMP levels
and results in inhibition of neurite growth. Inhibitors of these intracellular signalling
processes reverse inhibition of neurite growth on LI caused by NG2/HMPG, but
have no effect on neurite growth on LI alone (Dou 1997) (FIGURE 1.5.). This may
occur by decreasing calcium levels, which lowers the stability of the CS in the
neurites (Kater 1994) and cAMP directly enhancing neurite outgrowth, as it does
from chick embryonic cerebral implants (Wong 1991).
Other core proteins of rat CNS CSPGs inhibit neurite growth (Cole 1991).
Developing CNS anatomy suggests that NG2/HMPG-expressing cells help keep
growing parallel fibres stacked in the molecular layer ensuring they do not stray out


























Inhibition of rat neurite growth by NG2/HMPG.
Ll-Ll interaction stimulates neurite growth. Modification of
intracellular pH, calcium concentration and tyrosine kinase
activity are signalling events implicated in the pathway
resulting in cell elongation. NG2/HMPG binding to neurite cell surface
receptors activates Gi protein inhibition of adenylate cyclase and
calcium ion channels, resulting in decreased concentrations of
intracellular calcium and cAMP, which ultimately leads to inhibition
of neurite growth. Inhibitors ofGi proteins (pertussis toxin) and agents
which increase calcium (ionomycin, BAYK8044) or cAMP
(forskolin, 8BrcAMP) block NG2/HMPG mediated inhibition of neurite
growth.
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The role ofNG2/HMPG in the reponse to CNS injury
Injury to the mature rat CNS results in a transient increase in the number of
NG2/HMPG-positive cells, concomitant with an increase in the level ofNG2/HMPG
expression by individual cells and DNA synthesis. NG2/HMPG may be involved in
the inhibition of axonal re-growth, which is limited after injury (Levine 1994).
Sections of adult rat brain contain numerous 0-2A NG2/HMPG-expressing
cells which interact with microglia. In mice with inflammatory lesions in the brain
and de-myelination, for example in conditions such as autoimmune
encephalomyelitis, NG2/HMPG-positive cells increase in number immediately
around the affected area and become closer to microglia, suggesting a functional
interaction (Nishiyama 1997).
Antibody induced de-myelination in rat spinal cord also results in an increase
in the number ofNG2/HMPG-expressing cells in the lesion area, which persist until
re-myelination. This may be important in pathological conditions caused by failure
to re-myelinate such as multiple sclerosis (Keirstead 1998). 0-2A NG2/HMPG
positive progenitor cells express PDGFa-R in vivo, suggesting that these cells can
respond to both types of growth factor, which may account for re-population of de-
myelinated lesions by these cells during re-myelination (Redwine 1997).
1.8.3. Interaction ofNG2/HMPG with PDGF a receptor
NG2/HMPG and PDGFa-R are expressed co-ordinately during early stages of rat O-
2A cell development. In vivo in the embryo the number of blood vessels and glial
cells expressing NG2/HMPG and PDGFa-R, and degree of co-localisation to cell
bodies and processes, increases until peaking at postnatal day 10. After this time
expression and co-localisation ofNG2/HMPG and PDGFa-R declines; PDGFa-R
expression is restricted to the cell bodies, while NG2/HMPG is also found on cell
processes. In the mature brain both continue to be expressed with this distribution
(Nishiyama 1996a). This closely co-ordinated expression also occurs in vitro where
the expression ofNG2/HMPG coincides with the ability of 0-2A cells to respond to
PDGF (Nishiyama 1996b). 0-2A cells initially cells express NG2/HMPG and
PDGFa-R in a co-localised manner. After differentiation into mature
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oligodendrocytes, which do not express NG2/HMPG but continue to express
PDGFa-R (Raff 1988), or differentiation into type 2 astrocytes (Raff 1983) which
do not express PDGFa-R but continue to express NG2/HMPG, neither cell type
responds to PDGF (Flart 1992). 0-2A cells treated with PDGF are maintained as O-
2A precursor cells, with a delay in the down regulation ofNG2/HMPG and
PDGFa-R, an increase in the number of cells that express both NG2/HMPG and
PDGFa-R, a higher degree of co-localisation, and a quantifiable increase in the
amount of the two molecules expressed by each cell. Antibodies against PDGFa-R
precipitate both NG2/HMPG and the receptor from 0-2A cell lysates, suggesting the
two proteins form a molecular complex or part of a complex. When the expression
ofNG2/HMPG is interfered with by incubation of cells with anti-NG2 antibody, the
amounts of both protein decrease, do not co-localise and occur in patches. Cells also
no longer proliferate as much in response to PDGF. This indicates that correct
expression ofNG2/HMPG and PDGFa-R on the cell is required for optimal
response to PDGF (Nishiyama 1996a). FIGURE 1.6.
Developing and adult rat vascular smooth muscle cells also express
NG2/HMPG, PDGF and PDGFa-R. DNA synthesis and migration ofprimary
cultures ofpostnatal rat aortic smooth muscle is stimulated by the two forms of
PDGF, AA and BB. Stimulation by PDGF AA, but not BB, is inhibited by
incubation with anti-NG2 antibody, suggesting a specific response mediated by the









Cell proliferation, migration, differentiation
Figure 1.6
Interaction ofNG2/HMPG and PDGFa R.
NG2/HMPG interaction with PDGFa-R at the cell membrane results
in optimal cell response to PDGF, which involves tyrosine
phosphorylation, changes in intracellular calcium concentration
and pH, and actin cytoskeleton re-organisation. These events
stimulate cellular functions including proliferation, migration
and differentiation.
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Mechanism ofInteraction ofNG2/HMPG with PDGFa-R
Correct expression ofNG2/HMPG on the cell surface leads to an interaction between
NG2/HMPG and PDGFa-R, enabling the cells to respond optimally to PDGF during
development. NG2/HMPG may act by presenting an activated form ofPDGF to the
receptor. It may alter receptor conformation to activate receptor ligand interaction, or
affect down stream signalling. After development the inability of the two molecules
to form a functional complex may be responsible for the lack of response to PDGF,
either due to down regulation ofNG2/HMPG expression or of other molecules which
may be required. Expression ofNG2/HMPG is not down regulated in aortic smooth
muscle cells, where it may also play a role in mature cells in injury or disease
responses.
Functional Relevance ofInteraction ofNG2/HMPG with PDGFa-R
PDGF receptors are cell surface single span transmembrane tyrosine kinases (Matsui
1989), which dimerise upon ligand binding (Heldin 1995) and initiate a number of
responses, including intracellular calcium fluxes, cytoplasmic pH changes,
rearrangement of actin stress fibres, and membrane ruffling as well as long term
responses including migration, proliferation and differentiation (Heldin 1995).
PDGF and both types of receptor are widely expressed in neural and glial cells of the
central and peripheral nervous system (Valenzuela 1994), where they play an
important role in neuronal and glial cell development as well as in the mature and
pathological CNS.
NG2/HMPG modulation ofPDGF AA responses in postnatal rat cells may be
significant as this is the period during development when the smooth muscle cells
double in number due to the autocrine activities ofPDGF (Schwartz 1990).
NG2/HMPG is also expressed in adult rat aortic smooth muscle cells, therefore it
may also be important in adult cells in the modulation of response to PDGF, for
example after tissue damage such as arterial injury or atherosclerosis when smooth
muscle cells migrate to and proliferate in the affected areas. Unpublished studies
have revealed that NG2/HMPG is expressed by rat and human proliferating smooth
muscle cells in atherosclerotic arteries (Grako 1995).
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Many transformed cells synthesise PDGF and its receptor (Heldin 1995),
which may participate in the adhesion and spreading process ofmelanoma cells to
FN, in concert with NG2/HMPG and a4pi, possibly by tyrosine phosphorylation.
NG2/HMPG is expressed in a number of different cell types, many ofwhich
are developing and proliferating. Down regulation occurs once the cells mature and
proliferation decreases, for example the rat CNS and limb (Levine 1987a, Nishiyama
1991a). NG2/HMPG is also expressed pathological states of stimulated proliferation,
for example human melanoma and rat chondrosarcoma (Bumol 1982, Leger 1991).
This indicates that NG2/HMPG may regulate cell proliferation by modulating the
action ofPDGF via interaction with PDGFa-R.
1.8.4. Functions implicated by NG2/HMPG primary structure
Protein kinase Cphosphorylation sites.
The cytoplasmic domain ofNG2/HMPG contains three threonine residues whose
surrounding sequences conform to the motif for PKC phosphorylation sites. The
family ofPKC enzymes alter the function of target proteins by phosphorylating
specific serine/threonine residues, resulting in regulation of cell functions including
proliferation and differentiation (Nishizuka 1995). The major signalling pathways in
melanocytes involve PKC. This is altered in transformed cells, PKC (3 isoforms are
lost (Yamanishi 1994), and PKC activity directly correlates with the chemotactic and
invasive abilities ofmelanoma cells (La Porta 1997, Mapelli 1994). Phorbol esters
are potent tumour promoters which act by prolonging the activation ofPKC, resulting
in the phosphorylation of a3(31 integrins (Dumont 1994). Melanoma adhesion to,
and spreading on, FN requires activation ofPKC (Smith T.W 1996b, Tang 1995) and
expression of a4p 1 integrin (Saini 1997). PKC appears to be involved in promoting
melanoma metastasis, possibly by regulating adhesion to FN in concert with
integrins.
Processing ofNG2/HMPG to a 275 kD sized protein can be increased by
activation ofPKC and decreased by inhibition of PKC, suggesting that this enzyme
may play a role in NG2/HMPG function. Direct phosphorylation ofNG2/FLMPG
may result in a change in conformation and increased susceptibility to proteases.
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PKC is thought to modulate neural cell function by regulating potassium and calcium
ion channels (Nishiyama 1995).
Insulin receptor related receptor.
The insulin receptor (IR), insulin receptor related receptor (IRRR) and the insulin¬
like growth factor receptor (IGF-1R) belong to a family of tyrosine kinase receptors
(Zhang 1992), and are widely distributed in mammals (Siddle 1992), where they are
one of the primary regulators ofmetabolism and growth. (Shier 1989).
Fifteen amino acids in the third extracellular domain ofNG2/HMPG (2050-
2064) show 40% identity with a segment of the human IRRR. In particular three
cysteine residues are conserved in NG2/HMPG, IRRR, IR and IGF-1R. In IR and
IFG-1R they are thought to form intersubunit disulphide bonds, which enable the
formation of the active heterotetrameric receptors (Shier 1989). NG2/HMPG may
have a similar conformation.
SUMMARY
NG2/HMPG appears to act in the transduction of signals from one side of the
membrane to the other. In rat cell lines, NG2/HMPG does this by interaction with
the actin cytoskeleton to influence events such as control of cell adhesion and
migration. In rat neurites, NG2/HMPG employs a number of intracellular signalling
molecules to inhibit cell growth, including Gi protein-mediated control of adenylate
cyclase and calcium ion channel activity. NG2/HMPG in 0-2A cells and smooth
muscle is involved modulating the cell's response to PDGF, and as such may be
important in the control of cell proliferation. The restricted expression of
NG2/HMPG to developing or transformed cell types, both ofwhich undergo high
rates of cell division, supports a role for this PG in stimulation ofproliferation.
Structure analysis and studies using melanoma cells indicates that signal transduction
involving NG2/HMPG may involve PKC and tyrosine kinase activation to bring
about such effects as modulation of cell adhesion, cell spreading, proliferation and
growth.
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1.9. SUMMARY AND AIMS OF THESIS
NG2/HMPG is a structurally unique transmembrane CSPG of restricted distribution.
It appears to have different roles in each of the cell types studied. It acts as a cell
surface receptor for extracellular matrix molecules such as CVI and in signal
transduction to regulate cellular processes such as proliferation, adhesion and
spreading.
Developing cells and tissues
The distribution ofNG2/HMPG in rat developing tissues, and subsequent down
regulation in adult cells (Nishiyama 1991a) suggests a role in early developmental
stages of the NG2/HMPG-expressing tissues such as brain and cartilage.
NG2/HMPG is expressed by a unique class of rat glial cells which appear early in
development, where it acts as a cell surface receptor for CVI and other ECM proteins,
and binds to the actin cytoskeleton. Inability to anchor CVI correlates with
production of a truncated NG2/HMPG, possibly mediated by PKC, suggesting a
potential regulatory mechanism for NG2/HMPG-CVI interaction. NG2/HMPG is
expressed outside the CNS in rat developing limb cartilage until the chondroblasts
differentiate, at which time NG2/HMPG expression is down regulated. CVI exhibits
a similar spatial arrangement to NG2/HMPG during development, suggesting a
function in the growth and development of the limb cartilage and arteriole smooth
muscle cells, for example mediation of cell migration, and cell-cell interactions
during cell condensation or matrix organisation.
Transformed cells
In human melanoma cells NG2/HMPG influences cell-ECM interaction, but not via
linkage with CVI as in rat cells. It modulates cellular responses to FN via inside out
regulation of a4p 1 integrin interaction with the substrate, possibly using the actin
cytoskeleton and activation of tyrosine kinases. Interaction with ECM is important in
the process of tumour metastasis, where inhibition of cell-ECM interactions is
required for detachment from the primary tumour site, and migration and re¬
attachment to the secondary site.
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Pathologicallyproliferating cells
NG2/HMPG may also regulate cell proliferation. NG2/HMPG expression is
associated with abnormally proliferating cells, for example melanoma, sarcoma,
chondrosarcoma and astrocytomas. It is also associated with pericytes in the blood
vessels ofmelanoma tumour stroma and from adult brain, and in lesions associated
with vascular proliferation, for example acute myeloid and lymphoblastic leukaemia
blasts and capillary endothelial cells of glioblastoma tumour types. In vitro rat
postnatal smooth muscle and 0-2A progenitor cells require NG2/HMPG and
PDGFa-R for optimal response to PDGF AA. All NG2/HMPG-positive cell types
express the PDGFa-R and respond to PDGF by cell division and chemotaxis. They
also retain the ability to divide throughout the life of the organism. Despite
differences in morphology, vascular smooth muscle cells, brain endothelial cells and
02A progenitor cells can still divide after the appropriate stimulus. Injury to tissue
provides such as stimulus, which promotes cell division ofNG2/HMPG expressing
cells. NG2/HMPG is therefore a marker for cells that retain stem cell-like state, or
become hyperproliferative. Expression in developing cells, transformed cells, and
cells associated with other proliferative disorders suggests NG2/HMPG may have a
role in upregulating or maintaining proliferation of cells, perhaps by regulation of the
cell response to PDGF.
Adult Cells and Tissues
Mature cell types also express NG2/HMPG, for example smooth muscle cells in the
rat aorta. The expression ofNG2/HMPG in mature CNS is upregulated after injury.
NG2/HMPG has been shown to inhibit neurite elongation stimulated by LI and LN
in vitro, suggesting a role in the guidance of growing axons and repair of damaged
tissue. The function ofNG2/HMPG is unknown, but it may act to regenerate tissues
after injury or disease by regulating cell re-growth as it does during development.
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Expression ofNG2/HMPG as two forms.
NG2/HMPG is expressed as two forms at the cell surface, which raises questions as
to which is functionally active. The core protein is responsible for interaction with
ECM proteins, including CVI and cell surface receptors in neurites (Burg 1996, Dou
1997). However, the CS GAGs are essential for the correct folding ofNG2/HMPG
that allows this direct interaction. Melanoma cell interaction with FN also requires
CS chains (Iida 1992). Purified CS interacts with FN, suggesting that CS GAGs are
responsible for mediating CSPG adhesion to this protein (Barkalow 1994). CS
GAGs play a role in neural development (Sorreli 1996), PGs such as aggrecan fail to
inhibit neurite growth after removal of CS chains (Grumet 1996). CD44 and (3-
glycan exist at the cell surface as core proteins and PG forms (Jalkanen 1988, Lopez-
Casillas 1991). CD44 mediates cell adhesion to a number ofECM proteins,
including FN. The CS rich form of CD44 interacts with FN, whereas the core protein
is incapable of binding to FN, suggesting that the CS chains mediate the interaction
(Lesley 1993).
Expression as both a CSPG and protein core may regulate the activity of
NG2/HMPG at the cell surface, however the amounts and functions of the two
different forms in different tissues has not been characterised.
Aims and objectives
Preliminary investigation reveals a role for NG2/HMPG in cell adhesion with ECM
molecules. Several ECM proteins, including CVI, have been shown to bind
NG2/HMPG purified from rat cell lines (Burg 1996). Rat chondrocytes produce
CVI, which shows a similar pattern of expression to NG2/HMPG in vivo. This
suggests that NG2/HMPG and CVI interactions may have a functional relevance in
cartilage in the developing rat (Stallcup 1990). NG2/HMPG is a receptor for CVI for
rat neural cells, therefore it is likely that it may act as a rat chondrocyte CVI receptor.
Similarly, if expressed in human cartilage NG2/FIMPG may act as a CVI receptor.
Human cartilage expresses CVI in the pericellular matrix, which is thought to
function as a link between the ECM and the cell surface, maintaining the structure of
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the tissue, and transmitting signals between the inside and outside of the cell (Poole
1992). IfNG2/HMPG is expressed in human cartilage it may mediate interactions
with CVI and play an important role in cell adhesion and regulation of chondrocyte
function, either during development or in the adult cell. NG2/HMPG may be
important in cell-ECM interactions in either normal or OA cartilage. Alternatively,
NG2/HMPG may be involved in cell adhesion to CII or FN. NG2/HMPG has
previously been shown to interact directly with CII and to modulate human
melanoma cell interaction with FN (Burg 1997, Iida 1995). FN is localised to the
pericellular matrix of human cartilage, and CII is the major collagen component of
the entire cartilage ECM (Clemmensen 1982).
The purpose of this project was to determine whether NG2/HMPG is
expressed by human fetal and adult articular chondrocytes and, if so, to determine its
biochemical structure and possible cell function. This study also aimed to compare
expression in adult normal and OA cartilage, and to investigate a potential role in the
disease process.
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2.0. MATERIALS AND METHODS.
All reagents were purchased from Sigma, Poole UK, unless otherwise stated.
Antibodies, solutions and tissues sources used in this study are listed in appendices I,
II and HI.
All work with human material and cells was carried out in a class I tissue culture
hood. Gloves, lab coat and oversleeves were worn when handling tissue. If tissue was
found to be infected the joint was abandoned and the hood fumigated.
Fetal knee joints were obtained from second trimester miscarriages. Normal and
osteoarthritic adult articular cartilage was obtained at post mortem from patellae,
tibial plateaux and femoral condyles of adult knee joints.
2.1. ASSESSMENT OF CARTILAGE FOR OSTEOARTHRITIS
Joints were assessed for the presence or absence of osteoarthritis macroscopically and
graded according to Collins (Collins 1960) (TABLE 2.1.) (PLATES 2.1a-f).
TABLE 2.1.
Collins macroscopic grading of cartilage for disease (Collins 1960)
GRADE DESCRIPTION
0 normal healthy joint with smooth cartilage
1 superficial flaking of cartilage in areas ofpressure and
movement
2 more extensive destruction of cartilage not denuding
bone
3 total loss of cartilage in one or more pressure areas and
obvious marginal osteophytes
4 complete loss of cartilage from large areas with
eburnation of bone, prominent osteophytes
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PLATE 2.1a.
Patella obtained from knee joint of 68 year old female at post mortem, showing




Femoral condyle obtained from knee joint of 68 year old female at post mortem,
showing areas ofnormal smooth cartilage (N) with no destruction and Grade 1 OA
cartilage (OA) with superficial flaking.
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PLATE 2.1c.
Tibial plateau obtained from knee joint of 68 year old female at post mortem with
areas ofnormal smooth cartilage (N) and Grade 2 OA cartilage (OA), exhibiting
destruction of superficial and deep layers.
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PLATE 2.1d.
Femoral condyle obtained from knee joint of 72 year old female at post mortem with
areas of normal smooth cartilage (N) and Grade 2 OA cartilage (OA), exhibiting
destruction of superficial and deep layers.
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PLATE 2.1e.
Femoral condyle obtained from knee joint of 58 year old male at post mortem with
areas ofnormal smooth cartilage (N) and Grade 3 OA cartilage (OA), with extensive
destruction of deep layer cartilage and exposure of bone in areas ofpressure.
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PLATE 2.1f.
Femoral condyle obtained from knee joint of 83 year old male at post mortem, with
areas of Grade 4 OA cartilage (OA), with complete loss of cartilage from large areas
of the joint and osteophyte formation (OP).
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Cartilage was also assessed microscopically following safranin-0 staining (Mankin
1971) according to TABLE 2.2 (PLATES 2.2a, b.). Tissue samples were snap
frozen in liquid nitrogen and 4 pm sections cut with a Bright cryostat. Sections were
mounted on PLL coated glass slides and fixed with acetone (Fisher Scientific,
Loughborough UK) for 20 min at -20 °C. Sections were stained with haematoxylin
blue (Fisons, USA) for 10 min, washed with water, stained for 3 min with fast green
diluted 1:5000 in water, washed in 1 % acetic acid, then stained with 0.1 % safranin-
O for 5 min. Sections were then dehydrated in ascending grades of alcohol (64 %, 74
%, absolute), cleared in xylene (Genta Medical, UK) and mounted in pertex
(Cellpath, UK).




pannus + surface irregularities 2
clefts to transitional zone 3
clefts to radial zone 4














Section ofnormal cartilage from knee joint of 53 year old male, stained with
saffanin-0 used to assess the degree of disease. Original magnification x40. Normal
cartilage exhibits strong staining ofproteoglycans with safranin-O, no disruption of
tissue structure and no cell clustering or cloning.
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PLATE 2.2b.
Section ofOA cartilage from knee joint of 89 year old female, stained with saffanin-
O used to assess the degree of disease. Original magnification x40. The OA section
exhibits a reduction uptake of safranin-O, indicating a decrease in proteoglycan
synthesis, surface irregularities and clefts, hypercellularity and cell cluster formation.
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2.2. IMMUNOHISTOCHEMISTRY
Tissue samples were snap frozen in liquid nitrogen and 4 pm sections cut with a
Bright cryostat. Sections were mounted on PLL coated glass slides, placed into slide
racks and fixed with acetone for 20 min at -20 °C. Sections were placed in Tris
buffered saline (TBS) pH 7.6 for 5 min before loading into a Shandon Sequenza
(PLATE 2.3.) Sections were incubated in 100 pi normal rabbit serum (Law hospital,
UK) diluted 1:5 in TBS for 10 min, then 100 pi primary antibody diluted optimally in
normal serum/TBS for 30 min. Sections were stained with antibodies against rat NG2
(N143.8) and HMPG (M28B5, 9.2.27). Positive controls were obtained by staining
with KZ1 (anti-CD44) and negative controls by omission of the primary antibody.
Sections were washed twice for 5 min in TBS. Biotinylated rabbit anti-mouse
secondary antibody diluted optimally in 100 pi normal serum/TBS was applied for 30
min. At this stage the avidin-biotin (AB) conjugated horse radish peroxidase (HRP)
complex (DAKO, UK) was prepared by adding one drop each of solutions A and B
to 5 ml AB buffer. Sections washed twice for 5 min in TBS, then incubated in AB-
HRP complex for 30 min. Sections were washed twice for 5 min in TBS then
staining was visualised using 100 pi diamino benzidine (DAB) substrate solution for
3 min. Sections were removed from the sequenza and washed in running tap water.
Sections were counter stained lightly in haematoxylin blue for 30 s, blued up by
dipping in Scott's tap water substitute for 30 s and dehydrated in ascending grades of
alcohol (64 %, 74 %, absolute). Sections were cleared by incubation in xylene for 5
min and mounted in pertex mountant (Cellpath, UK). Sections were examined using










The Shandon sequenza used for immunohistochemical staining of cartilage sections.
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2.3. WESTERN BLOTTING
2.3.1. Isolation and culture of chondrocytes.
Knee joints were obtained at autopsy. Articular cartilage was aseptically removed
from macroscopically normal or osteoarthritic appearing patellae, tibial plateaux and
femoral condyles of knee joints and graded macro and microscopically. Cartilage
was cut into small pieces and incubated in antimicrobial solution for 1 h (PLATE
2.4). Cartilage pieces were washed twice with phosphate buffered saline (PBS)
(Oxoid, Basingstoke UK) and sequentially digested for 30 min at 37 °C with 0.25 %
trypsin (GIBCO, Paisley UK), then for 24 h at 37 °C with 3 mg/ml collagenase. The
sample was checked for digestion by examination under the microscope. Single cells
should be clearly visible. If it was possible to see extracellular matrix around the
cells and/or the cells were still clumped together, the collagenase digestion was
repeated. The cell suspension was collected using a sterile pastette and strained
through a sterile strainer to remove undigested cartilage fragments. The cell
suspension was centrifuged at 1000 rpm, the supernatant discarded and the pellet re-
suspended in PBS. This was repeated twice more to give three PBS washes. The
cells were re-suspended in 10 ml serum-free HAMs F12 medium (GIBCO, Paisley
UK) and filtered through a 70 micron cell sieve (Falcon, Becton Dickinson UK) to
remove large cell clumps and pieces of debris. Cells were counted using a
haemocytometer and viability checked using trypan blue. Cell suspension was made
up to give lxlO5 cells/ml in HAMs F12 containing 10 % FCS (Advanced Protein
Products, West Midlands UK). Large culture flasks (Nunc, Life Technologies UK)
were seeded with 70 ml of cell suspension, medium flasks (Nunc, Life Technologies
UK) with 30 ml to give a cell density of4xl04 cells/cm2. Cells were grown for 5-10
days in monolayer culture at 37 °C in HAMs F12 medium supplemented by 10 %




Cartilage after removal from the tibial plateau and dissection. Cartilage was obtained
from a normal knee joint from a 77 year old male.
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2.3.2. Assessment of cell number and viability
A haemocytometer was washed in 74 % ethanol, rinsed under tap water and dried.
With cover slip in place 10 pi cell suspension was added to one chamber by touching
the tip of the pipette to the edge of the coverslip and allowing the chamber to fill by
capillary action. To the other chamber 10 pi of a 1:1 cell suspensiomtrypan blue was
added in the same way. The number of cells without trypan blue was assessed by
counting all the cells in the 1 mm centre square and four 1 mm corner squares. Each
square represents a total volume of 10"4 cm3, and since 1 cm3 is equal to 1 ml the
number of cells per ml is equal to the average count per square x dilution factor x
104. The total number of cells is equal to the number of cells per ml x the original
volume of fluid from which the cell sample was removed. Viability of cells was
assessed within 2 min of trypan blue addition. Cell viability (%) is equal to the total
number of viable cells (unstained with trypan blue) divided by the total number of
cells (stained and unstained) xlOO.
2.3.3. Removal of cell monolayers from tissue culture flasks
10 ml of 0.02 % EDTA in PBS per flask was warmed to 37 °C. The cell monolayers
were washed twice with PBS and then incubated with the warm EDTA/PBS for 10
min at 37°C. The flask was tapped to release cells and detachment or rounding up
was looked for using a light microscope. The cell suspension was decanted into
sterile universals, the flask rinsed with PBS and this wash added to the rest. The cell
suspensions were centrifuged at 1000 rpm for 10 min at 10 °C. The supernatant was
discarded and the cell pellet re-suspended in PBS. The centrifugation was repeated
twice, combining pellets from the same preparation into one universal. The final cell
pellet was re-suspended in a volume ofmedium appropriate for the experiment and
filtered through a 70 micron cell sieve to remove clumps. The cell number and
viability was determined to be greater than 95 % by trypan blue exclusion.
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2.3.4. Chondroitinase digestion
Cells were incubated with 1 U/ml chondroitinase ABC for 1 h at 37 °C before protein
extraction.
2.3.5. Cell lysis
Cells were centrifuged at 1000 rpm for 10 min at 10 °C. The supernatant was
discarded and the cell pellet re-suspended in 1 ml lysis buffer. The cells were
allowed to lyse on ice or at 4 °C for 30 min and then microcentrifuged at high speed
for 15 min at 4 °C. The supernatant was kept and either used immediately or frozen
at -20 °C for future use. The pellet containing nuclear debris was discarded.
2.3.6. Lowry determination of protein concentration
Bovine serum albumen (BSA) (First link, UK) standards increasing in concentration
from 0 (SI) - 400 (S8) pg/ml were set up in triplicate and vortexed. Test sample (T)
tubes were set up in triplicate by adding 5 pi sample to 195 pi 0.1 N NaOH. Blank
tubes (B) containing 200 pi NaOH were also set up in triplicate The tubes were
vortexed to mix the sample. To all tubes 1 ml of alkaline carbonate solution was
added, the tubes were vortexed and allowed to stand at room temperature for 10 min.
To each tube 100 pi Folin's reagent was added, the tubes were vortexed and allowed
to stand at room temperature for 30 min. An aliquot of 200 pi of each sample was
transferred to a 96 well tissue culture plate (Nunc, Life Technologies UK) according
to the template in TABLE 2.3., and the absorbance read on a Dynatech MR 500
microplate reader at 570 nm. The average concentration for each sample was
calculated using a standard curve ofBSA protein concentrations (GRAPH 2.1.).
73
TABLE 2.3.
Template used for Lowry determination of protein concentration
1 2 3 4 5 6 7 8 9 10
A B1 Sl.l SI.2 SI.3 Tl.l T1.2 T1.3 T9.1 T9.2 T9.3
B B2 S2.1 S2.2 S2.3 T2.1 T2.2 T2.3 T10.1 T10.2 T10.3
C B3 S3.1 S3.2 S3.3 T3.1 T3.2 T3.3 Tll.l Til.2 T11.3
D B4 S4.1 S4.2 S4.3 T4.1 T4.2 T4.3 T12.1 T12.2 T12.3
E B5 S5.1 S5.2 S5.3 T5.1 T5.2 T5.3 T13.1 T13.2 T13.3
F B6 S6.1 S6.2 S6.3 T6.1 T6.2 T6.3 T14.1 T14.2 T14.3
G B7 S7.1 S7.2 S7.3 T7.1 T7.2 T7.3 T15.1 T15.2 T15.3
H B8 S8.1 S8.2 S8.3 T8.1 T8.2 T8.3 T16.1 T16.2 T16.3
B blank wells containing NaOH
S standard wells containing BSA increasing in concentration from 0-400 pg/ml
T test wells containing protein samples
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GRAPH 2.1
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The values shown represent the mean of 3 experiments +/- SEM.
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2.3.7. Sodium Dodecyl Sulphate Poly Acrylamide Gel
Electrophoresis (SDS-PAGE)
Proteins were analysed by SDS-PAGE according to the method of Laemmeli
(Laemmeli 1970), using equipment from Bio-Rad. Glass gel plates (12 cm x 10 cm
and 12 cm x 9 cm ) and spacers were cleaned with ethanol. Glass plate sandwiches
were assembled into the clamp assembly and the unit transferred to the casting stand.
A comb was placed in between the plates and a mark made 1 cm below the edge of
the teeth. A separating gel solution was prepared of appropriate acrylamide (National
diagnostics, UK) percentage for the resolution required. The solution was mixed and
poured between the plates up to the mark using a pasteur pipette. The solution was
overlaid with distilled water and allowed to polymerise for 45 min. The water was
poured off and the gel dried with filter paper. The stacking gel solution was prepared
and poured over the separating gel to the top of the plates. A 10 or 5 well comb was
placed in the sandwich and the gel allowed to polymerise for 30 min. When
polymerised the comb was removed, the clamp assemblies removed from the casting
stand and attached to the inner cooling core. The electrode buffer was prepared from
a lOx stock by diluting 50 ml with 450 ml dfUO. The top buffer chamber was filled
with electrode buffer. Samples were prepared by adding 1 part sample to 3 parts
sample buffer and boiled for 3 min and then loaded onto the gel. The inner cooling
core was placed into the cell and electrode buffer poured into the lower chamber so
that at least 1 cm of gel was covered. The samples were electrophoresed through the
gel at a constant voltage of 200 V and stopped when the line of bromophenol blue
dye reached the bottom of the resolving gel. SDS-PAGE was carried out using a 5 %
acrylamide separating gel with a 4.5 % acrylamide stacking gel and a 3-20 %
acrylamide gradient separating gel with a 2.5 % acrylamide stacking gel.
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2.3.8. Electrophoretic transfer of proteins to nitro-cellulose
The gel assembly was removed from the gel apparatus, the glass plates separated and
the gel removed. For each gel a piece of nitro-cellulose (Amersham, UK) and two
pieces of 3MM filter paper (Whatman, UK) was cut to a size 0.5 cm bigger than the
gel. These, along with two fibre pads per gel were equilibrated in transfer buffer for
10 min. The plastic holder for the gel membrane sandwich was opened, a nylon pad
placed onto it followed by a piece of filter paper, then the gel, the nitro-cellulose, the
second piece of filter paper and finally the second fibre pad. The holder was closed
and squeezed to exclude air bubbles then placed in the blotting apparatus ensuring
that the nitro-cellulose lies between the cathode and the gel (FIGURE 2.1.). The
tank was filled with transfer buffer sufficient to cover the gel/membrane sandwich
without touching the electrodes and transfer was carried out at 100V for 1 h, using a
pre-frozen cooling unit.
FIGURE 2.1.












2.3.9. Development of blot using alkaline phosphatase
The plastic holder was removed from the blotting apparatus and opened on a flat
surface. The nitro-cellulose was removed and marked for orientation by cutting off
the top left hand corner. The nitro-cellulose was placed in 20 ml blocking solution
and incubated for 1 h at room temp or overnight at 4 °C. The blocking solution was
poured off and the membrane was washed 3 times with 20 ml TBS Tween (TBST)
with rotation. The membrane was incubated with primary anti-HMPG antibodies
M28B5 or 9.2.27, anti-FN antibody IST-4 or anti-phosphothreonine antibody diluted
optimally in 20 ml TBST for 1 h with rotation or over night at 4°C, then washed as
above. The membrane was incubated with secondary rabbit anti mouse biotinylated
antibody diluted 1:1000 in 20 ml TBST for 1 h with rotation, then washed as above.
The membrane was then incubated in AB-Alkaline phosphatase (AP) complex
(DAKO, UK) in TBST for 1 h with rotation and then washed as above. The
membrane was then incubated in AP substrate solution for 5-20 min in the dark with
rotation. The membrane was washed in distilled water.
2.3.10. Development of blot using Enhanced Chemiluminescence
(ECL)
The plastic holder was removed from the blotting apparatus and opened on a flat
surface. The nitro-cellulose was removed and marked for orientation by cutting off
the top left hand corner. The nitro-cellulose was placed in 20 ml blocking solution
(Amersham ECL kit) and incubated for 1 h at room temperature or overnight at 4 °C.
The blocking solution was poured off and the membrane was washed 3 times with 20
ml TBST with rotation. The membrane was incubated with primary antibody diluted
optimally in 20 ml TBST for 1 h with rotation or overnight at 4 °C, then washed for 5
min 3 times. The membrane was incubated with secondary rabbit anti mouse
biotinylated antibody diluted 1:1000 in 20 ml TBST for 1 h with rotation, then
washed as above. The membrane was incubated in AB-HRP complex in TBST for 1
h at room temp with rotation. The membrane was washed once for 15 min with
TBST and twice for 5 min with TBST with rotation. The proteins were then
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visualised by ECL detection. Onto one membrane 5 ml of solution A and 5 ml of
solution B (Amersham, UK) were poured and the membrane shaken gently for 1 min.
The membrane was removed, the fluid drained off and the membrane wrapped in
Saran wrap. Any air pockets were smoothed out. The blot was placed in an
autoradiography cassette and exposed to ECL hyper film (Amersham, UK) for 1 min.
The film was developed by hyperprocessor (Amersham, UK) and the blot re-exposed
as required depending on the strength of the signal.
2.3.11. Estimation of protein size
The molecular weight of proteins analysed by SDS-PAGE was determined by
comparison with proteins of known size electrophoresed on the same gel. The
proteins used for these standards are given in TABLE 2.4. (Novex, Oxon UK).
TABLE 2.4.














2.3.12. Quantification of band intensity
Equal amounts ofprotein, determined by Lowry assay, were loaded onto gels. Band
intensity was compared by densitometric analysis using Enhanced Analysis System
(EASY) computer and hardware (Herolab, Scotlab UK). A value of 100 was
assigned to the most intense band and the intensity of other bands expressed relative
to this.
2.3.13. Statistical analysis
Non parametric Mann Whitney U tests were used to determine the significance of
results. This test avoids assumptions about the underlying sample distribution and
allows comparison of data from two different populations with numerically graded
data. Significant results correspond to p values less than 0.05.
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2.4. IMMUNOPRECIPITATION
Immunoprecipitation ofNG2/HMPG was carried out as previously described
(Stallcup 1990). Chondrocytes were isolated from knee joints as described above
and cultured for 5-10 days. Cells were removed from culture flasks using PBS
containing 0.02 % EDTA and washed twice with PBS. Cells were counted and
viability determined by trypan blue exclusion. Cells in 1 ml PBS were labelled with
125I by incubation with 5 pM glucose, 24 mU glucose oxidase, 20 mU
lactoperoxidase and 200 pCi Nal125 (BDH, Lutterworth UK) at room temperature
with occasional mixing. After 20 min the reaction was stopped by the addition of 2
mM KI. The labelled cells were washed with PBS and 1 mM KI and lysed as above.
Aliquots of the extract were incubated for 2 h on ice with the primary mouse
monoclonal antibody M28B5 or 9.2.27 and immunoprecipitation accomplished by
subsequent incubation with protein A-Sepharose (Pharmacia, St. Albans UK) for 2 h
at 4 °C. The immune complexes were washed three times with PBS containing 0.2
% NP-40 and 0.02 % SDS, then dissolved in electrophoresis sample buffer. SDS-
PAGE was performed using gels with a stacking gel of 2.5 % acrylamide and a
separating gel with a gradient of 3-20 % acrylamide, dried with Dry Ease gel drying
system (Novex, Oxon UK) and used for autoradiography with Kodak film (Kodak,
UK). Negative controls were obtained by omission ofprimary antibody and labelling
efficiency was assessed by omission ofprotein A-Sepharose.
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2.5. IMMUNOFLUORESCENCE
2.5.1. Single immunofluorescent staining of cultured chondrocytes
Chondrocytes from normal and OA adult articular cartilage were cultured at a
concentration of 5xl04/ml as a monolayer for 5-10 days on 53 mm tissue culture
grade petri dishes (Nunc, Life Technologies UK). Non specific background was
blocked by incubation with normal rabbit serum diluted 1:10 in 1 ml TBS for 1 h.
The serum was tapped off and the cells were incubated for 30 min with primary
antibody diluted optimally in 1 ml HAMS F12 medium with 2 % FCS. Cases were
stained with monoclonal antibodies against HMPG (M28B5 and 9.2.27). The
negative control was obtained by omission ofprimary antibody. The cells were
washed with 2 ml HAMs F12 medium with 2 % FCS three times for 5 min with
rotation. The cells were incubated with rabbit anti-mouse fluorescein isothiocyanate
(FITC) labelled secondary antibody diluted 1:100 in 1 ml HAMS F12 medium with 2
% FCS for 30 min in the dark. The cells were washed with 2 ml PBS three times for
5 min with rotation. The cells were then fixed using 1 ml of a 1:1 methanol/acetone
mixture per dish for 5 min at -20 °C. Coverslips were cleaned with ethanol and
allowed to air dry, then the cells were mounted using Citifluor mountant (UKC
Chem. lab., UK) and the edges of the coverslip secured by painting with clear nail
varnish. The cells were visualised using a Zeiss axiophot fluorescence microscope.
2.5.2. Double immunofluorescent staining of cultured chondrocytes
using mono and polyclonal antisera.
Chondrocytes from normal adult articular cartilage were cultured at a concentration
of 5xl04/ml as a monolayer for 5-10 days on 53 mm tissue culture grade petri dishes.
The cells were incubated for 1 hour with normal goat serum diluted 1:10 in TBS,
then simultaneously with primary mouse monoclonal anti-HMPG M28B5 and rabbit
polyclonal PDGFa-R, FN, CII or CVI antibodies diluted optimally in 1 ml FIAMs
F12 medium with 2 % FCS, for 30 min RT. The cells were washed with 2 ml HAMs
F12 medium with 2 % FCS three times for 5 min with rotation. The cells were
incubated simultaneously with appropriately labelled secondary antibodies (goat anti
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mouse tetramethyl rhodamine thiocyanate (FITC) conjugate and goat anti rabbit
TRITC conjugate for FN, CII and CVI, and goat anti mouse TRITC conjugate and
goat anti rabbit FITC conjugate for PDGFa-R) diluted 1:100 in 1 ml HAMS F12
medium with 2 % FCS for 30 min in the dark. The cells were washed with 2 ml PBS
three times for 5 min with rotation. The cells were then fixed using 1 ml of a 1:1
methanol/acetone mixture per dish for 5 min at -20 °C. Coverslips were cleaned with
ethanol and allowed to air dry, then the cells were mounted using Citifluor mountant
and the edges of the coverslip secured by painting with clear nail varnish. The cells
were visualised using a Zeiss axiophot fluorescence microscope.
2.5.3. Double immunofluorescent staining of cultured chondrocytes
using rhodamine phalloidin and monoclonal antisera
Chondrocytes from normal adult articular cartilage were cultured at a concentration
of 5xl04/ml as a monolayer for 5-10 days on 53mm tissue culture grade petri dishes.
The cells were then fixed using 1 ml of a 1:1 methanol/acetone mixture per dish for 5
min at -20 °C. The cells were permeabilised in 1 ml 0.1 % Triton x-100 in TBS for 5
min. The cells were washed using 2 ml TBS with rotation three times for 5 min. The
cells were treated with rhodamine conjugated phalloidin diluted 1:20-50 with 1 ml
TBS for 30 min This and all subsequent steps were carried out in the dark. The cells
were washed using 2 ml TBS at room temp with rotation three times for 5 min. Non
specific background was blocked by incubation with normal rabbit serum diluted
1:10 in 1 ml TBS for 1 h. The serum was tapped off and the cells were incubated
overnight at 4 °C with primary anti-HMPG monoclonal antibody M28B5 diluted
optimally in 1 ml TBS. The cells were washed with 2 ml TBS three times for 5 min
with rotation. The cells were incubated with rabbit anti-mouse FITC labelled
secondary antibody diluted 1:100 in 1 ml TBS for 30 min in the dark. The cells were
washed with 2 ml TBS three times for 5 min with rotation. Coverslips were cleaned
with ethanol and allowed to air dry, then the cells were mounted using Citifluor
mountant and the edges of the coverslip secured by painting with clear nail varnish.
The cells were visualised using a Zeiss axiophot fluorescence microscope.
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2.6. CELL ADHESION
2.6.1. Methylene blue cell adhesion assay.
96 well tissue culture flat bottomed plates were coated with 10 pg/ml ofECM
proteins FN, CII and CVI in 50 pi PBS, overnight at 4 °C. Wells were blocked with
100 pi filter sterilised BSA at 2 mg/ml in PBS for 1 h at 37 °C. Chondrocytes were
isolated from normal and OA areas of adult knee joints as described above and
cultured for 5-10 days. Cells were removed from flasks as above, centrifuged and
extraction medium removed. After 2 washes in PBS, cells were re-suspended in 10
ml serum-free HAMs F12 medium. The cell suspension was filtered through a 70
micron cell sieve. The cell number and viability was determined. The cell suspension
was made up to give 1.0 x 10s cells per ml in serum-free HAMs F12 medium. 100 pi
of cells were transferred to respective wells in test plate and incubated at 37 °C, for 3
hours. Wells were washed gently twice with PBS using a multichannel pipette,
taking care not to touch or scrape the bottom of the wells with the tips as this could
remove adherent cells. 100 pi of 4 % formalin in PBS was added to each well and
cells allowed to fix for 1 h. The plate was centrifuged at 1000 lpm for 5 min to
ensure that all adherent cells remain in wells and the formalin discarded. 100 pi of
pre-filtered 1 % methylene-blue in distilled water was added to each well for 30 min.
The plate was washed several times in distilled water to remove excess blue dye. 100
pi of 0. IN HC1 in distilled water was added to each well for 5 min and mixed
thoroughly, ensuring all particulate matter was in even solution. The plate was read
at 630 nm. The number of adherent cells is proportional to the amount of dye bound
which is proportional to absorbance at 630 nm (GRAPH 2.2.). All experiments were
carried out in triplicate.
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GRAPH 2.2.
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Chondrocytes were isolated from normal areas of articular cartilage obtained from
the tibial plateaux and femoral condyles of 1 female (age 77 years) and 2 males
(median age 72 years, range 58-86) and from OA areas of articular cartilage obtained
from the tibial plateaux and femoral condyles of 2 females (median age 68, range 67-
71 years) and 1 male (age 58 years). All experiments were carried out in triplicate.
The number of adherent cells is proportional to the amount of dye bound which is




The cell suspension was pre-incubated with anti-HMPG antibody M28B5, anti-pi
integrin antibodies TS2/16 and P4C10 and irrelevant anti-CD3 antibody for 30 min at
4 °C before addition to the 96 well plate.
2.6.3. Inhibitors
The cell suspension was pre-incubated with inhibitors for 30 min at 37 °C. The
inhibitors were used at the following concentrations: genistein (gen) 40 pM,
staurosporine (st) 2xlO"6M, cytochalasin D (cd) 1x10~6M, pertussis toxin (pt) lxl0~5
M. Cells were then incubated with antibody for 30 min at 37 °C before addition to
the 96 well plate.
2.6.4. Statistical analysis
The variance of the two groups was assessed by comparing the F ratio of the standard
deviations for each pair of values. If the variance of the two groups was not
significantly different, the Student pooled variance T test was used to compare the
means of two groups of data, with small sample numbers. If there was a significant
difference between the standard deviations of the two groups, the non parametric
Mann Whitney U test was used to investigate the significance of results between
groups, as no inferences are made about the population from which the sample was
taken and analysis of numerically graded data is possible. Significant results
correspond to p values less than 0.05.
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2.7. TYROSINE PHOSPHORYLATION
2.7.1. Stimulation of chondrocytes.
Tissue culture 84 mm petri dishes (Nunc, Life Technologies UK) were coated with
10 pg/ml FN or CVI overnight at 37 °C. Non specific binding sites were blocked
with 1 mg/ml BSA for 3 h at 37 °C. Dishes to capture antibody were pre-coated with
rabbit anti-mouse IgG at a dilution of 1:500 in PBS overnight at 37 °C. Antibodies
TS2/16, KZ1 or M28B5 were added at 10 pg/ml for 3 h at 37 °C and then the plates
were blocked with BSA as above. 5-10 day old chondrocytes taken from normal
adult articular cartilage were removed from flasks, centrifuged and washed twice in
PBS. Cells were re-suspended in 10 ml serum-free F12 medium, counted and
viability determined to be greater than 95% by trypan blue exclusion. Ixl06/ml cells
were plated onto the coated petri dishes and allowed to adhere at 37 °C for specified
periods of time, before protein extraction for assessment of protein tyrosine
phosphorylation.
2.7.2. Assessment of protein tyrosine phosphorylation
Cells were lysed by addition of 0.5 ml 2x lysis buffer for 20 min at 4 °C. Insoluble
material was removed by centrifugation, lysates were transferred to microcentrifuge
tubes and microcentrifuged for 15 min at high speed at 4 °C. Supernatants were
dissolved in electrophoresis sample buffer and SDS-PAGE performed using slab
gels with a gradient of 3-20 % acrylamide. Proteins were transferred to nitro¬
cellulose and incubated sequentially with primary mouse monoclonal anti-
phosphotyrosine antibody, followed by biotinylated rabbit anti-mouse
immunoglobulins then AP-conjugated AB complex. The colour development
substrates 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and nitroblue tetrazolium
(NBT) were used as visualising reagents. Alternatively anti-phosphotyrosine
antibody directly conjugated to HRP was incubated with the nitro-cellulose at 1:1000
in 20 ml TBST for 1 h. The membrane was washed once for 15 min with TBST and




Raw data can be found in appendix IV
3.1. EXPRESSION OF NG2/HMPG IN HUMAN CARTILAGE IN
VIVO
3.1.1. Immunohistochemistry
NG2/HMPG expression in human cartilage was assessed by immunohistochemistry.
Samples of normal articular cartilage were obtained from the patellae, tibial plateaux
and femoral condyles of 1 female (age 67 years) and 7 males (median age 71 years,
range 53 - 88). Samples of osteoarthritic articular cartilage were obtained from the
patellae, tibial plateaux and femoral condyles of 13 males (median age 71 years,
range 53 - 88). Fetal knee joints were obtained from 10 second trimester
miscarriages (median age 17 weeks, range 14-20 weeks). NG2/HMPG was identified
in both fetal and adult chondrocytes (TABLE 3.1.).
TABLE 3.1.
Immunoreactivity of human cartilage with anti-NG2/HMPG antibodies.
All cases of fetal cartilage and cartilage from normal and OA adult joints showed
strong immunostaining.











All cells in all cases of fetal cartilage showed similar staining patterns (PLATES
3.1a-f.). In each of 10 cases, chondrocytes in articular, epiphyseal and growth plate
cartilage were strongly positive with antibodies against NG2 (N143.8) and HMPG
(9.2.27, M28B5). Similarly, in cartilage from normal (8 cases) (PLATE 3.2a.) and
osteoarthritic (13 cases) (PLATE 3.2b.) joints, strong immunostaining of
chondrocytes was seen. There was no difference in immunoreactivity of sections
removed from adult donors of different age or sex, from different areas of the knee
joint (femoral condyle, tibial plateau or patella) or in chondrocytes at different
positions within the cartilage (superficial or deep layer). In normal and OA cartilage
the staining appears to be localised to the cell surface. In OA cartilage single
chondrocytes and cell clusters both stain for NG2/HMPG.
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PLATE 3.1a.
Articular cartilage from second trimester fetal knee joint stained with anti-HMPG
antibody 9.2.27, showing strong immunoreactivity in all cells. Identical results were
obtained with anti-HMPG antibody M28B5 and anti-NG2 antibody N143.8. Original
magnification x50.
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PLATE 3.1b.
Articular cartilage from second trimester fetal knee joint negative control, showing
no immunoreactivity in the absence of antibody. Original magnification x50.
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PLATE 3.1c.
Epiphyseal cartilage from second trimester fetal knee joint stained with anti-HMPG
antibody 9.2.27, showing strong immunoreactivity in all cells. Identical results were
obtained with anti-HMPG antibody M28B5 and anti-NG2 antibody N143.8. Original
magnification x50.
PLATE 3.Id.
Epiphyseal cartilage from second trimester fetal knee joint negative control, showing
no immunoreactivity in the absence of antibody. Original magnification x50.
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PLATE 3.1e.
Growth plate cartilage from second trimester fetal knee joint stained with anti-HMPG
antibody 9.2.27, showing strong immimoreactivity in all cells. Identical results were















Growth plate cartilage from second trimester fetal knee joint negative control,
showing no immunoreactivity in the absence of antibody. Original magnification x50.
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PLATE 3.2a.
Section of normal articular cartilage from knee joint of 67 year old female,
immunostained with anti-HMPG antibodyM28B5, showing NG2/HMPG
localisation at the cell surface. Identical results were obtained with anti-HMPG
antibody 9.2.27 and anti-NG2 antibody N143.8. Original magnification x50.
PLATE 3.2b.
Section ofOA cartilage from knee joint of 71 year old male, immunostained with
anti-HMPG antibody M28B5, showing NG2/HMPG positive cell clusters. Identical
results were obtained with anti-HMPG antibody 9.2.27 and anti-NG2 antibody
N143.8. Original magnification x50.
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3.1.2. Quantification of immunohistology
In normal cartilage the vast majority of chondrocytes were positive, but in OA
cartilage a number of chondrocytes were found to be negative or showed only weak
staining at standard dilutions of the antibodies used. To identify whether there was
any difference in immunoreactivity of chondrocytes in normal and OA cartilage with
anti-NG2/HMPG antibodies, sections were immunostained over a range of antibody
dilutions. Samples of normal articular cartilage were obtained from the patellae,
tibial plateaux and femoral condyles of 1 female (age 67 years) and 10 males (median
age 71 years, range 53 - 88). Samples ofmild osteoarthritic cartilage were obtained
from the patellae, tibial plateaux and femoral condyles of 4 males (median age 61
years, range 53 - 69), samples ofmoderate osteoarthritic cartilage were obtained from
the patellae, tibial plateaux and femoral condyles of 6 males (median age 64 years,
range 53 - 74), and samples of severe osteoarthritic cartilage were obtained from the
patellae, tibial plateaux and femoral condyles of 3 males (age 88 years). The results
show that immunoreactivity is maintained in normal cartilage at lower dilutions than
in OA cartilage (TABLE 3.2.). This suggests that expression ofNG2/HMPG is
lower in OA chondrocytes than normal chondrocytes or that antibody binding is
restricted in sections ofOA cartilage. There appeared to be no difference in
immunoreactivity in sections removed from adult donors of different age and sex,
from different areas of the knee joint (femoral condyle, tibial plateau or patella), in
chondrocytes at different positions within the cartilage (superficial or deep layer) or
single cells compared to clusters of cells in OA samples.
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TABLE 3.2.
Immunoreactivity of chondrocytes in normal and osteoarthritic human cartilage over
a range of anti-HMPG antibody dilutions.






L5 1:20 1:40 1:70
++ + - ++ + - ++ + - ++ + -
Normal (11) 11 0 0 0 11 0 0 10 1 0 3 8
OA
Mild (4) 4 0 0 0 4 0 0 3 1 0 0 4
Moderate (6) 3 3 0 0 5 1 0 0 6 0 0 6
Severe (3) 2 1 0 0 3 0 0 1 2 0 0 3
++ majority of cells stain positive




This is the first description ofNG2/HMPG in human cartilage. It is not lost during
maturation as in rat chondrocytes, but continues to be expressed in fully
differentiated cells. It is also expressed by chondrocytes isolated from both normal
and OA cartilage. Expression may be down regulated in chondrocytes from OA
cartilage compared to chondrocytes from normal cartilage, or the NG2/HMPG
epitope may become less accessible. This may be either as a result of a change in
conformation or masking by interaction with another protein in OA cartilage.
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3.2. EXPRESSION OF NG2/HMPG IN HUMAN
CHONDROCYTES - IN VITRO
3.2.1. Western blotting
It has been shown previously that NG2/HMPG is expressed by rat cell lines and
human melanoma cells as both a CS rich PG ofmolecular weight greater than 400
kD, and a CS unmodified core protein which migrates at 250 kD (Bumol 1982,
Stallcup 1990). Western blotting was carried out to establish whether the molecule
expressed by human articular chondrocytes identified by histology has similar
biochemical properties. Chondrocytes were isolated from normal cartilage obtained
from the tibial plateaux, femoral condyles and patellae of 3 females (median age 71
years, range 66 - 75) and 9 males (median age 62 years, range 46 - 78).
Chondrocytes were isolated from osteoarthritic cartilage obtained from the tibial
plateaux, femoral condyles and patellae of 1 female (age 66 years) and 4 males
(median age 64 years, range 50 - 78). Cells were lysed and the constituent proteins
analysed by SDS PAGE and western blotting using two anti-HMPG monoclonal
antibodies. Results with both antibodies were identical. Immunoblotting of extracts
from untreated chondrocytes showed a smeared component ofmolecular weight
greater than 400 kD and a faint band at 250 kD (PLATE 3.3.). When chondrocytes
were incubated with chondroitinase ABC before protein extraction the 250 kD
protein became predominant (PLATE 3.3.). This was seen in chondrocytes from
both normal and OA cartilage. There is no difference in results from experiments
using chondrocytes removed from donors of different age and sex or from different





Western blot of lysates extracted from chondrocytes isolated from normal articular
cartilage from the femoral condyle of a 78 year old male, probed with anti-HMPG
antibody M28B5. Identical results were seen with anti-HMPG antibody 9.2.27.
Without chondroitinase ABC digestion (-cABC) a smeared component ofmolecular
weight greater than 400 kD and a faint band at 250 kD are visible. The 250 kD





Western blot of lysates extracted from chondrocytes isolated from OA articular
cartilage from the femoral condyle of a 50 year old male, probed with anti-HMPG
antibody M28B5. Identical results were seen with anti-HMPG antibody 9.2.27.
Without chondroitinase ABC digestion (-cABC) a smeared component ofmolecular
weight greater than 400 kD and a faint band at 250 kD are visible. The 250 kD
protein becomes predominant upon digestion with chondroitinase ABC (+cABC).
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3.2.2. Densitometry
To investigate whether chondrocytes isolated from normal cartilage express more
NG2/HMPG than chondrocytes isolated from OA cartilage in vitro, equal amounts of
total protein from extracts of cells were loaded onto gels. Chondrocytes were
isolated from normal and OA articular cartilage obtained from the tibial plateaux and
femoral condyles of 1 female (age 66 years) and 2 males (median age 70 years, range
61-78). After detection on western blots with anti-HMPG antibody M28B5, the
intensity of each protein band was analysed. Quantitation of band intensity suggests
that significantly less NG2/HMPG is present in chondrocytes isolated from OA
cartilage compared to normal cartilage, hi contrast FN expression is markedly
upregulated in OA cartilage compared to normal cartilage (GRAPH 3.1.).
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GRAPH 3.1a.
Relative band intensities ofNG2/HMPG from western blots of chondrocyte lysates.
The band intensities ofNG2/HMPG CSPG and core protein from untreated cells (-
cABC) and core protein from cells treated with chondroitinase ABC (+cABC) are
significantly greater in lysates of chondrocytes isolated from normal cartilage
compared to OA cartilage. The values represent the mean of 3 experiments +/-the
standard error of the mean (SEM).
*




















Relative band intensities ofFN from western blots of chondrocyte lysates. The band
intensity ofFN is significantly greater in lysates of chondrocytes isolated from OA
cartilage compared to normal cartilage. The values shown represent the mean of 3
experiments +/- SEM.
*
p <0.01 (Mann Whitney U Test)
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3.2.3. Threonine phosphorylation
Analysis of the primary structure ofNG2/HMPG reveals three threonine residues,
which together with surrounding amino acids form, potential PKC phosphorylation
sites (Nishiyama 1991b, Pluschke 1996). Chondrocytes were isolated from normal
articular cartilage obtained from the tibial plateaux and femoral condyles of 2 females
(median age 70 years, range 65 - 74) and 3 males (median age 64 years, range 50 -
77). Western blots of chondrocyte lysates analysed with anti-phosphothreonine
antibodies show that a wide range of proteins are phosphorylated on threonine,
including one which migrates at 250 kD (PLATE 3.4.). The profile of proteins that
are phosphorylated on threonine varies between samples, however the 250 kD protein
is consistently phosphorylated in all samples. There is no difference in results from
experiments using chondrocytes removed from donors of different age and sex or
from different areas of the knee joint (femoral condyle, tibial plateau or patella).
This supports the theory that NG2/HMPG may contain potential phosphorylation
sites. Immunoprecipitation ofNG2/HMPG before detection with anti-
phosphothreonine antibodies will determine whether it is phosphorylated. Further




Western blot of chondrocyte lysates isolated from normal cartilage from the femoral
condyle of a 74 year old female, probed with anti-phosphothreonine antibodies. A
wide range ofproteins are phosphorylated on threonine residues including one with a
molecular weight of 250 kD.
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SUMMARY
NG2/HMPG is expressed by human articular chondrocytes in culture. Both the
CSPG and the unmodified core protein are simultaneously expressed in chondrocytes
isolated from both normal and OA cartilage. Lower band intensities of both the
CSPG and unmodified core protein are detected in western blots using chondrocytes
extracted from OA cartilage. This evidence supports the immunohistochemical data
which suggests that less NG2/HMPG is expressed by OA cartilage.
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3.3. FUNCTION OF NG2/HMPG IN HUMAN CHONDROCYTES
- INTERACTION WITH ECM
The best characterised interaction ofNG2/HMPG is that with CVI. Anti-NG2
antibodies co-precipitate CVI and NG2 from rat cell lines, and the two proteins co-
localise on the cell surface (Stallcup 1990). Rat cell lines exist which do not express
NG2/HMPG and these cells secrete CVI from the cell surface (Nishiyama 1993).
Transfection with NG2/HMPG cDNA results in NG2/HMPG expression by these
cells and retention ofCVI at the cell surface (Nishiyama 1993). Direct binding
assays show that NG2/HMPG core protein interacts with CVI, indicating that
NG2/HMPG acts as a cell surface receptor for CVI via a direct interaction between
the two proteins (Burg 1996). Evidence also suggests that NG2/HMPG plays a role
in human melanoma cell interaction with FN (Iida 1995). To attempt to demonstrate
whether NG2/1TMPG in human articular chondrocytes interacts with proteins of the
ECM, the following experimental procedures were used.
3.3.1. Immunoprecipitation
Immunoprecipitation was used to detect whether NG2/HMPG is closely associated
with any molecules at the surface of chondrocytes. Chondrocytes were isolated from
normal articular cartilage obtained from the tibial plateaux and femoral condyles of 2
females (median age 74 years, range 56 - 89) and 2 males (age 74 years).
Immunoprecipitation ofNG2/HMPG from normal adult chondrocytes with M28B5
resulted in a single band ofmolecular weight 250 kD (PLATE 3.5.). There is no
difference in results from experiments using chondrocytes removed from donors of








Autoradiograph showing band obtained after immunoprecipitation with protein A
sepharose and anti-HMPG antibody M28B5 from radiolabeled chondrocyte lysates
isolated from normal cartilage from the femoral condyle of a 74 year old male. No




Immunofluorescence was used to study the distribution ofNG2/HMPG at the
chondrocyte cell surface and compare it to that ofECM proteins, in order to detect
any co-localisation. Chondrocytes were isolated from normal articular cartilage
obtained from the tibial plateaux and femoral condyles of 6 females (median age 72
years, range 59 - 84) and 8 males (median age 65 years, range 40 - 90).
Chondrocytes were isolated from OA articular cartilage obtained from the tibial
plateaux and femoral condyles of 2 females (median age 60 years, range 59-61) and
3 males (median age 69 years, range 61 - 77). In chondrocytes isolated from normal
adult cartilage in vitro NG2/HMPG was distributed in a punctate pattern (PLATE
3.6a.) similar to that described previously in human melanoma and rat cell lines
(Bumol 1984, Stallcup 1984). Identical localisation was seen in chondrocytes
isolated from OA adult cartilage (PLATE 3.6b.). The immunolocalisation of
NG2/HMPG was compared to that of a number of putative extracellular ligands by
double immunofluorescence staining. Chondrocytes were isolated from normal
articular cartilage obtained from the tibial plateaux and femoral condyles of 2 females
(median age 76 years, range 67 -84) and 1 male (age 82 years). The
immunolocalisation ofNG2/HMPG was different from that of a number of putative
extracellular ligands, including FN, CII and CVI which are distributed in a fibrillar
pattern at the cell surface (PLATES 3.7a-f.). There is no difference in results from
experiments using chondrocytes removed from donors of different age and sex or
from different areas of the knee joint (femoral condyle, tibial plateau or patella).
SUMMARY
No direct interaction between NG2/HMPG and CVI has been demonstrated in
chondrocytes using immunoprecipitation and immunofluorescence, as has previously
been detected in rat cell lines (Stallcup 1990), nor does NG2/HMPG appear to co-




Staining of chondrocytes isolated from normal cartilage obtained from the femoral
condyle of a 90 year old male with anti-HMPG antibody M28B5 shows that
NG2/HMPG is distributed in a punctate pattern. Identical results were obtained




Staining of chondrocytes isolated from OA cartilage obatined from the femoral
condyle of a 59 year old female with anti-HMPG antibody M28B5 shows that
NG2/HMPG is distributed in a punctate pattern. Identical results were obtained
using anti-HMPG antibody 9.2.27.
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PLATE 3.6c.
Negative control obtained by omission ofprimary antibody. No immunoreactivity is
observed in the absence ofantibody in chondrocytes isolated from normal cartilage
isolated from the femoral condyle of a 90 year old male.
Ill
PLATES 3.7a-f.
Double immunofluorescent localisation ofNG2/HMPG and ECM proteins associated
with chondrocytes.
Chondrocytes were isolated from normal cartilage obtained from the femoral condyle
of 82 year old male showing that NG2/HMPG is distributed in a punctate pattern,






3.3.3. Cell Adhesion assays
Adhesion assays were used to characterise chondrocyte adhesion to ECM proteins
FN, CII and CVI, and to study the effect of anti-HMPG antibodies on this interaction.
Chondrocyte adhesion to ECMproteins.
Chondrocytes extracted from normal and OA cartilage were allowed to adhere to
ECM proteins FN, CII and CVI. Chondrocytes were isolated from normal cartilage
obtained from the tibial plateaux and femoral condyles of 2 females (median age 71
years, range 65 - 77) and 2 males (median age 67 years, range 58 - 76) and from OA
cartilage obtained from the tibial plateaux and femoral condyles of 3 females (median
age 68 years, range 65 - 71) and 1 male (age 58 years). All experiments were carried
out in triplicate. Non specific binding to BSA occurred at low levels. Both
chondrocytes isolated from normal and OA cartilage adhere to FN, CII and CVI.
There was no significant difference in the adhesion of chondrocytes to either FN, CII
or CVI. There was no significant difference in the adhesion of chondrocytes isolated







Adhesion of chondrocytes extracted from normal and OA cartilage to FN, CII and
CVI.
The values shown represent the mean of 4 experiments carried out in triplicate +/-
SEM. There is no significant difference in the adhesion of chondrocytes isolated
from normal cartilage to either FN, CII or CVI. Likewise there is no significant
difference in the adhesion of chondrocytes isolated from OA cartilage to either FN,
CII or CVI. (Mann WhitneyU Test). There is no significant difference in the
adhesion of chondrocytes isolated from normal cartilage compared to the adhesion of
chondrocytes isolated from OA cartilage, to FN, CII or CVI (Mann WhitneyU Test).
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Effect ofantibodies.
Anti-HMPG antibodies have been shown to modulate melanoma cell adhesion and
spreading on FN (Iida 1995). The effect of anti-HMPG antibody M28B5 on
chondrocyte adhesion to FN, CII and CVI was studied. Monoclonal antibodies
against pi integrin were used as positive controls. P4C10 inhibits attachment of cells
to ECM proteins (Carter 1990) and TS2/16 stimulates cell attachment to ECM
ligands (Arroyo 1992). Chondrocytes were isolated from normal articular cartilage
obtained from the tibial plateaux and femoral condyles of 1 female (age 77 years) and
2 males (median age 71 years, range 65 - 77). Chondrocytes were isolated from
osteoarthritic articular cartilage obtained from the tibial plateaux and femoral
condyles of 1 female (age 77 years) and 2 males (median age 57 years, range 49 - 65).
In the absence of antibody chondrocytes isolated from normal cartilage adhere
to FN. P4C10 significantly inhibits this adhesion by 53 %. Treatment of cells with
TS2/16 results in a small but not statistically significant (7 %) stimulation of
adhesion. Treatment of cells with M28B5 results in a small but not statistically
significant (13 %) stimulation of adhesion. (GRAPH 3.3.)
In the absence of antibody chondrocytes isolated from normal cartilage adhere
to CII. P4C10 significantly inhibits this adhesion by 59 %. Treatment of cells with
TS2/16 results in a small but not statistically significant (7 %) stimulation of
adhesion. Treatment of cells with M28B5 results in a small but not statistically
significant (15 %) stimulation of adhesion. (GRAPH 3.4.)
hi the absence of antibody chondrocytes isolated from normal cartilage adhere
to CVI. P4C10 significantly inhibits this adhesion by 61 %. Treatment of cells with
TS2/16 results in a significant (35 %) stimulation of adhesion. Treatment of cells
with M28B5 results in a significant (26 %) stimulation of adhesion. (GRAPH 3.5.)
The adhesion of chondrocytes isolated from OA cartilage to ECM molecules FN, CD
and CVI was studied in the same way. P4C10 significantly inhibited adhesion to FN
by 37 %, to CII by 65 % and to CVI by 59 %. TS2/16 and M28B5 have a small but




Adhesion of chondrocytes to FN - effect of anti pi integrin and HMPG antibodies.
The adhesion of chondrocytes isolated from normal cartilage to FN in the absence of
antibodies was compared to adhesion of cells treated with monoclonal antibodies for
30 min at 4°C. The values shown represent the mean of 3 experiments carried out in
triplicate +/- SEM.
In the absence of antibody chondrocytes adhere to FN. P4C10 significantly inhibits
this adhesion. Treatment of cells with TS2/16 and M28B5 results in a small but not
statistically significant stimulation of adhesion to FN.
*
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GRAPH 3.4.
Adhesion of chondrocytes to CII - effect of anti pi integrin and HMPG antibodies.
The adhesion of chondrocytes isolated from normal cartilage to CII in the absence of
antibodies was compared to adhesion of cells treated with monoclonal antibodies for
30 min at 4°C. The values shown represent the mean of 3 experiments carried out in
triplicate +/- SEM.
In the absence of antibody chondrocytes adhere to CD. P4C10 significantly inhibits
this adhesion. Treatment of cells with TS2/16 and M28B5 results in a small but not
statistically significant stimulation ofadhesion to CEL.
*
p <0.05 (Mann Whitney U Test)
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GRAPH 3.5.
Adhesion of chondrocytes to CVI - effect of anti pi integrin and HMPG antibodies.
The adhesion of chondrocytes isolated from normal cartilage to CVI in the absence of
antibodies was compared to adhesion of cells treated with monoclonal antibodies for
30 min at 4°C. The values shown represent the mean of 3 experiments carried out in
triplicate +/- SEM.
In the absence of antibody chondrocytes adhere to CVI. P4C10 significantly inhibits
this adhesion. Treatment of cells with TS2/16 and M28B5 results in a significant
stimulation of adhesion to CVI
*
p <0.05 (Mann Whitney U Test)
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GRAPH 3.6.
Adhesion of chondrocytes to FN - effect of anti pi integrin and HMPG antibodies.
The adhesion of chondrocytes isolated from OA cartilage to FN in the absence of
antibodies was compared to adhesion ofcells treated with monoclonal antibodies for
30 min at 4°C. The values shown represent the mean of 3 experiments carried out in
triplicate +/- SEM.
In the absence of antibody chondrocytes adhere to FN. P4C10 significantly inhibits
this adhesion. Treatment of cells with TS2/16 and M28B5 results in a small but not
statistically significant stimulation of adhesion to FN.
*
p <0.05 (Mann Whitney U Test)
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GRAPH 3.7.
Adhesion of chondrocytes to C1I - effect of anti pi integrin and HMPG antibodies.
The adhesion of chondrocytes isolated from OA cartilage to OH in the absence of
antibodies was compared to adhesion of cells treated with monoclonal antibodies for
30 min at 4°C. The values shown represent the mean of 3 experiments carried out in
triplicate +/- SEM.
In the absence of antibody chondrocytes adhere to CII. P4C10 significantly inhibits
this adhesion. Treatment of cells with TS2/16 and M28B5 results in a small but not
statistically significant stimulation of adhesion to CII.
*
p <0.05 (Mann Whitney U Test)
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GRAPH 3.8.
Adhesion of chondrocytes to CVI - effect of anti p 1 integrin and HMPG antibodies.
The adhesion of chondrocytes isolated from OA cartilage to CVI in the absence of
antibodies was compared to adhesion of cells treated with monoclonal antibodies for
30 min at 4°C. The values shown represent the mean of 3 experiments carried out in
triplicate +/- SEM.
In the absence of antibody chondrocytes adhere to CVI. P4C10 significantly inhibits
this adhesion. Treatment of cells with TS2/16 and M28B5 results in a small but not
statistically significant stimulation of adhesion to CVI.
*
p <0.05 (Mann Whitney U Test)
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Dose response effect ofM28B5 antibody on chondrocyte adhesion to CVI.
To demonstrate a dose response, chondrocytes were stimulated with increasing
concentrations ofM28B5. Chondrocytes were isolated from normal articular cartilage
obtained from the tibial plateaux and femoral condyles of 1 female (age 74 years) and
2 males (median age 67 years, range 66 - 68). All experiments were carried out in
triplicate. Stimulation of adhesion by M28B5 of chondrocytes isolated from normal
cartilage to CVI increases in a dose dependent manner (GRAPH 3.9.). In contrast
increasing concentrations of irrelevant antibody anti-CD3, UCHT-1, have no effect
on adhesion to CVI (GRAPH 3.10.). Chondrocytes were obtained from normal
articular cartilage obtained from the tibial plateaux and femoral condyles of 1 male




Effect of increasing concentrations ofM28B5 on adhesion of chondrocytes to CVI.
Stimulation of adhesion by M28B5 of chondrocytes isolated from normal cartilage to
CVI increases in a dose dependent manner. The values shown represent the mean of
3 experiments carried out in triplicate +/- SEM.
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GRAPH 3.10.
Effect of increasing concentrations ofUCHT-1 on adhesion of chondrocytes to CVI.
The values shown represent the mean of 1 experiment carried out triplicate




Chondrocytes isolated from both normal and OA cartilage adhere to FN, CII and
CVI. Function blocking anti-P 1 integrin antibodies inhibit adhesion of chondrocytes
isolated from both normal and OA cartilage to FN, CII and CVI. This confirms that
pi integrins mediate chondrocyte interaction with these proteins (Enomoto 1993,
Loeser 1997). The adhesion of chondrocytes isolated from normal cartilage to CVI is
stimulated by anti-HMPG antibody M28B5 in a dose dependent manner. Anti-
HMPG antibody M28B5 has no effect on chondrocyte binding to FN or CII. There is
a small stimulation of adhesion that does not reach significance. Similarly anti-
HMPG antibody M28B5 has no significant effect on the adhesion of chondrocytes
isolated from OA cartilage to FN, CII or CVI. NG2/HMPG may be involved in
modulating the interaction of chondrocytes isolated from normal cartilage with CVI,
but this process is altered in chondrocytes isolated from OA cartilage.
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3.4. FUNCTION OF NG2/HMPG IN HUMAN CHONDROCYTES -
SIGNAL TRANSDUCTION
3.4.1. Cell adhesion assays
The work described previously in this study has provided no evidence for a direct
interaction between NG2/HMPG and CVI as has been seen in rat cell lines (Stallcup
1990). However stimulation ofNG2/HMPG in melanoma cells lines with anti-
HMPG antibody indirectly affects cell interaction with FN. NG2/HMPG is thought
to modulate pi interaction with FN via inside out signalling (Iida 1995). Treatment
of chondrocytes isolated from normal cartilage with M28B5 results in an increase in
adhesion to CVI suggesting that NG2/HMPG has an albeit indirect but possibly
important function in the regulation of chondrocyte adhesion to the ECM. Therefore
the function ofNG2/HMPG in the adhesion of chondrocytes isolated from normal
cartilage to CVI was further investigated. To determine the intracellular events
which occur during M28B5 stimulated chondrocyte adhesion to CVI, chondrocytes
were allowed to adhere to CVI in the presence of antibody and inhibitors of various
intracellular signalling molecules.
Chondrocytes were isolated from normal cartilage obtained from the tibial plateaux
and femoral condyles of 1 female (age 89 years) and 2 males (median age 67 years,
range 66 - 68). The adhesion to CVI of chondrocytes isolated from normal cartilage,
treated with genistein, an inhibitor of tyrosine kinases, was compared to cells treated
with both M28B5 and genistein. Genistein has no significant effect on chondrocyte
adhesion to CVI in the absence of antibody or on the increased chondrocyte adhesion
to CVI resulting from stimulation with M28B5 (GRAPH 3.11.). Staurosporine,
which inhibits calcium dependent protein kinase C activity, also has no significant
effect either on adhesion to CVI or the M28B5 stimulated adhesion to CVI (GRAPH
3.12.). Cytochalasin D, which disrupts the actin cytoskeleton, significantly inhibits
both adhesion to CVI (61%) and M28B5 stimulated adhesion to CVI (82 %)
(GRAPH 3.13.). Pertussis toxin, which inhibits Gi protein function, has no
significant effect on adhesion to CVI in the absence of antibody but abolishes the



















BSA CVI CVI+gen CVI+M28B5 CVI+M28B5+gen
GRAPH 3.11.
Adhesion of chondrocytes to CVI - effect of genistein.
The adhesion of chondrocytes isolated from normal articular cartilage and treated
with genistein for 30 min at 37 °C to CVI was compared to adhesion of chondrocytes
not treated with inhibitor. In some cases cells were subsequently incubated with
antibody M28B5 for 30 min at 37 °C. The values shown represent the mean of 3
experiments carried out in triplicate +/- SEM.
Non specific binding to BSA is minimal. Chondrocytes adhere to CVI. M28B5
stimulates chondrocyte adhesion to CVI. Genistein has no significant effect on
chondrocyte adhesion to CVI or to the stimulated chondrocyte adhesion to CVI





















Adhesion of chondrocytes to CVI - effect of staurosporine.
The adhesion of chondrocytes isolated from normal articular cartilage and treated
with staurosporine for 30 min at 37 °C to CVI was compared to adhesion of
chondrocytes not treated with inhibitor. In some cases cells were subsequently
incubated with antibody M28B5 for 30 min at 37 °C. The values shown represent the
mean of 3 experiments carried out in triplicate +/-SEM.
Non specific binding to BSA is minimal. Chondrocytes adhere to CVI. M28B5
stimulates chondrocyte adhesion to CVI. Staurosporine has no significant effect on
chondrocyte adhesion to CVI or to the stimulated chondrocyte adhesion to CVI




Adhesion of chondrocytes to CVI - effect of cytochalasin D.
The adhesion of chondrocytes isolated from normal articular cartilage and treated
with cytochalasin D for 30 min at 37 °C to CVI was compared to adhesion of
chondrocytes not treated with inhibitor. In some cases cells were subsequently
incubated with antibody M28B5 for 30 min at 37 °C. The values shown represent the
mean of 3 experiments carried out in triplicate +/- SEM.
Non specific binding to BSA is minimal. Chondrocytes adhere to CVI. Cytochalasin
D significantly inhibits adhesion to CVI. M28B5 stimulates chondrocyte adhesion to
CVI. Cytochalasin D also significantly inhibits the stimulated chondrocyte adhesion
to CVI resulting from treatment with M28B5.
*





















BSA CVI CVI+pt CVI+M28B5 CVI+M28B5+pt
GRAPH 3.14.
Adhesion of chondrocytes to CVI - effect ofpertussis toxin.
The adhesion of chondrocytes isolated from normal articular cartilage and treated
with pertussis toxin for 30 min at 37 °C to CVI was compared to adhesion of
chondrocytes not treated with inhibitor. In some cases cells were subsequently
incubated with antibody M28B5 for 30 min at 37 °C. The values shown represent the
mean of 3 experiments carried out in triplicate +/-SEM.
Non specific binding to BSA is minimal. Chondrocytes adhere to CVI. Pertussis
toxin has no significant effect on chondrocyte adhesion to CVI. M28B5 stimulates
chondrocyte adhesion to CVI. Pertussis toxin abolishes stimulated adhesion to CVI
caused by treatment with M28B5.
*
p <0.05 (Student T Test)
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SUMMARY
The adhesion of chondrocytes isolated from normal cartilage to CVI in the absence of
M28B5 antibody is unaffected by inhibitors of tyrosine specific kinases, calcium
dependent protein kinase C and Gi proteins, suggesting that these intracellular
signalling molecules are not involved in chondrocyte adhesion to CVI.
Chondrocyte adhesion to CVI in the presence of antibody M28B5 is also
unaffected by genistein and staurosporine but is inhibited by pertussis toxin. This
suggests that the stimulated adhesion of chondrocytes to CVI does not involve
tyrosine specific kinases and calcium dependent protein kinase C but does involve Gi
protein mediated signalling.
Cytochalasin D inhibits chondrocyte adhesion to CVI in the absence or
presence ofM28B5, suggesting that the actin cytoskeleton plays a role in the
adhesion of chondrocytes to CVI. However it is not possible to determine the extent
of inhibition of stimulated adhesion by M28B5 specifically.
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3.4.2. Tyrosine phosphorylation
Human melanoma cells allowed to adhere to a mixture ofFN and 9.2.27, spread and
form focal contacts, and two proteins become tyrosine phosphorylated (Iida 1995).
To determine whether adhesion of chondrocytes to FN or a composite substrate of
FN and M28B5 results in the stimulation of tyrosine kinase activity, chondrocytes
were allowed to adhere to FN or M28B5 and FN for 1 h, after which time the profile
of tyrosine phosphorylated proteins was compared to that of unstimulated cells
allowed to adhere to BSA. Chondrocytes were isolated from normal articular
cartilage obtained from the tibial plateaux and femoral condyles of 1 female (age 75
years) and 2 males (median age 55 years, range 52 - 60). Many proteins of a wide
range ofmolecular weights are tyrosine phosphorylated, however no difference
between untreated and stimulated cells was seen (PLATE 3.8.). The same was
observed when cells were allowed to adhere to CVI, KZ1 or TS2/16 were compared
to control cells. This suggests that adhesion of chondrocytes to these substrates for 1
h does not stimulate the activity of tyrosine specific kinases.
Cells were also allowed to adhere from 1 min to 1 h to anti-HMPG antibody
M28B5 and no change in the profile of proteins that were phosphorylated on tyrosine
residues was observed compared to chondrocytes that were plated on BSA,
confirming that M28B5 alone does not stimulate tyrosine kinase activity over this
time course.
There is no difference in results from experiments using chondrocytes
removed from donors of different age and sex or from different areas of the knee






Western blot of chondrocyte lysates isolated from normal articular cartilage obtained
from the femoral condyle of a 75 year old female, plated on dishes coated with BSA,
FN or FN and M28B5 for 1 h. When probed with anti-phosphotyrosine antibodies
identical phosphorylation profiles are seen. Identical results were seen when
chondrocytes were stimulated with CVI, KZ1 and TS2/16 and when chondrocytes
were allowed to adhere to M28B5 for 1 min, 5 min 15 min, 30 min or 1 h.
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3.4.3. Interaction with actin
In rat cell lines NG2/HMPG has been shown to co-localise with actin stress fibres
(Lin 1996a). Disruption of the actin cytoskeleton with cytochalasin D results in a
release ofNG2/HMPG from the cell surface (Lin 1996a), suggesting that
NG2/HMPG acts as a cytoskeletal anchor by binding to actin. Chondrocytes were
isolated from normal articular cartilage obtained from the tibial plateaux and femoral
condyles of 1 female (age 76 years) and 3 males (median age 59 years, range 40 - 77)
and stained with both anti-HMPG antibody M28B5 and phalloidin. Double
immunofluorescence labelling for NG2/HMPG and actin in human chondrocytes did
not show any clear association between the two molecules (PLATE 3.9.). There is
no difference in results from experiments using chondrocytes removed from donors
of different age and sex or from different areas of the knee joint (femoral condyle,
tibial plateau or patella).
3.4.4. Interaction with PDGF a receptor
NG2/HMPG and PDGFa-R are expressed co-ordinately during the early stages of O-
2A cell development and interaction between the two molecules is required for
optimal response to PDGF (Nishiyama 1996a,b). Developing and adult rat vascular
smooth muscle cells also require correct expression ofNG2/HMPG and PDGFa-R
to respond to PDGF (Grako 1995). Chondrocytes were isolated from normal
articular cartilage obtained from the tibial plateaux and femoral condyles of 2 females
(median age 65 years, range 61 - 69) and 1 male (age 61 years) and stained with
antibodies against both HMPG and PDGFa-R. Adult articular chondrocytes express
PDGFa-R (PLATE 3.10a.). Double immunofluorescence labelling for NG2/HMPG
and PDGF a-R in human chondrocytes did not show any clear association between
the two molecules (PLATE 3.10b,c.). There is no difference in results from
experiments using chondrocytes removed from donors of different age and sex or
from different areas of the knee joint (femoral condyle, tibial plateau or patella).
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PLATE 3.9.
Immimofluorescent localisation of actin and NG2/HMPG.
Double labelling of chondrocytes isolated from normal articular cartilage obtained






Immunofluorescent localisation ofPDGFa-R and NG2/HMPG.
PDGFa-R is expressed by human articular chondrocytes isolated from normal
cartilage obtained from the femoral condyle of a 61 year old male (a). Double
labelling of chondrocytes isolated from normal cartilage obtained from the femoral
condyle of a 61 year old male for PDGFa-R and NG2/HMPG shows no clear






These studies have demonstrated that NG2/HMPG is expressed by human
chondrocytes. It is present in both normal and OA adult articular cartilage, and in
articular, epiphyseal and growth plate fetal cartilage. Expression is down regulated in
chondrocytes isolated from OA cartilage. Biochemical analysis ofNG2/HMPG in
adult articular chondrocytes shows that it is expressed as the CS rich PG and the 250
kD protein core. These studies also provide evidence that NG2/HMPG is located in a
distinct punctate pattern in vitro in chondrocytes isolated from normal and OA
cartilage, and does not co-localise with any putative ligands such as actin, PDGFa-R,
FN, CII and CVI. Anti-HMPG antibodies stimulate normal chondrocyte binding to
CVI in a dose dependent manner, and this stimulation can be inhibited by pertussis
toxin.
4.1. EXPRESSION OF NG2/HMPG BY HUMAN
CHONDROCYTES
Initial reports on NG2/HMPG show expression to be predominantly restricted to
developing tissues. Expression was first described in rat cell lines with
characteristics of both neural and glial cells (Stallcup 1981). NG2/HMPG is also
expressed in 0-2A glial progenitor cells of the rat cerebellum, although it ceases to
be expressed following differentiation to mature oligodendrocytes (Stallcup 1987).
In extra-neural tissues of rats, expression is also confined to developing tissues, in
particular those ofmesenchymal origin, including chondroblasts and smooth muscle
progenitor cells (Nishiyama 1991a). NG2/HMPG expression has been studied in
fetal and adult human tissue, and is found in malignant cells such as chondrosarcoma
(Leger 1991) and melanoma (Reisfeld 1984, 1987), but not in several other
carcinoma cell types, including lung and bladder, nor in normal cell types, including
melanocytes, T and B cell lines or in normal tissues, including lung and colon
(Reisfeld 1984, 1987). It therefore appears to have a limited distribution, suggesting
a specialised function in cells.
Normal cartilage is rich in PGs, they constitute approximately 50% of the
total tissue weight, ofwhich the majority are chondroitin sulphated (Bayliss 1983).
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In OA cartilage, chondrocytes assume a fetal phenotype, including increased
proliferation and secretion ofECM molecules. This proceeds until the rate of
reparative ECM protein synthesis is exceeded by the increase in ECM degradation
and the tissue is destroyed (Poole 1993, Hamerman 1989).
The aim of this project was to determine whether NG2/HMPG is expressed in
human cartilage by adult or fetal chondrocytes, and to compare expression in normal
and OA cartilage. Immunohistochemical staining of human cartilage sections
demonstrated that NG2/HMPG is expressed by fetal and adult normal cartilage in
vivo. Expression is not down regulated once chondrocytes undergo terminal
differentiation, as in the rat. NG2/HMPG is also expressed in vivo by chondrocytes
from both normal and OA cartilage. However, immunohistological staining over a
range of anti-HMPG antibody dilutions reveals that immunoreactivity is maintained
at lower antibody concentrations in normal cartilage compared to OA cartilage. This
suggests that expression ofNG2/HMPG may be down regulated in OA tissue.
Densitometric analysis ofwestern blots of lysates of chondrocytes isolated from
normal and OA cartilage probed with anti-HMPG antibodies show a down regulation
of expression ofNG2/HMPG in chondrocytes from OA cartilage. FN expression is
known to be upregulated in OA cells (Burton-Wurster 1990), western blots of lysates
of chondrocytes isolated from normal and OA cartilage probed with anti-FN
antibodies show an increase in expression in chondrocytes isolated from OA
cartilage. This in vitro work suggests that the decrease in immunoreactivity seen in
vivo is due to a downregulation in expression ofNG2/HMPG, and not due to
inaccessibility of the NG2/HMPG epitope. The decrease in NG2/HMPG protein
expression may result from degradation, secretion from the cell surface, or a change
in the regulation or rate of synthesis. Breakdown products have been detected in rat
cell lines, as has secreted NG2/HMPG (Nishiyama 1995), suggesting that it may be
worthwhile to look for these forms of the protein in human chondrocytes.
Alternatively, a down regulation in the synthesis ofNG2/HMPG messenger RNA, or
the rate of translation, may account for the lower levels ofNG2/HMPG detected in
OA cartilage, indicating that analysis of amounts ofmRNA produced by normal and
diseased tissue would be of interest.
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NG2/HMPG expression in fetal and adult chondrocytes suggests that it may
be important in chondrocyte function during development and throughout adulthood.
The downregulation ofNG2/HMPG expression observed in OA chondrocytes raises
the possibility that it is important in the disease process. NG2/HMPG may play a
regulatory role in the onset and progression ofOA, the loss ofNG2/HMPG may be a
trigger for the initiation of osteoarthritis. Initial studies reveal that expression of
NG2/HMPG is decreased even in mild cases of osteoarthritis, however it is unclear
exactly when NG2/HMPG is lost from OA cartilage, or how this is regulated.
Alternatively, the decrease in expression ofNG2/HMPG may occur as a result of the
imbalance in chondrocyte homeostasis that occurs in OA cartilage. An increased
secretion of proteases and inability of chondrocytes to balance this destruction by
increased PG synthesis, results in loss ofPGs from the tissue. The significance of
NG2/HMPG expression in normal and OA tissues remains unclear until more about
its function is known.
4.2. BIOCHEMICAL PROPERTIES OF NG2/HMPG IN HUMAN
CHONDROCYTES
In cell types other than chondrocytes, NG2/HMPG is expressed as two forms
simultaneously at the cell surface, both the CS rich PG and the unmodified protein
core (Bumol 1982, Stallcup 1990). The role of the different forms, CS-rich and CS-
free NG2/HMPG, has been addressed. In rat cell lines the protein core is responsible
for mediating interactions with ECM ligands (Tillet 1997). However, CS GAG
chains are essential for human melanoma cell interaction with FN (Iida 1992).
Anionic GAG CS chains purified from various cell types, including chondrocytes,
have been shown interact with FN (Hook 1984, Barkalow 1994). It was not
determined whether NG2/HMPG could modulate integrin interaction with FN
without CS chains (Iida 1995).
To determine the biochemical characteristics ofNG2/HMPG in cartilage, and
to compare them to that ofNG2/HMPG in rat cell lines and human melanoma cells,
western blotting of lysates of chondrocytes was carried out. NG2/HMPG is
expressed simultaneously as both the CS rich PG and the unmodified protein core in
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human chondrocytes isolated from both normal and OA cartilage, as in rat and
melanoma cell lines.
The function of the two forms ofNG2/HMPG is unclear, expression as both a
CSPG and a CS-free protein core may act as a signal for transport to cell surface, or a
regulatory mechanism. CD44 is expressed as both a PG and unmodified core protein.
This integral membrane protein has a tissue specific variation in expression. In
lymphocytes the majority ofCD44 is expressed as unmodified protein core, but in
epithelial cells core protein amino acid composition differs and the majority of CD44
is expressed as CS/HSPG. CD44 interacts with FN, collagen and HA. However, not
all CD44-expressing cells bind HA, and different CD44-expressing cell types bind
HA with different affinities. Only the CS modified form ofCD44 interacts with FN.
The expression of this protein as different forms is a possible means of regulating
function (Hardingham 1992). Syndecan is a PG which has a structure similar to
NG2/HMPG, consisting of a short intracellular domain with a single transmembrane
span and a large extracellular region. The GAG content of the molecule expressed is
cell specific. Simple mouse uterine epithelia express syndecan with 2HS and 2CS
attached. Stratified vaginal epithelia express syndecan with only 1HS and ICS
attached. Transforming growth factor-p (TGFP) increases the CS content of
syndecan expressed by mouse mammary cells. The addition of CS enables
interaction with thrombospondin. Therefore, ligand specificity is encoded by the
GAG attached, and can be modified by cytokines during development and
differentiation (Hardingham 1992). Thrombomodulin is expressed as a CS-rich and
CS-free PG, both ofwhich have distinct functions, the former mediates anti¬
coagulation events, and the latter is involved in their regulation (Hardingham 1992).
NG2/HMPG is expressed as both a CSPG and a CS free core protein in
human chondrocytes. Addition of CS may enable NG2/HMPG to interact with
ligands, and the core protein may be responsible for regulating these interactions. In
this way, two distinct functions can be performed by different forms of one protein.
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4.3. DIRECT INTERACTION OF NG2/HMPGWITH ECM IN
HUMAN CHONDROCYTES
Putative roles for NG2/HMPG in the binding ofCII and CVI and in modulating
melanoma cell interactions with FN have been proposed (Burg 1996, Iida 1995).
These are particularly relevant to chondrocytes, as both CVI and FN are expressed in
the pericellular matrix of cartilage (Clemmensen 1982, Poole 1992), and CII is the
main collagen component of the ECM (Kuhn 1987). Human melanoma cells adhere
to FN, laminin, CIV or anti-HMPG antibody 9.2.27 without cell spreading and focal
contact formation (Iida 1995). However, when cells are allowed to adhere to a
composite of both FN and 9.2.27, cell spreading and focal contact formation is
observed (Iida 1995), suggesting that NG2/HMPG acts as a co-receptor for FN, and
is involved in the control ofmelanoma cell spreading and focal contact formation.
Studies with rat cell lines have suggested roles in binding to CVI.
Immunoprecipitation ofNG2/HMPG with anti-NG2 antibody from some rat cell
lines including B49, but not others, results in a 140 kD component being co-
precipitated along with the CSPG and unmodified core protein ofNG2/HMPG
(Stallcup 1990). This was subsequently identified as CVI, suggesting an interaction
between the two (Stallcup 1990). Further studies have shown that CVI and
NG2/HMPG co-localise on the surface of these cells (Stallcup 1990). In cell lines
that secrete, but do not retain CVI, transfection with NG2/HMPG cDNA and
subsequent expression ofNG2/HMPG enables these cells to retain CVI on the cell
surface (Nishiyama 1993). Adhesion assays using purified proteins have further
characterised this interaction, and shown that it can be inhibited by decorin,
indicating that they bind to the same, or closely related domains in CVI (Burg 1996).
These binding studies also showed that NG2/HMPG interacts with CII (Burg 1996).
This evidence prompted an examination ofwhether NG2/HMPG interacts
with these molecules in human cartilage. Immunofluorescence staining revealed that
NG2/HMPG is distributed in a punctate pattern on chondrocytes isolated from
normal and OA cartilage, identical to that seen at the cell surface of rat cell lines and
human melanoma cells. Immunoprecipitation and double immunofluorescence
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labelling ofchondrocytes isolated from normal cartilage suggests that no direct
interaction occurs with FN, CD or CVI.
In this study, only the unmodified core protein was precipitated from
radiolabeled chondrocyte extracts. Rettig (1986) used M28B5 antibody to
precipitate NG2/HMPG from human and mouse hybrid neuroblastoma cells, and
noted that the 250 kD glycoprotein was the major component of the
immunoprecipitate, and that the CSPG was detectable but relatively minor. Other
groups, using different antibodies, report an absence ofCSPG due to ineffective
labelling or transfer to nitro-cellulose as a result of its large size or culture conditions
of the melanoma cells from which it was isolated (Carrel 1981, Morgan 1981). The
CSPG could only be isolated from large amounts ofprotein source, and detected as a
minor band after labelling with radio iodine and extended exposure to x-ray film
(Wilson 1981), and was not detected by Coomassie Blue staining ofmelanoma ghost
preparations (Ross 1983).
In contrast to B49 rat cell lines, NG2/HMPG in human chondrocytes does not
appear to directly interact with CVI. However, in other rat cell lines no co-
precipitation or co-localisation was shown (Stallcup 1990), indicating that
NG2/FIMPG's role may be cell as well as tissue specific. NG2/HMPG also does not
appear to interact with CII or FN. However this does not rule out a functional
partnership, as has been demonstrated for FN in human melanoma cells (Iida 1995).
4.4. A ROLE FOR NG2/HMPG IN MEDIATING
CHONDROCYTE ADHESION TO CVI
This thesis presents no evidence that NG2/HMPG interacts directly with any ECM
protein tested. NG2/HMPG in human melanoma cells is not localised to focal
contacts, and no direct interaction with FN has been demonstrated (Iida 1995).
Instead, NG2/HMPG influences melanoma cell interaction with FN indirectly, by
modulating (31 integrin binding of this ECM protein (Iida 1995). Normal human
chondrocytes express integrins aipi, a3pi, a5pi and aVp5 (Salter 1992, Loeser
1997, Woods 1994). Integrins aipi and a3pi are involved in the binding of human
chondrocytes to CD, and a3pi, a5pi and aVp5 to FN (Loeser 1995, Enomoto
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1993). Human chondrocyte attachment to CVI is less well characterised, but is
thought to occur by interaction with al pi integrins (Salter unpublished
observations), which is supported by studies with bovine chondrocytes (Loeser 1997)
and other cell types (Pfaff 1993).
Adhesion assays were used to characterise chondrocyte adhesion to ECM
proteins FN, CII and CVI, and to study the effect of anti-HMPG and anti-pi integrin
antibodies on this process. Chondrocytes isolated from normal and OA cartilage
adhere to FN, CII and CVI. Binding to BSA is minimal and non specific. Anti-pl
integrin antibody P4C10 inhibits the adhesion to FN, CII and CVI of chondrocytes
isolated from normal and OA cartilage, confirming that p 1 integrins are involved in
mediating chondrocyte adhesion to all three substrates. Anti-HMPG antibody
M28B5 and anti-pi integrin antibody TS2/16 have little effect on adhesion of
chondrocytes isolated from normal cartilage to FN and CH, and adhesion of
chondrocytes isolated from OA cartilage to FN, CII and CVI. However, they do
significantly stimulate the adhesion of chondrocytes isolated from normal cartilage to
CVI, in a dose dependent manner.
NG2/HMPG may have a role in influencing the interaction of chondrocytes
from normal cartilage to CVI. This is altered in chondrocytes isolated from OA
cartilage allowed to adhere to CVI, and in both cell types when allowed to adhere to
FN or CII. Cell adhesion molecules, for example p 1 integrin and CD44, not only
mediate chondrocyte adhesion to ECM proteins but also regulate many other cell
functions. Similarly NG2/HMPG appears to be important in modulating chondrocyte
adhesion to CVI, and this may have implications for NG2/HMPG's role in a wide
variety of chondrocyte functions, including regulation ofmatrix synthesis and
degradation and proliferation. The expression of cell adhesion molecules is altered in
OA cartilage, for example an upregulation in both pi integrin and CD44 occurs. As
both these molecules are involved in mediating cell-ECM interactions, which
regulate chondrocyte function in normal cartilage, changes in expression suggests an
alteration of these processes in OA cartilage. NG2/HMPG expression is also altered
in OA cartilage, raising the possibility that the chondrocyte-ECM interactions it
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modulates are altered which may affect subsequent regulation of cellular function and
this may play a role in the onset and progression of osteoarthritis.
CVI interacts with several cartilage ECM proteins, for example CD and
decorin (Bidanset 1990, Burrows 1994). Its localisation in the pericellular matrix
also enables it to interact with cell surface receptors (Poole 1992). Chondrocyte
interactions with CVI are important in the organisation of the ECM, to maintain
tissue stability, provide structural support for the cells, and in the determination of
cell morphology. However, the ECM also modulates cell behaviour by interacting
with cell surface receptors and transmitting signals from the outside of the cell to the
inside (Gimond 1992). Cell adhesion and spreading of smooth muscle and
melanoma cells, is promoted by CVI and mediated by integrins (Aumailley 1989).
CVI promotes migration in rat cell lines which express NG2/HMPG, but not in cell
lines that do not express NG2/HMPG (Burg 1997), and melanoma cells that express
CVI are more invasive than those that do not (Daniels 1996). CVI stimulates
proliferation of transformed mesenchymal cells in vitro at a site different from that
used to adhere to the cells via pi integrins (Atkinson 1996). In these cells,
NG2/HMPG is a candidate for mediating the proliferative effect ofCVI.
NG2/HMPG may be important in controlling normal chondrocyte adhesion to CVI,
and therefore in the maintenance of cartilage structure and function.
NG2/HMPG does not appear to mediate chondrocyte attachment to CVI
directly, but may do so by modulating p 1 integrin interaction with CVI, as occurs
with NG2/HMPG and FN in human melanoma cells (Iida 1995). The work presented
in this thesis confirms that P1 integrins do mediate chondrocyte adhesion to CVI, as
well as to FN and CII. Cellular recognition ofECM proteins involves the co¬
ordinated action of several distinct receptors. For example, fibroblasts require both
the RGD-containing and heparin binding domains ofFN to adhere to, and form focal
contacts on FN, suggesting that both integrins and GAGs are involved (Guan 1991).
Chinese hamster ovary cells, deficient in GAGs, adherent to FN form fewer focal
contacts (Lebaron 1988). In human melanoma cells both CSPG and a4pi integrin
are involved in the interaction with FN (Iida 1992). Stimulation of both a4pi and
NG2/HMPG are required for cell spreading and focal contact formation on FN,
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however they do not have to be localised on the same substrate to collaborate (Iida
1995). Presentation of antibody 9.2.27 on beads to cells already adherent on FN
causes the same stimulation of spreading and focal contact formation as allowing
cells to adhere to a composite substrate of FN and 9.2.27. The same is not true for
FN presented on beads to cells adherent to 9.2.27. This suggests that oc4(31 must be
in contact with the FN substrate, but that NG2/HMPG need not, and modulates the
interaction of a4(31 integrin via inside out signalling (Iida 1995). In other cell types
integrin affinity for ECM ligands is regulated by inside out pathways involving
intracellular signalling cascades, leading to a change in the conformation of the
integrin (Hynes 1992). The mechanisms by which this change in conformation
modulates ligand interaction are not well established.
Stimulation of chondrocytes, isolated from OA cartilage, with anti-HMPG
antibodies does not result in the same increase of adhesion to CVI, suggesting that
NG2/HMPG is not involved in mediating adhesion to CVI in the same way in
chondrocytes isolated from OA cartilage as those isolated from normal cartilage. OA
cells produce less NG2/HMPG and more CVI and pi integrin (Swoboda 1998,
Loeser 1995). This increase in pi and CVI may be a reparative event to remodel
cartilage, to balance degradation by proteases, p 1 integrin and FN production are
upregulated in OA cartilage, and mediate cell-ECM interactions during cartilage
repair (Clancy 1997). Degradation ofNG2/HMPG, which in normal cartilage
promotes interaction between P1 and CVI, may cause an increase in the production of
these molecules to compensate for loss of stimulatory effect. Alternatively,
NG2/HMPG stimulation of cell-CVI interaction may only be needed in normal cells
when lower amounts ofCVI are present, and when levels of these proteins are
upregulated, a parallel down regulation in NG2/HMPG expression may occur.
However, the small number of samples used in this study, the wide margin of
error of adhesion values, and the lack of effect of TS2/16 on adhesion to C13 and FN,
suggests that a larger number of experiments may reveal that treatment of both
normal and OA cells with M28B5 may stimulate binding to CVI or CII and FN.
NG2/HMPG may not specifically modulate the adhesion of chondrocytes isolated
from normal cartilage to CVI, but influence both the adhesion of chondrocytes
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isolated from normal and OA cartilage to a wider range of substrates. This needs to
be examined using a greater number of tests.
NG2/HMPG may modulate (31 integrin interaction with CVI which,
potentially regulates normal cartilage structure and function, and which is altered in
OA cartilage.
4.5. NG2/HMPG IN CHONDROCYTE SIGNAL TRANSDUCTION
How does NG2/HMPG modulate chondrocyte adhesion to CVI? With regards to a
signalling molecule, NG2/HMPG appears to have many potential roles. As a
transmembrane molecule it can influence events on both sides of the membrane.
NG2/HMPG has been shown to stimulate the activity of tyrosine specific kinases in
human melanoma cells (Iida 1995), to act as a cytoskeletal anchor by interacting with
actin in rat cell lines (Lin 1996a), to mediate optimal cell response to PDGF by
interacting with PDGFa-R in rat 0-2A and smooth muscle cell lines (Nishiyama
1996a,b, Grako 1995), to activate Gi proteins by binding to a cell surface receptor on
rat neurites (Dou 1994), and it may also be a substrate for PKC (Nishiyama 1995).
To further dissect how NG2/HMPG can regulate chondrocyte interaction with
CVI; chondrocytes isolated from normal cartilage to CVI were used in adhesion
assays in the presence of inhibitors of intracellular signalling molecules.
4.5.1. G protein mediated signalling
Many cellular responses stimulated by extracellular signals use guanosine
triphosphate (GTP) binding regulatory proteins (G proteins) to transduce the message
into the cell. These signalling molecules are found on the intracellular face of the
cell membrane and commonly function as receptors for hormones. Pertussis toxin
sensitive Gi proteins regulate the activity of a wide variety of effector molecules,
including adenylate cyclase, calcium, potassium and sodium ion channels and
phospholipase enzymes, and intracellular concentrations of cyclic guanine
monophosphate (cGMP), inositol triphosphate and diacyl glycerol (DAG) (Hepler
1992, Neer 1995).
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Pertussis toxin, which inhibits the activity of Gi proteins, has no effect on
chondrocyte adhesion to CVI in the absence of anti-HMPG antibody M28B5,
however it inhibits the adhesion to CVI stimulated by the antibody. This indicates
that chondrocyte adhesion to CVI in the absence ofM28B5 does not involve
pertussis toxin sensitive G proteins, however the stimulated adhesion of chondrocytes
to CVI does involve Gi protein mediated signalling.
This thesis proposes that NG2/HMPG mediates the interaction of human
chondrocytes isolated from normal cartilage with CVI, not via direct binding but
indirectly by modulating p 1 integrin interaction with CVI. Integrin affinity for
ligands is regulated in some cells by G proteins. Stimulation ofmuscarinic receptors
which are coupled to G proteins, results in DAG activation ofPKC, which causes an
increase in the affinity of integrins for the ECM, the number of stress fibres and focal
contacts formed, and the tyrosine phosphorylation ofpaxillin and focal adhesion
kinase (FAK) (Slack 1998). Integrin mediated adhesion of fibroblasts to FN involves
Gi protein activation (Sung 1996). Interaction of alip3 integrin with fibrinogen in
lymphocytes can be activated by pathways involving Gi proteins (Qi 1998). Gi
proteins are more abundantly expressed in highly metastatic melanoma cells
compared to normal cell counterparts or poorly metastatic melanoma cells (Lester
1991). In rat neurites NG2/HMPG binding to a cell surface receptor inhibits cell
growth. This involves activation of Gi proteins and ion channels, and changes in the
levels of intracellular cAMP and calcium (Dou 1994).
There is little evidence concerning the signal transduction pathways involving
CVI, and none to suggest that Gi proteins are involved. However, the effect of some
ECM proteins on Gi protein-mediated signal transduction has been studied. Tumour
necrosis factor-a inhibits expression of the collagen I gene via G protein-mediated
signalling (Hernadez-Munro 1997). FN interaction with integrins on rat neurite cells
causes the activation of Gi proteins which alter the activity ofpotassium channels
resulting in cell hyperpolarisation and increased cell growth (Arcangeli 1993).
Pertussis sensitive G proteins and integrin aVp3 are involved in human melanoma
cell migration on vitronectin (Aznavoorian 1996), and a4pi adhesiveness for FN is
decreased by chemokines, which is mediated by Gi proteins (Weber 1996).
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No work has been done on CVI-induced signalling in human chondrocytes.
This thesis is the first to report that NG2/HMPG may be involved in modulating
chondrocyte interaction with CVI. The function ofNG2/HMPG in human adult
articular chondrocytes isolated from normal cartilage may be to stimulate cell
adhesion to CVI by Gi protein mediated signalling, possibly by modulating (31
integrin interaction with this ECM protein.
Evidence exists for G protein regulation of chondrocyte function. In
chondrocytes from species other than humans, TGF-f3 decreases adhesion to CVI by
decreasing expression of its receptor aipi (Loeser 1997). TGF-(3 enhances
chondrocyte differentiation via activation ofGi proteins (Schwartz 1988). Insulin
like growth factor (IGF) interaction with IGF-1R and IR stimulates chondrocyte
proliferation and ECM protein synthesis by activation of Gi proteins and stimulation
ofphospholipase C (PLC)/inositol triphosphate-mediated opening of endoplasmic
reticular calcium ion channels to create an increase in intracellular calcium
concentration (Poiraudeau 1997). Mechanical force results in a change in shape of
bovine chondrocytes, an increase in GAG and metalloproteinase synthesis and
eventual degradation of cartilage. The increase in GAG synthesis involves nitric
oxide release and Gi protein activation ofPLC, by DAG generation, and may activate
PKC which has been shown to increase GAG synthesis in cultured chondrocytes (Das
1997). Gi proteins therefore are involved in the control of cartilage metabolism in
the degenerative disease of this tissue. In human chondrocytes NG2/HMPG may use
Gi proteins to control cell adhesion to CVI, which in OA cartilage may be involved
in initial up regulation ofPG synthesis. The question remains as to how NG2/HMPG
modulation of chondrocyte interaction with CVI is regulated.
4.5.2. Phosphorylation of NG2/HMPG by PKC
NG2/HMPG was sequenced and found to show little homology to any other protein
yet characterised (Nishiyama 1991b, Pluschke 1996). The internal domain of
NG2/HMPG contains three threonine residues (Nishiyama 1991b, Pluschke 1996)
which, together with surrounding amino acids, form amotif for potential PKC
phosphorylation (Kemp 1990), indicating that NG2/HMPG may be modified on these
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amino acids and so play a role in intracellular signalling. Western blots of
chondrocyte lysates probed with anti-phosphothreonine antibodies reveal a wide
range of proteins which are phosphorylated on threonine, including one which
migrates at 250 kD, suggesting that NG2/HMPG may be a substrate for PKC.
Further work is needed to confirm that NG2/HMPG is phosphorylated by
PKC. The PKC phosphorylation site is one of very few sequences present in
NG2/HMPG that is highly conserved in both the rat and human molecule and other
proteins (Nishiyama 1991b, Pluschke 1996). In rat cell lines, activation ofPKC
stimulates the production of a truncated form ofNG2/HMPG and an inability to
anchor CVI. PKC may directly phosphorylate NG2/HMPG, causing a change in
conformation and a decrease in affinity for CVI, without which interaction
NG2/HMPG is not protected from proteolytic enzymes, a property conferred by the
protease inhibitor sequences ofCVI (Nishiyama 1995). Alternatively, PKC
activation may result in the synthesis of a protease responsible for the truncation of
NG2/HMPG which renders it incapable of interaction with CVI (Nishiyama 1995).
In this way PKC may act as a means of regulating the direct interaction of
NG2/HMPG and CVI. However, NG2/HMPG does not directly interact with CVI in
human chondrocytes. PKC may regulate the direct interaction ofNG2/HMPG with a
novel or unidentified ligand.
Alternatively PKC may mediate other chondrocyte functions. The adhesion
assay results show that inhibition of calcium dependent PKC has no effect on
adhesion to CVI of chondrocytes isolated from normal areas of knee joints either in
the absence or presence of stimulating anti-HMPG antibody M28B5. This suggests
that PKC is not involved in the adhesion of chondrocytes to CVI in the absence of
antibody, or when stimulated by anti-HMPG antibody M28B5.
In some cell types, including chondrocytes, PKC is not involved in the
adhesion of cells to ligands, but in cellular functions that occur after this, for example
cell spreading, focal contact formation and migration, hi B and T cells, integrin-
ligand interaction promotes cell adhesion, but direct activation ofPKC or additional
receptor ligand interaction is required for focal contact formation (Woods 1992).
Platelet activation involves two steps, PKC independent, GTP regulatory protein
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dependent (Daniel 1992) attachment of platelets to collagen by a2(31 integrins,
followed by platelet aggregation and secretion, for which PKC is required (Karnguian
1990). Similarly, integrin interaction with the RGD domain ofFN is sufficient for
human fibroblast adhesion and spreading, however the heparin binding domain and
PKC activation is required for focal contact formation (Woods 1992). The additional
signals needed for focal contact formation are provided by the HSPG syndecan,
which is localised to focal contacts and is thought to act as a co-receptor which
modulates pi integrin interaction with FN (Woods 1994). Fluman melanoma cells
are able to adhere to FN, they require stimulation ofNG2/HMPG to spread and form
focal contacts (Iida 1995). A similar mechanism may occur in chondrocytes;
NG2/FFMPG stimulation of adhesion of integrins to CVI via a Gi protein dependent,
PKC independent pathway, followed by PKC dependent spreading and focal contact
formation.
4.5.3. Stimulation of tyrosine kinase activity by NG2/HMPG
Human melanoma cells are able to adhere to FN, but they require stimulation of
NG2/HMPG to spread and form focal contacts (Iida 1995). During the stimulated
cell spreading and focal contact formation two proteins of molecular weight 120 and
130 kD are tyrosine phosphorylated. This can be inhibited by tyrosine kinase
inhibitors (Iida 1995). There is little information about tyrosine phosphorylation of
specific proteins in chondrocytes. Mechanical strain promotes the phosphorylation of
FAK and paxillin (Lee 1998). Lipocortin tyrosine phosphorylation is upregulated by
inhibition of protein tyrosine phosphatases (Grima 1994), and MAP kinases ERK 1
and 2 phosphorylation is stimulated by EL-1, PDGF and IGF-1 (Geng 1996).
Preliminary comparison of the profile of proteins tyrosine phosphorylated in
human chondrocytes isolated from normal cartilage and plated on BSA and those
stimulated by allowing them to adhere to FN, CVI, M28B5, KZ1, TS2/16 and
mixtures ofFN and M28B5 antibody, showed no difference. However chondrocytes
were only allowed to adhere to substrates for 1 h, with the exception ofM28B5,
where cells were plated on a time course ranging from 1 min to 1 h. This length of
time is sufficient for chondrocytes to adhere, however after 1 h the chondrocytes are
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still rounded and have not begun to spread, suggesting that tyrosine kinase activity is
not required for the initial attachment to substrates. Further work is needed to study
the tyrosine phosphorylation events in chondrocytes which have been allowed to
adhere for longer periods of time, and spread and form focal contacts.
The adhesion assay results showed that inhibition of tyrosine specific kinases
has no effect on adhesion to CVI of chondrocytes isolated from normal cartilage
either in the absence or presence of stimulating anti-HMPG antibody M28B5. This
suggests that these kinases are not involved in the intracellular signals required for
cellular interaction with CVI. Tyrosine kinases, like PKC may be involved in
functions such as cell spreading, focal contact formation and migration.
Chondrocyte adhesion to FN, CI and CII is not affected by inhibitors of
tyrosine kinases, however migration promoted by FN, types I and II collagen is
blocked (Shimizu 1997). Expression ofNG2/HMPG by rat cell lines correlates with
the ability to migrate to CVI (Burg 1997) although the mechanism by which this
occurs is not known. FN binding of a5pi integrin in chondrocytes is followed by
integrin clustering and focal contact formation including actin, and tyrosine kinase
FAK and Rho A recruitment (Clancy 1997). Nitric oxide inhibits focal contact
formation but not integrin ligation or clustering (Clancy 1997), and nitric oxide
release is dependent on tyrosine kinase activity (Geng 1995).
PKC and tyrosine specific kinases appear not to be involved in initial cell
adhesion, but may play a role in cell spreading, focal contact formation or migration.
In adenocarcinoma cells PKC activation correlates with FAK phosphorylation, cell
spreading and focal contact formation, involving recruitment of actin and P1
integrins (Ghiso 1997). Crosslinking of a4pi in T cells induces migration on FN,
laminin and CIV. This is inhibited by PKC and tyrosine kinase inhibitors.
Crosslinking of CD3 triggers ligand binding and migration (Hauzenberger 1997).
Phosphorylation events play a role in the regulation of integrin-ligand affinity.
In T cells, cross linking of the CD3 cell surface molecule results in activation of
a4p2 integrin and stronger adhesion to ligands via the activation ofPKC (Hynes
1992). Src tyrosine phosphorylation of P1 integrin in transformed cells decreases P1
binding to talin and FN. Serine phosphorylation of a5pi integrin in mitotic cells
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reduces binding to FN, and allows cells to round up and detach in preparation for cell
division (Hynes 1992). Damage to the endothelial lining causes an increased
adhesion of platelets to collagen via a2pi integrins which stimulates tyrosine
phosphorylation ofPLC, resulting in its increased activity and platelet aggregation
and secretion (Poole 1997). In the same way NG2/HMPG may facilitate integrin
interaction of chondrocytes with CVI via Gi proteins, and trigger cell spreading, focal
contact formation and migration involving PKC and tyrosine kinases.
4.5.4. Interaction of NG2/HMPG with actin
NG2/HMPG expression in flattened rat cell lines is found to be in ordered linear
arrays which co-localise with the cytoskeletal stress fibres of actin, but not
microtubules or intermediate filaments (Lin 1996a). Cytochalasin D, which disrupts
actin polymerisation, destroys both patterns of expression and causes NG2/HMPG to
be released from the cell. In cells which have rounded up in preparation for
migration or a change in adhesive environment, the two no longer co-localise,
suggesting that the co-localisation is specific, and functions in the regulation of cell
adhesion and spreading (Lin 1996a). Human adult articular chondrocytes in culture
do not form stress fibres, but actin is distributed in spindle like arrays, which radiate
out from the centre of the cells to the edges (Wright 1997).
Disruption of the cytoskeleton with cytochalasin D results in a dramatic
decrease in chondrocyte ability to interact with CVI, both with and without M28B5.
This is unsurprising, as the actin cytoskeleton acts as an anchor for p 1 integrins in
focal contacts, which are involved in CVI adhesion. From these studies, it is
impossible to determine whether this agent is inhibiting general chondrocyte
adhesion to CVI, or M28B5 stimulated chondrocyte adhesion to CVI.
Actin is not clearly co-localised with NG2/HMPG, which is expressed in a
punctate pattern, suggesting that, in human chondrocytes, at least in vitro,
NG2/HMPG does not appear to be involved in the anchoring of the cytoskeleton and
subsequent regulation of cell adhesion, as in some rat cell lines. The actin
cytoskeleton is required for chondrocyte interaction with CVI, however the lack of
co-localisation in chondrocytes with NG2/HMPG suggests that it does not do so via
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an interaction with NG2/HMPG. It exerts its effect by interacting with other
molecules such as integrins, and NG2/HMPG may act by interacting with other
intracellular proteins.
4.5.5. Interaction ofNG2/HMPG with PDGFa-R
In rat 0-2A cells in vitro and in vivo, NG2/HMPG and PDGFa-R expression is
closely co-localised and co-regulated throughout development, until maturation in the
postnatal/adult rat (Nishiyama 1996a). In vitro co-expression and interaction of the
two molecules corresponds with cell ability to respond optimally to PDGF
(Nishiyama 1996b). In rat smooth muscle cell cultures, NG2/HMPG and PDGFa-R
are also co-expressed, and anti-NG2 antibodies interfere with the ability of cells to
respond to PDGF, implicating NG2/HMPG in the regulation of PDGF and PDGFa-R
interaction (Grako 1995). Normal human adult articular chondrocytes in culture do
not proliferate, but are slow growing cells (Caterson 1997). PDGFa-R is not clearly
co-localised with NG2/HMPG, which is expressed in a punctate pattern, suggesting
that in human chondrocytes, at least in vitro, NG2/HMPG does not appear to be
involved in the regulation ofPDGF and PDGFa-R interaction and subsequent
modulation of cell proliferation as in rat 0-2A and smooth muscle cell lines.
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4.6. CONCLUSIONS
The results of this study show that the novel cell membrane associated CSPG
NG2/HMPG is expressed by chondrocytes in human adult and fetal cartilage.
Currently the role ofNG2/HMPG in chondrocytes remains unclear. Work with rat
cell lines and melanoma cells suggest that NG2/HMPG function may be cell type
specific (Stallcup 1990, Iida 1995). NG2/HMPG modulates the adhesion to CVI of
chondrocytes isolated from normal cartilage. NG2/HMPG does not directly interact
with any protein so far tested, therefore it may indirectly influence this adhesion.
Indeed, previous work suggests that articular chondrocytes use integrins
predominantly in their adhesive interactions with these molecules (Loeser 1995,
1997, Enomoto 1993, Durr 1993). This raises the possibility that NG2/HMPG
regulates chondrocyte-ECM interaction indirectly via modulation of integrin affinity
for its ligands. This modulation of chondrocyte adhesion to CVI requires the
activation ofGi proteins, which may directly, or through the activation of one or
more effector molecules, alter the affinity of (11 integrin for CVI.
NG2/HMPG may also be involved in signalling pathways which activate
PKC and tyrosine specific kinases, but which are not involved in cell adhesion to
CVI. They may mediate alternative cellular functions, such as migration, spreading
and focal contact formation. This is important in vitro, however is of limited
relevance in vivo, where chondrocytes do not spread or migrate.
This theory proposes two separate functions for NG2/HMPG. NG2/HMPG
potentially participates in two or more distinct signalling pathways, in the regulation
of cell adhesion to CVI via G protein-mediated control of integrin affinity, in the
activation of tyrosine kinases, and as a substrate for PKC which may be involved in
other cell functions such as migration, spreading and focal contact formation
(FIGURE 4.1.). The expression ofNG2/HMPG as both unmodified protein core and
CSPG may be a means of regulating multiple functions, for example, which
signalling pathway occurs, and ligand affinity and specificity.
NG2/HMPG expression is down regulated in OA cartilage. Stimulation of
chondrocytes from OA cartilage with anti-HMPG antibodies does not increase
















Proposed role ofNG2/HMPG in normal human articular chondrocytes.
NG2/HMPG indirectly stimulates chondrocyte adhesion, by modulating
integrin affinity for CVI via inside out signalling pathways involving Gi




The function ofNG2/HMPG in chondrocytes isolated from normal cartilage
The role ofNG2/HMPG in adhesion to the ECM. This thesis has provided evidence
that NG2/HMPG does not directly interact with FN, CII or CVI, however it may
directly bind to other proteins found in the ECM of cartilage. Direct binding assays
have shown NG2/HMPG isolated from rat cell lines to interact with other proteins
found in cartilage ECM (Tillet 1997). Other candidate ligands should be explored,
for example laminin and tenascin, including the possibility that NG2/FIMPG directly
binds a novel ligand. Future work should also include determination of any direct
interaction ofNG2/HMPG with ECM proteins after removal of the CS GAGS.
Giprotein mediated signal transduction. In human chondrocytes NG2/HMPG may
use Gi proteins to control cell adhesion to CVI. The question remains as to how
NG2/HMPG modulation of chondrocyte interaction with CVI is regulated and how
integrins are involved. The up/downstream events, such as how stimulation of
NG2/HMPG occurs and how the activation of Gi proteins leads to an increase in the
adhesion of chondrocytes to CVI, should be investigated. For example, does
NG2/UMPG interact directly with the G protein, or via an extra loop involving other
membrane protein receptors or secreted proteins, and how does this affect adhesion
and regulate integrin function? Potential intracellular second messengers include
adenylate cyclase, PLC, inositol triphosphate, DAG, PKC, ion channel regulation and
decreased cGMP concentrations. The effect of inhibitors of downstream molecules,
and any changes in intracellular molecule concentration, for example calcium,
cAMP, DAG, inositol triphosphate and arachidonic acid should be studied.
Alternatively, NG2/HMPG may signal via a novel intracellular pathway.
The role ofNG2/HMPG in chondrocyte spreading andfocal contactformation.
Chondrocytes were stimulated with antibody or ECM proteins, and changes in
tyrosine phosphorylation looked for. However, cells were only allowed to adhere to a
limited set of substrates for a short period of time. Cells must be allowed to adhere
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to, and spread on, anti-HMPG antibodies, FN, CVI and composite substrates.
Chondrocyte focal contact formation should be also studied. It will be important to
extend the time course to enable events beyond adhesion to be analysed.
NG2/HMPG's primary sequence suggests that it is a substrate for PKC.
Activation ofPKC in rat cells stimulates the appearance and secretion of a truncated
NG2/HMPG, and a decrease in interaction with CVI. The effect ofPKC activation
on NG2/HMPG expression, size, retention at the cell surface, and ability to stimulate
adhesion to CVI should be looked at. It will also be important to determine whether
NG2/HMPG is a substrate for phosphorylation.
The participation ofNG2/HMPG in signalling pathways which may involve
growth factor stimulation suggests that studying the effect of growth factors
including TGF-P, PDGF or cytokines such as IL-1 on NG2/HMPG expression may
be of interest. Understanding ofwhat regulates NG2/HMPG expression may provide
insight into the function ofNG2/HMPG in both normal cartilage and in the OA
disease process, as well as the starting point for the stimulated adhesion to CVI.
Other intracellular functions. This work has shown no co-localisation of
NG2/HMPG with actin in chondrocytes isolated from normal cartilage; however,
NG2/HMPG may have a different function in chondrocytes isolated from OA
cartilage. In cell types other than rat cell lines, potential intracellular ligands have not
been studied. Actin does not comprise the whole cytoskeleton, for example, in focal
contacts integrins are connected to actin stress fibres by an indirect linkage via talin,
vinculin, paxillin, a-actinin and capping protein. Microtubules, intermediate
filaments, and actin accessory proteins for example filamin and myosin, also form
part of the intracellular network. There are antibodies available which recognise
these proteins, by which NG2/HMPG may transduce signals between the outside and
inside of the cell.
The function of NG2/HMPG in chondrocytes isolated from OA cartilage
It will be important to determine why expression ofNG2/HMPG is down regulated in
OA cartilage, and if this contributes to the disease process. The function of
161
NG2/HMPG should be investigated in chondrocytes derived from OA cartilage,
including a comparison of the localisation ofNG2/HMPG with ECM proteins and
actin, and repetition of the adhesion assays to FN, CII and CVI in the presence of
M28B5. NG2/HMPG in OA cartilage may modulate chondrocyte adhesion to
different substrates, using different intracellular signalling pathways from those used
in normal cartilage.
The function of the unmodified core and the CSPG
It will be important to identify which form ofNG2/HMPG, the unmodified protein
core or the CSPG, is functionally active and if expression is a means of regulating
function. Quantitation of the different forms ofNG2/HMPG expressed in normal
and OA cartilage would provide an insight into the function in the different cell
types, as would the effect of chondroitinase digestion on the function ofNG2/HMPG.
Molecular analysis
NG2/HMPG function appears to be cell type specific. Determination of the DNA
and AA sequence ofNG2/HMPG from chondrocytes isolated from both normal and
OA cartilage would allow sequence homology to rat NG2 and HMPG to be
compared. Determination of cell specific variation in DNA or protein may account
for different function. A comparison of the positions of exons/introns of
NG2/HMPG, and ofmRNA expressed in human chondrocytes to those seen in other
species, may reveal splice variation that could account for the functional differences.
The production and expression of fragments and mutant forms ofNG2/HMPG may
also provide an insight into the precise functional mechanisms of this protein.
It will be important to establish how NG2/HMPG is involved in the regulation of
integrin function and identify potential ligand(s) in cartilage, to investigate possible
functions of this molecule in cell signalling and regulation of chondrocyte activity in
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APPENDIX I
Monoclonal antibodies used throughout this study.
ANTIBODY CLONE TYPE SOURCE
Anti-rat NG2 N143.8 mouse monoclonal William Stallcup, La Jolla
Cancer Research
Foundation, California USA
Anti-human HMPG 9.2.27 mouse monoclonal William Stallcup, La Jolla
Cancer Research
Foundation, California USA




Anti-CD44 KZ1 mouse monoclonal David Anstee, International
Blood Group Reference
Laboratory, Bristol UK
Anti-FN IST-4 mouse monoclonal Luciano Zardi, Milan
Anti-
phosphothreonine
PTR-8 mouse monoclonal Sigma, Poole UK
Anti-pi integrin TS2/16 mouse monoclonal Francisco Sanchez-Madrid,
Madrid




Anti-CD3 UCHT-1 mouse monoclonal
IgGl
Seward, UK
Anti-phosphotyrosine PT-66 mouse monoclonal Sigma, Paisley UK
HRP-conjugated anti-
phosphotyrosine
PY-20 mouse monoclonal Transduction laboratories,
Exeter UK
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Polyclonal antibodies used throughout this study.
ANTIBODY TYPE SOURCE
























goat polyclonal Harlan labs, Loughborough UK
FITC/TRITC conjugated
anti-rabbit Ig






Solutions used throughout this study.
Solutions used in immunohistology
I0X TBS
To 500 ml of 0.5 M Tris add approximately 200 ml 1 N HC1 until pH is 7.6, make up
to 2000 ml with distilled water and re-adjust pH to 7.6. For use dilute 1:10 with
normal saline.
Normal saline 42.50 g sodium chloride
AB Buffer
To 12 ml 0.2 M Tris add 19 ml 0.1 N HC1 and 19 ml distilled water.
DAB Substrate Solution
To 0.2 ml DAB add 4.8 ml DAB buffer and 0.1 ml hydrogen peroxide solution.
Hydrogen peroxide solution 0.2 ml distilled water
0.1 ml 30 %w/w hydrogen peroxide
DAB buffer (pH 7.6) 0.2 M Tris
5000 ml distilled water
0.1 NHC1
19 ml distilled water
0.01 M imidazole








Solutions used in isolation and culture of chondrocytes.
Collagenase
Type H collagenase: 3 mg per sample made up in 10 ml of serum free HAMs F12
medium and filter sterilised.
Anti microbial solution.
To 100 ml PBS add 5 ml each ofPenicillin/Streptomycin (10 mg/ml), L-Glutamine
(200 mM) and Fungizone (250 pg/ml).
Solution used for chondroitinase digestion
Chondroitinase ABC
Stock solution: 2 units lyophilised chondroitinase ABC dissolved in 1 ml PBS and
stored at -20 °C. For use dilute with PBS.
Solutions used for cell lysis




1 mM phenyl methyl sulphonyl fluoride (PMSF)
10 ml dH20
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Solutions used for Lowry determination of protein concentration
Alkaline carbonate solution
To 5 ml copper sulphate solution add 5 ml sodium potassium tartrate and 490 ml
alkaline carbonate stock solution.
Copper sulphate solution 1 g CuSC>4 in 100 ml dPTO
Sodium potassium tartrate 2 g NaKtartrate in 100 ml dLLO
Alkaline carbonate stock solution 20 g Na HCO3, 4 g NaOH in 1 1 dLLO
Folin's reagent
Dilute 10 ml stock solution with 10 ml dPPiO, store in dark.
BSA Standards
Dilute stock BSA with 0.1 N NaOPP to give final concentrations.
Stock BSA 1 mg BSA
1 ml distilled water









SI 400 80 120
S2 200 40 160
S3 150 30 170
S4 100 20 180
S5 75 15 185
S6 50 10 190
S7 25 5 195
S8 0 0 200
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Solutions used for SDS PAGE
Separating gel composition
FINAL STOCK 30 % SEPARATING dH20 10 % TEMED
ACRYLAMIDE ACRYLAMIDE GEL BUFFER (ml) APS (MO
CONC. (%) (ml) (ml) (Ml)
3 3.7 9.25 24.3 200 20
5 6.2 9.25 21.8 200 20
20 25.0 9.25 3.0 200 20


















2.5 0.85 2.5 6.35 30 10
4.5 1.5 2.5 5.7 30 10
Separating gel buffer
pH to 8.8 and store at room temperature.
1.5 M Tris
0.5 % SDS
500 ml distilled water
Stacking gel buffer
pH to 6.8 and store at room temperature.
0.5 M Tris
0.5 % SDS
500 ml distilled water
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1 1 distilled water
Sample buffer
0.5 M Tris pH 6.8
3.8 ml dH20
0.8 ml glycerol
1.6 ml 10% SDS
0.8 ml 0.1 M dithiothreitol (DTT)
0.2 ml 0.05 % bromophenol blue
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Solutions used for electrophoretic transfer of proteins to nitro-cellulose
Transfer buffer




800 ml distilled water
Solutions used for development of blot using alkaline phosphatase
Blocking solution
10 mM Tris pH 8.0
150 mMNaCl
2 % BSA
0.02 % Na azide
TEST




0.1 M Tris pH 9.0
O.lMNaCl
5 mM MgCl2
66 pl/10 ml Stock NBT
33 pi/10 ml Stock BCIP
Stock NBT 50 mg/ml in 70 % Dimethyl formamide
Stock BCIP 50 mg/ml in 100 % Dimethyl formamide
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Solutions used for assessment of protein tyrosine phosphorylation
2x Lysis buffer
prepare immediately before use
1 ml 1M Tris-Cl pH 8.0
2.3 ml 3 M NaCl
10 ml 50 % (v/v) glycerol
5 ml 10 % (v/v) NP-40
5pi 50 mM p-nitrophenyl guanidinobenzoate
50 pi 10 mg/ml aprotinin
50 pi 10 ml/ml leupeptin
0.5ml0.1MNa orthovanadate
0.2 ml 0.5 M EDTA pH 8.0
H2O to 25 ml
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APPENDIX III
Tissues sources used throughout this study.




SOURCE NUMBER SEX MEDIAN AGE RANGE
Normal patella, tibia,
femur
1 F 67 YEARS
Normal patella, tibia,
femur









10 17 WEEKS 14-20
WEEKS













10 M 71 53-88
OA (mild) patella, tibia,
femur
4 M 61 53-69
OA (moderate) patella, tibia,
femur
6 M 64 53-74




Tissues used in western blotting to detect NG2/HMPG




Normal tibia, femur 3 F 71 66-75
Normal tibia, femur 9 M 62 46-78
OA tibia, femur 1 F 66
OA tibia, femur 4 M 64 50-78
Tissues used to determine band intensities ofNG2/HMPG and FN




Normal tibia, femur 1 F 66
Normal tibia, femur 3 M 70 61-78
OA tibia, femur 1 F 66
OA tibia, femur 3 M 70 61-78
Tissues used in western blotting to detect threonine phosphorylated proteins




Normal tibia, femur 2 F 70 65-74
Normal tibia, femur 3 M 64 50-77
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Normal tibia, femur 4 F 74 59-89
Normal tibia, femur 2 M 74









Normal tibia, femur 6 F 72 59-84
Normal tibia, femur 8 M 65 40-90
OA tibia, femur 2 F 60 59-61
OA tibia, femur 3 M 69 61-77
Tissues used in immunofluorescent localisation of NG2/HMPG and ECM









Normal tibia, femur 2 F 76 67-84
Normal tibia, femur 1 M 82
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Normal tibia, femur 1 F 76
Normal tibia, femur 3 M 59 40-77









Normal tibia, femur 2 F 65 61-69
Normal tibia, femur 1 M 61










Normal tibia, femur 2 F 71 65-77
Normal tibia, femur 2 M 67 58-76
OA tibia, femur 3 F 68 65-71
OA tibia, femur 1 M 58
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Tissues used in cell adhesion assays to study the effect of anti-pl and HMPG









Normal tibia, femur 1 F 77
Normal tibia, femur 2 M 71 65-77
OA tibia, femur 1 F 77
OA tibia, femur 2 M 57 49-65
Tissues used in cell adhesion assays to study the effect of increasing doses of









Normal tibia, femur 1 F 74
Normal tibia, femur 2 M 67 66-68
Tissues used in cell adhesion assays to study the effect of increasing doses of









Normal tibia, femur 1 M 68
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Tissues used in cell adhesion assays to study the effect of inhibitors of









Normal tibia, femur 1 F 89
Normal tibia, femur 2 M 67 66-68









Normal tibia, femur 1 F 75




Comparison of expression of NG2/HMPG in normal and OA cartilage by
densitometry ofwestern blots (Band intensity)
EXP. 1 EXP. 2 EXP. 3 EXP. 4 MEAN SEM
CSPGN 100 100 100 100 100 0
CSPG OA 56 56 42 50 51 4.7
CORE-
cABCN
100 100 100 100 100 0
CORE-
cABC OA
40 43 36 41 40 2
CORE
+cABC N
100 100 100 100 100 0
CORE
+cABC OA
41 47 43 46 44 1.8
Comparison of expression ofFN in normal and OA cartilage by densitometry of
western blots (Band intensity)
EXP. 1 EXP. 2 EXP. 3 EXP. 4 MEAN SEM
FNN 56 31 17 20 31 8.85
FN OA 100 100 100 100 100 0
Normal chondrocyte adhesion to FN, CII and CVI (Relative adhesion)
Substrate EXP. 1 EXP. 2 EXP. 3 MEAN SEM
BSA 100 100 100 100 0
FN 542 303 1853 899 481.8
cn 587 323 2100 1003 553.6
CVI 595 263 763 540 146.9
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OA Chondrocyte adhesion to BSA, FN, CII and CVI (Relative adhesion)
Substrate EXP. 1 EXP. 2 EXP. 3 MEAN SEM
BSA 100 100 100 100 0
FN 908 611 1407 975 232.2
cn 1019 623 1425 1022 231.5
CVI 929 377 748 685 162.4
Effect of anti [31 integrin and HMPG antibodies on the adhesion of
chondroyctes isolated from normal cartilage to FN (Relative adhesion)
Substrate EXP. 1 EXP. 2 EXP. 3 MEAN SEM
No antibody 100 100 100 100 0
P4C10 48 52 41 47 3.2
TS2/16 83 151 86 107 22.1
M28B5 86 149 103 113 18.8
Effect of anti [31 integrin and HMPG antibodies on the adhesion of
chondroyctes isolated from normal cartilage to CII (Relative adhesion)
Substrate EXP. 1 EXP. 2 EXP. 3 MEAN SEM
No antibody 100 100 100 100 0
P4C10 47 53 23 41 9.2
TS2/16 87 154 81 107 23.4
M28B5 101 145 100 115 14.8
Effect of anti (31 integrin and HMPG antibodies on the adhesion of
chondroyctes isolated from normal cartilage to CVT (Relative adhesion)
Substrate EXP. 1 EXP. 2 EXP. 3 MEAN SEM
No antibody 100 100 100 100 0
P4C10 55 37 25 39 8.7
TS2/16 101 163 141 135 18.1
M28B5 104 119 118 114 1.5
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Effect of anti pi integrin and HMPG antibodies on the adhesion of
chondroyctes isolated from OA cartilage to FN (Relative adhesion)
Substrate EXP. 1 EXP. 2 EXP. 3 MEAN SEM
No antibody 100 100 100 100 0
P4C10 63 64 62 63 0.58
TS2/16 101 115 97 104 5.5
M28B5 93 136 109 113 12.5
Effect of anti pi integrin and HMPG antibodies on the adhesion of
chondroyctes isolated from OA cartilage to CII (Relative adhesion)
Substrate EXP. 1 EXP. 2 EXP. 3 MEAN SEM
No antibody 100 100 100 100 0
P4C10 9 56 40 35 13.8
TS2/16 88 104 120 104 9.2
M28B5 80 117 147 115 19.4
Effect of anti pi integrin and HMPG antibodies on the adhesion of
chondroyctes isolated from OA cartilage to CVI (Relative adhesion)
Substrate EXP. 1 EXP. 2 EXP. 3 MEAN SEM
No antibody 100 100 100 100 0
P4C10 32 41 49 41 4.9
TS2/16 98 177 125 133 23.2
M28B5 85 136 157 126 21.4
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Effect of increasing concentrations ofM28B5 and UCHT-1 on chondrocyte















0 100 100 100 100 0 100
1 259 132 186 192 36.8 102
10 263 145 218 209 34.4 106
50 318 173 225 230 42.4 111
100 370 179 243 264 56.1 108
500 456 188 290 311 78.1 98
Effect of inhibitors of intracellular signalling molecules on chondrocyte
adhesion to CVI (Relative adhesion)
Substrate EXP. 1 EXP. 2 EXP. 3 MEAN SEM
BSA 100 100 100 100 0
CVI 691 696 404 597 97
CVI+M28B5 1940 1476 1394 1603 170
CVI+gen 832 624 492 649 99
CVI+M28B5+gen 1921 1461 1586 1656 137
CVI+st 483 767 447 566 101
CVI+M28B5+st 1755 1285 1348 1463 147
CVI+cd 370 135 191 232 71
CVI+M28B5+cd 1075 130 575 593 141
CVI+pt 590 663 405 553 77
CVI+M28B5+pt 957 435 894 762 165
208
Publications:
Midwood KS and Salter DM. (abstract) NG2 Proteoglycan is expressed in human
adult articular chondrocytes. International Journal ofExperimental Pathology 1996;
77:6 A28-45.
Midwood KS and Salter DM.(abstract) Expression and function ofNG2 proteoglycan
in human articular chondrocytes. Bone 1997; 20: 4 (supp).
Midwood KS and Salter DM. Expression ofNG2 proteoglycan in human articular
chondrocytes. Osteoarthritis and Cartilage 1998; 6: (5) 297-305.
Midwood KS and Salter DM. (abstract) NG2/HMPG modulates human articular
chondrocyte interaction with type VI collagen. Journal of Pathology 1999; (in
press).
Midwood KS and Salter DM Modulation of human articular chondrocyte interaction
with type VI collagen by NG2/HMPG. Osteoarthritis and Cartilage (submitted Jan
1999).
